WO2023228116A1 - Intranasal administration of thermostable rna vaccines - Google Patents
Intranasal administration of thermostable rna vaccines Download PDFInfo
- Publication number
- WO2023228116A1 WO2023228116A1 PCT/IB2023/055355 IB2023055355W WO2023228116A1 WO 2023228116 A1 WO2023228116 A1 WO 2023228116A1 IB 2023055355 W IB2023055355 W IB 2023055355W WO 2023228116 A1 WO2023228116 A1 WO 2023228116A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nlc
- rna
- oil
- vaccine
- sorbitan
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract description 282
- -1 cationic lipid Chemical class 0.000 claims abstract description 183
- 239000004094 surface-active agent Substances 0.000 claims abstract description 84
- 150000002632 lipids Chemical class 0.000 claims abstract description 80
- 206010022000 influenza Diseases 0.000 claims abstract description 27
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 23
- 230000000241 respiratory effect Effects 0.000 claims abstract description 21
- 239000003921 oil Substances 0.000 claims description 123
- 235000019198 oils Nutrition 0.000 claims description 120
- 239000000203 mixture Substances 0.000 claims description 113
- 238000002255 vaccination Methods 0.000 claims description 90
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 55
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical group OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 54
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 50
- 208000015181 infectious disease Diseases 0.000 claims description 50
- 229940031439 squalene Drugs 0.000 claims description 50
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 50
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 48
- 229920006395 saturated elastomer Polymers 0.000 claims description 33
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 31
- 230000003472 neutralizing effect Effects 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 23
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 239000001294 propane Substances 0.000 claims description 17
- 208000025721 COVID-19 Diseases 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 14
- 229920000136 polysorbate Polymers 0.000 claims description 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 9
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 9
- 235000012343 cottonseed oil Nutrition 0.000 claims description 9
- 239000002385 cottonseed oil Substances 0.000 claims description 9
- 230000016379 mucosal immune response Effects 0.000 claims description 9
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 9
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims description 9
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 230000002458 infectious effect Effects 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 8
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 claims description 7
- 239000004359 castor oil Substances 0.000 claims description 7
- 235000019438 castor oil Nutrition 0.000 claims description 7
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 7
- 235000012424 soybean oil Nutrition 0.000 claims description 7
- 239000003549 soybean oil Substances 0.000 claims description 7
- 229940032094 squalane Drugs 0.000 claims description 7
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims description 6
- 208000023504 respiratory system disease Diseases 0.000 claims description 6
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 6
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 5
- 150000002313 glycerolipids Chemical class 0.000 claims description 5
- 239000004006 olive oil Substances 0.000 claims description 5
- 239000001587 sorbitan monostearate Substances 0.000 claims description 5
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 5
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- 230000000536 complexating effect Effects 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 150000002759 monoacylglycerols Chemical class 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000008347 soybean phospholipid Substances 0.000 claims description 4
- 229940113164 trimyristin Drugs 0.000 claims description 4
- 229960001947 tripalmitin Drugs 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 3
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims description 3
- 241000282472 Canis lupus familiaris Species 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 235000019485 Safflower oil Nutrition 0.000 claims description 3
- 235000019486 Sunflower oil Nutrition 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 3
- 229960001950 benzethonium chloride Drugs 0.000 claims description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 3
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 3
- 239000003240 coconut oil Substances 0.000 claims description 3
- 235000019864 coconut oil Nutrition 0.000 claims description 3
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 claims description 3
- 235000021323 fish oil Nutrition 0.000 claims description 3
- 239000008169 grapeseed oil Substances 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 235000005713 safflower oil Nutrition 0.000 claims description 3
- 239000003813 safflower oil Substances 0.000 claims description 3
- 239000001593 sorbitan monooleate Substances 0.000 claims description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 3
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 3
- 239000002600 sunflower oil Substances 0.000 claims description 3
- 239000010497 wheat germ oil Substances 0.000 claims description 3
- OFBLZCXWVROESG-PKPIPKONSA-N (2s)-1,2,3-trihydroxyheptan-4-one Chemical compound CCCC(=O)C(O)[C@@H](O)CO OFBLZCXWVROESG-PKPIPKONSA-N 0.000 claims description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 claims description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 101001064302 Homo sapiens Lipase member I Proteins 0.000 claims description 2
- 102100030659 Lipase member I Human genes 0.000 claims description 2
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 claims description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- JBIROUFYLSSYDX-UHFFFAOYSA-M benzododecinium chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 JBIROUFYLSSYDX-UHFFFAOYSA-M 0.000 claims description 2
- SMTUJUHULKBTBS-UHFFFAOYSA-N benzyl(trimethyl)azanium;methanolate Chemical compound [O-]C.C[N+](C)(C)CC1=CC=CC=C1 SMTUJUHULKBTBS-UHFFFAOYSA-N 0.000 claims description 2
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 claims description 2
- 229960000228 cetalkonium chloride Drugs 0.000 claims description 2
- 229960002798 cetrimide Drugs 0.000 claims description 2
- 229940074979 cetyl palmitate Drugs 0.000 claims description 2
- 229940115457 cetyldimethylethylammonium bromide Drugs 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- VUFOSBDICLTFMS-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CC VUFOSBDICLTFMS-UHFFFAOYSA-M 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- 239000010699 lard oil Substances 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960002285 methylbenzethonium chloride Drugs 0.000 claims description 2
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 claims description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 125000005208 trialkylammonium group Chemical group 0.000 claims description 2
- KMVDECFGXJKYHV-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C KMVDECFGXJKYHV-UHFFFAOYSA-L 0.000 claims description 2
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims 4
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 claims 3
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims 2
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920002477 rna polymer Polymers 0.000 claims 1
- 229960004274 stearic acid Drugs 0.000 claims 1
- 238000012384 transportation and delivery Methods 0.000 abstract description 92
- 241001678559 COVID-19 virus Species 0.000 abstract description 71
- 108700021021 mRNA Vaccine Proteins 0.000 abstract description 58
- 239000002245 particle Substances 0.000 abstract description 53
- 230000005847 immunogenicity Effects 0.000 abstract description 51
- 229940022005 RNA vaccine Drugs 0.000 abstract description 48
- 229910019142 PO4 Inorganic materials 0.000 abstract description 24
- 239000010452 phosphate Substances 0.000 abstract description 24
- 241000700605 Viruses Species 0.000 abstract description 21
- 239000007791 liquid phase Substances 0.000 abstract description 20
- 239000007790 solid phase Substances 0.000 abstract description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 213
- 241001465754 Metazoa Species 0.000 description 100
- 241000699800 Cricetinae Species 0.000 description 76
- 210000002966 serum Anatomy 0.000 description 73
- 210000004027 cell Anatomy 0.000 description 69
- 210000001744 T-lymphocyte Anatomy 0.000 description 68
- 238000009472 formulation Methods 0.000 description 66
- 230000004044 response Effects 0.000 description 59
- 241000699670 Mus sp. Species 0.000 description 52
- 210000004072 lung Anatomy 0.000 description 45
- 230000009885 systemic effect Effects 0.000 description 39
- 230000003612 virological effect Effects 0.000 description 34
- 239000008358 core component Substances 0.000 description 33
- 238000007918 intramuscular administration Methods 0.000 description 33
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 230000036039 immunity Effects 0.000 description 30
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 29
- 230000001965 increasing effect Effects 0.000 description 27
- 241001112090 Pseudovirus Species 0.000 description 23
- 239000000546 pharmaceutical excipient Substances 0.000 description 22
- 230000006698 induction Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 20
- 210000001185 bone marrow Anatomy 0.000 description 19
- 239000000872 buffer Substances 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 19
- 210000000952 spleen Anatomy 0.000 description 19
- 102100032937 CD40 ligand Human genes 0.000 description 18
- 230000005867 T cell response Effects 0.000 description 18
- 210000000628 antibody-producing cell Anatomy 0.000 description 18
- 230000003247 decreasing effect Effects 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 17
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 17
- 108091027544 Subgenomic mRNA Proteins 0.000 description 17
- 238000002296 dynamic light scattering Methods 0.000 description 17
- 239000000306 component Substances 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 15
- 230000037396 body weight Effects 0.000 description 15
- 239000002736 nonionic surfactant Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 229940022962 COVID-19 vaccine Drugs 0.000 description 13
- 239000008346 aqueous phase Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 125000002091 cationic group Chemical group 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 238000004108 freeze drying Methods 0.000 description 13
- 230000003053 immunization Effects 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 239000002105 nanoparticle Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 11
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 11
- 230000007515 enzymatic degradation Effects 0.000 description 11
- 229940126582 mRNA vaccine Drugs 0.000 description 11
- 230000003248 secreting effect Effects 0.000 description 11
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000006386 neutralization reaction Methods 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 230000014599 transmission of virus Effects 0.000 description 9
- 150000005691 triesters Chemical class 0.000 description 9
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 8
- 108010029697 CD40 Ligand Proteins 0.000 description 8
- 241000494545 Cordyline virus 2 Species 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 239000012867 bioactive agent Substances 0.000 description 8
- 230000005540 biological transmission Effects 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000015654 memory Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000001509 sodium citrate Substances 0.000 description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 7
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000002850 nasal mucosa Anatomy 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 6
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 6
- 206010039101 Rhinorrhoea Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000006172 buffering agent Substances 0.000 description 6
- 239000004067 bulking agent Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 238000011201 multiple comparisons test Methods 0.000 description 6
- 208000010753 nasal discharge Diseases 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000000743 Interleukin-5 Human genes 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 238000011887 Necropsy Methods 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 239000012979 RPMI medium Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 125000005907 alkyl ester group Chemical group 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 150000005846 sugar alcohols Chemical class 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 4
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- 241000251730 Chondrichthyes Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000013691 Interleukin-17 Human genes 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000007969 cellular immunity Effects 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 150000005690 diesters Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000019256 formaldehyde Nutrition 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000004180 plasmocyte Anatomy 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699673 Mesocricetus auratus Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 206010064097 avian influenza Diseases 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 3
- GZWGEAAWWHKLDR-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enoyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)[N+](C)(C)C(=O)CCCCCCC\C=C/CCCCCCCC GZWGEAAWWHKLDR-JDVCJPALSA-M 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 102000048657 human ACE2 Human genes 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 229940097496 nasal spray Drugs 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000011870 unpaired t-test Methods 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 229940125575 vaccine candidate Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000121237 Nitrospirae Species 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 2
- 108091007488 SARS-CoV-2 spike ectodomains Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 210000001552 airway epithelial cell Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 2
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 150000002195 fatty ethers Chemical class 0.000 description 2
- 229940013317 fish oils Drugs 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 231100000516 lung damage Toxicity 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940053050 neomycin sulfate Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 229940093916 potassium phosphate Drugs 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 239000010686 shark liver oil Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- YYGNTYWPHWGJRM-AAJYLUCBSA-N squalene group Chemical group CC(C)=CCC\C(\C)=C\CC\C(\C)=C\CC\C=C(/C)\CC\C=C(/C)\CCC=C(C)C YYGNTYWPHWGJRM-AAJYLUCBSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000007485 viral shedding Effects 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108050003866 Bifunctional ligase/repressor BirA Proteins 0.000 description 1
- 102100033743 Biotin-[acetyl-CoA-carboxylase] ligase Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 244000140063 Eragrostis abyssinica Species 0.000 description 1
- 235000014966 Eragrostis abyssinica Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 206010073753 Fear of injection Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101710189104 Fibritin Proteins 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010052014 Liberase Proteins 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940026207 Moderna COVID-19 vaccine Drugs 0.000 description 1
- 101000574446 Mus musculus Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 description 1
- 241001180649 Myrcia group Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- PVNJLUVGTFULAE-UHFFFAOYSA-N [NH4+].[Cl-].[K] Chemical compound [NH4+].[Cl-].[K] PVNJLUVGTFULAE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- GLMQHZPGHAPYIO-UHFFFAOYSA-L azanium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [NH4+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O GLMQHZPGHAPYIO-UHFFFAOYSA-L 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000013378 biophysical characterization Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000007750 congenital bile acid synthesis defect Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical group 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010064833 guanylyltransferase Proteins 0.000 description 1
- 238000011553 hamster model Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229960001226 live attenuated influenza Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000007255 peripheral T cell response Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920003074 plasdone C polymer Polymers 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940023867 prime-boost vaccine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 150000004671 saturated fatty acids Chemical group 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229940069764 shark liver oil Drugs 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 238000013068 supply chain management Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- POZPMIFKBAEGSS-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O POZPMIFKBAEGSS-UHFFFAOYSA-K 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 230000005924 vaccine-induced immune response Effects 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- RNA-based vaccine in contrast, can be developed more rapidly, and allows cross-over intramuscular to intranasal vaccination without developing a new vaccine, allowing for significantly greater utility in pandemic situations.
- Intranasal vaccine delivery promises many benefits over typical intramuscular or subcutaneous vaccine administration, particularly in the induction of the highly specialized mucosal immune system that confers early and effective protection against infectious respiratory diseases.
- intranasal vaccines offer greater ease of administration, eliminating the need for medically-trained personnel as well as potentially improving patient acceptance and compliance. Thus, it is extremely desirable to be able to administer vaccines intranasally.
- the challenges of intranasally administering RNA vaccines are significant.
- the particle size and charge of an intranasally-administered vaccine affect crossing of the mucosa and uptake by airway epithelial cells.
- RNA is a molecule particularly prone to degradation
- the stability of an intranasal vaccine delivery system affects the ability to deliver the vaccine via a liquid or powdered nasal spray. Due to these and other challenges, it is inherently difficult to adapt a vaccine platform to a new route of administration.
- NLC is not saturated with bound RNA
- a negative zeta potential reflects the fact that NLCs are approaching complete saturation with RNA. Therefore, the zeta potential, and thus by necessity the N/P ratio, is a parameter to take into consideration when optimizing the vaccine to maximize efficacy in a specific application while minimizing cytotoxicity risk.
- the identity of the liquid phase lipid in the oil core of the NLC is also a factor in minimizing reactogenicity and optimizing immunogenicity, as discussed below.
- FIG. 9E shows anti-N IgG in serum of naive cagemates that were re-paired for 24 hours with vaccinated-infected and sham-vaccinated-infected groups.
- FIG.9F shows lung pathology scores calculated for naive cagemates that were re-paired for 24 hours with sham-vaccinated-infected and vaccinated- infected animals.
- FIG. 10 shows a non-human primate study diagram for a SARS-CoV-2 self- amplifying RNA/NLC vaccine, indicating timepoints where samples were taken.
- FIGS.11A-D show serum antibody titers induced by self-amplifying RNA/NLC vaccination against SARS-CoV-2.
- FIGS. 12C shows IgG levels in the nasal mucosa.
- FIG. 12D shows IgA levels in the nasal mucosa.
- FIGS. 13A-C show serum pseudovirus neutralization titers for SARS-CoV-2 vaccination.
- FIGS.14A-D shows T cell immunogenicity in non-human primates for SARS- CoV-2 vaccination.
- FIGS.15 A-D show IgG antibody secreting cells post-challenge in non-human primates for SARS-CoV-2 vaccination.
- FIG.16 shows viral load in non-human primates post-challenge for SARS-CoV- 2 vaccination.
- FIGS.20A-D show cryo-TEM imaging of NLCs alone or in complex with self- amplifying RNA at various N/P ratios.
- FIG.20A shows the NLC alone.
- FIG. 21 shows illustrates the design of a self-amplifying RNA/NLC vaccine delivery system for influenza.
- FIG.1A shows a diagram of the self-amplifying RNA/NLC construct.
- FIG.1B shows a diagram of the self-amplifying RNA/NLC complex.
- FIG.22 shows a timeline of sample collection and assays performed for an initial N/P dosing comparison for influenza vaccination.
- FIGS. 23A-B show H5 vaccine-induced serum antibody responses.
- FIG. 23A shows serum H5-specific IgG responses measured post-prime and post-boost.
- FIG. 23B shows serum H5 pseudovirus neutralizing antibody titers measured post-prime and post- boost.
- FIG. 24 shows ELISpot measurements of the levels of H5 IgG-secreting antibody secreting cells (ASCs) in bone marrow.
- ASCs H5 IgG-secreting antibody secreting cells
- the disclosed delivery systems allow delivery of an intranasal RNA vaccine that induces respiratory mucosal immune responses resulting in protective efficacy equal to intramuscular administration and benefits unique to intranasal administration.
- These delivery systems are generally composed of NLC particles comprising (a) an oil core comprising a liquid phase lipid and a solid phase lipid, (b) a cationic lipid, (c) a hydrophobic surfactant, and (d) an additional surfactant.
- NLC particles comprising (a) an oil core comprising a liquid phase lipid and a solid phase lipid, (b) a cationic lipid, (c) a hydrophobic surfactant, and (d) an additional surfactant.
- RNA vaccine delivery system for effective intranasal vaccination.
- This delivery system yielded vaccines that showed prophylactic effects and were also surprisingly effective at preventing transmission from infected subjects to uninfected subjects.
- vaccines may be delivered intranasally to inoculate subjects against respiratory viruses such as, but not limited to, SARS-CoV-2 and influenza while benefitting from the known advantages in vaccine administration and efficacy exhibited by intranasal vaccine delivery.
- the self-amplifying RNA vaccine expresses antigens associated with the H5N1 strain of influenza or another strain of influenza.
- the disclosed delivery system allows intranasal administration of an alphavirus- based self-amplifying RNA vaccine using an NLC delivery system.
- An optimized NLC delivery system allows for safe and effective intranasal delivery of an RNA vaccine that elicits a robust mucosal immune response.
- Tuning the size and charge of the vaccine nanoparticle makes it possible to achieve uptake at mucosal surfaces.
- the level of immune stimulation at the site of administration may be optimized to allow for maximum vaccine immunogenicity.
- immunogenicity of an intranasally-delivered RNA vaccine may be optimized by varying particle composition through different liquid oils and effective surface charge.
- the immunostimulatory properties of the NLC vaccine carrier may be optimized by incorporation of different liquid oils and assessing their effect on vaccine immunogenicity.
- Miglyol ® 810 as a liquid oil may provide superior immunostimulatory properties relative to squalene, because intranasal delivery of squalene may cause an overly strong immune response.
- the effective surface charge of the vaccine particles may be varied to optimize RNA delivery.
- RNA vaccine With respect to vaccination against SARS-CoV-2, the intranasally administered RNA vaccine induced systemic immunity in both the humoral and cellular compartments that rivaled intramuscular administration. Additionally, intranasal administration elicited not only robust populations of spike-responsive polyfunctional T cells in the spleen but also in the lung, demonstrating induction of key respiratory mucosal T cell populations by an RNA vaccine. Further, it was demonstrated that the disclosed system may be used as an intranasal booster of prior intramuscular vaccine-induced immunity, a common real-life scenario given the largely COVID-experienced population to whom the delivery system is expected to be used to deliver vaccines.
- Intranasal SARS-CoV-2 self-amplifying RNA vaccination induces systemic and mucosal immunity in mice and prevents morbidity and blocks viral transmission in hamsters. Similar results are observed in non-human primates.
- the extensive biophysical characterization of differently formulated self- amplifying RNA/NLC vaccine candidates described herein demonstrates that a parameter governing the size, charge, and ability of the NLC formulation to effectively protect RNA from enzymatic degradation is the N/P ratio, or ratio of delivery NLC formulation to RNA in the complexed vaccine. It was found that enzymatic degradation occurs when the zeta potential of the vaccine is a positive value, which occurs at N/P ratios of about 3 or greater.
- NLC is not saturated with bound RNA
- a negative zeta potential reflects the fact that NLCs are approaching complete saturation with RNA. Therefore, the zeta potential, and thus by necessity the N/P ratio, is a parameter to take into consideration when optimizing the vaccine to maximize efficacy in a specific application while minimizing cytotoxicity risk.
- RNA/NLC vaccine for intranasal delivery was shown to effectively induce serum neutralizing antibodies at high titer, as well as bone marrow antibody-secreting cells and both systemic and lung-resident antigen-specific polyfunctional T cell responses. It was observed that certain T-cell responses, such as CD69+ lung cells, were enhanced specifically by i.n. vaccine delivery relative to standard i.m. vaccination.
- intranasal vaccination or intranasal vaccine boosting of intramuscular vaccination may help raise RNA vaccine technologies to a new level, through stimulating respiratory T cell and B cell populations and generating effector subsets within the lungs and nasal mucosa primed to respond rapidly at the first point of infection. Beyond its efficacy at stimulating T RM subsets and bolstering systemic immunity, intranasal administration may also be desirable as a needle-less delivery method with potentially higher uptake, particularly in pediatric and vaccine-hesitant populations.
- the disclosed unique intranasally delivered RNA vaccine that elicits strong systemic and mucosal immunity is a promising new technology ripe for further development and application.
- the solid lipids are mixed with liquid lipids in a solid/liquid lipid weight ratio of from about 70:30 to about 99.9:0.1 or from about 1:10 to about 1:30. In some aspects, the solid lipids are mixed with liquid lipids in a solid/liquid lipid weight of about 1:16.
- the total oil core component (solid lipid + liquid oil) of the NLC-based composition or formulation is typically present in an amount from about 0.2% to about 50% (w/v).
- nanostructured lipid carrier comprising 3.75% w/v GMP shark squalene, 0.24% w/v Dynasan 114, 3.00% w/v DOTAP (1,2-dioleoyl-3- trimethylammonium-propane), 3.70% w/v Span 60, 3.70% Tween 80, and 10 mM sodium citrate.
- the complex had an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of 15, creating vaccine nanoparticles in a liquid solution of 5 mM citrate, 10% sucrose for isotonicity.
- the vaccinated-infected hamsters had increased clearance of viral subgenomic N RNA that declined to undetectable levels by day 6 (i.m.-i.n. and i.m.-i.m. groups) and day 8 (i.n.-i.n. group) post-infection.
- the sham-vaccinated-infected control animals had detectable viral subgenomic N RNA until day 10, indicating that vaccination promoted more rapid reduction in replicating virus.
- the viral RNA measurements from nasal swipes suggested that none of the self- amplifying RNA/NLC vaccination regimens induced sterilizing immunity following direct intranasal instillation with 1x10 6 pfu of SARS-CoV-2.
- the sham-vaccinated-infected and vaccinated-infected hamsters were re-paired with their naive cagemates on day 2 post-infection (day 39 on timeline in FIG.8A; day 0 on timeline in FIG.9A) for a period of 24 hours, as shown in FIG.9A, and assessed morbidity, nasal swipe viral RNA, serum IgG antibodies, and lung immunopathology in the naturally virally challenged cagemates.
- naive cagemates of the sham- vaccinated-infected animals began losing weight within 24 hours of re-pairing, reaching maximum weight loss of 6-7% by day 7 post-re-pairing and exhibiting minimal body weight recovery by the termination of the study, as shown in FIG.9B.
- Total viral N RNA which reflects both replicating and non-replicating virus, was present in nasal swipes from all the naive cagemates as early as 24 hours post-re-pairing with infected hamsters, as shown in FIG. 9C.
- the naive cagemates paired with vaccinated-infected hamsters had on average 70-fold lower total viral N RNA at 24 hours post-re-pairing compared to naive hamsters that were co-housed with sham-vaccinated-infected animals, as shown in FIG.9C.
- Vaccinated animals showed increased titers after prime and boost vaccination, with boost particularly beneficial to boosting the i.n.- vaccinated animals.
- the i.m. vaccinated animals showed generally higher serum IgG titers than the i.n. vaccinated animals.
- Titers had dipped slightly by the day of challenge (5 weeks post-boost) but increased by the day of necropsy (7/8 days post challenge, in response to challenge), with both i.m. and i.n. vaccinated animals demonstrating high titers at necropsy.
- Antibody levels were also assessed in the mucosal tract, specifically in the BAL and nasal mucosa, as shown in FIG. 12. Only the i.m.
- vaccinated primates elicited IgG antibodies in either of these compartments prior to infection.
- the i.n. vaccinated animals peaked to the same BAL IgG antibody levels as seen in the i.m. vaccinated animals.
- the i.n. vaccinated animals were capable of eliciting BAL anti-RBD IgA after infection, indicating seeding of a mucosal antibody response in this compartment.
- the nasal mucosa there was no response initially noted in the i.n. vaccinated animals.
- there was indication of a higher IgA response in the i.n. vaccinated animals as well.
- vaccinated group showed a dramatic induction in CD4+ and CD8+ T cells found in peripheral blood. No circulating CD4+ T cells were seen in i.n. vaccinated animals, and only transient populations of circulating CD8+ T cells were detected prior to challenge. However, similar to the pattern seen with humoral immune responses, upon viral challenge both CD4+ and CD8+ T cells were detected at high levels in PBMCs in the i.n.-vaccinated animals, at levels that rivaled or exceeded the levels seen in i.m.-vaccinated animals, representing a robust recall response to infection. Unvaccinated animals were again unable to produce detectable T cell responses to viral challenge within this timeframe.
- mice Both male and female mice were used in most study groups to avoid sex-driven data biases and allow for identification of any sex-specific differences in vaccine immunogenicity.
- n 5 all-female mice were used per group to provide statistical power of 80% to detect two-fold differences in serum antibody titers. The use of all female mice in this study was conducted to reduce data variability sufficiently to minimize animal use without compromising the main study immunogenicity readouts.
- Data inclusion/exclusion criteria No data were excluded from any plots or analyses except two cases: (1) for flow cytometry after ICS where ⁇ 50,000 cells were collected in the well (this was established as a guideline prospectively) and (2) one i.n.
- a SEAP-expressing plasmid was also used as a control, created similarly with the SEAP sequence in the place of the vaccine antigen. Sanger sequencing was used to confirm plasmid sequences. These were then amplified in Escherichia coli and extracted using Qiagen maxi- or gigaprep kits, linearized with NotI (New England Biolabs), and purified using a Qiagen DNA purification kit.
- RNA Manufacture [0198] NotI-linearized DNA plasmids containing T7 promoters were used as templates for in vitro transcription (IVT) of self-amplifying RNA for vaccination.
- RNA transcripts with guanylyltransferase (Aldevron), GTP, and S-adenosylmethionine (New England Biolabs).
- CaptoCore 700 resin GE Healthcare was used to chromatographically purify the RNA followed by diafiltration and concentration. self-amplifying RNA material was filtered through a 0.22- ⁇ m polyethersulfone filter and stored at -80°C until further use.
- RNA size and integrity was characterized by gel electrophoresis, and RNA concentration was quantified by UV absorbance (NanoDrop 1000) and RiboGreen assay (Thermo Fisher).
- NLC Manufacture [0199] A mixture of trimyristin (IOI Oleochemical), squalene (Sigma-Aldrich), sorbitan monostearate (Sigma-Aldrich), and the cationic lipid 1,2-dioleoyl-3-trimethylammonium- propane (DOTAP; Corden) was heated at 70°C in a bath sonicator.
- DOTAP cationic lipid 1,2-dioleoyl-3-trimethylammonium- propane
- mice were between 6 and 8 weeks of age at study onset and evenly split between male and female. At arrival, mice were simultaneously randomized into study groups, half male and half female, housed separately 3-5 mice per cage with irradiated bedding in Allentown individually ventilated cages.
- Recombinant SARS-CoV-2 Spike His Protein, Carrier Free was diluted at 2 ⁇ g/mL in ELISpot coating buffer (eBioscience), and plates were coated with 100 ⁇ L. Plates were incubated overnight at 4°C. The next day, plates were washed with PBS with 0.1% Tween 20 and blocked with cRPMI medium for 2 hours.
- Femurs were removed from mice and inserted into a snipped-end 0.6-mL Eppendorf tube and then inserted into a 1.5-mL Eppendorf tube with 1 mL of cRPMI medium. Femurs were centrifuged for 15 seconds at 10,000 rpm, and supernatant was discarded.
- RNA/NLC self-amplifying RNA/NLC delivered i.m. (50 mL per rear quadriceps muscle, 100 mL total) or i.n. (25 mL/nare, 50 mL total). Sham-vaccinated hamsters received dPBS i.m. Vaccinated and sham-vaccinated animals were re-paired with naive cagemates after 24 hours. Cagemates were separated on day 28, and vaccinated animals were boosted with the same vaccine given via the i.m. or i.n. route.
- Animals were re-paired after 24 hours.
- Uninfected controls received 100 mL (50 mL/nare) of dPBS (vehicle).
- the infected animals were re- paired with the uninfected, unvaccinated naive cagemates at 48 hours post-infection. Cagemates were separated 24 hours later and remained apart until the end of the study. Hamster weights were measured before infection and daily until day 15 post-infection.
- Hamster Nasal Wash Samples [0220] Hamsters were sedated with isoflurane and euthanized with an intraperitoneal injection of tribromoethanol (500 mg/kg, 3 mL/animal). The trachea was exposed, an incision was made, and a blunt 19-gauge needle attached to a 1-mL insulin syringe was inserted into the trachea.
- Biotinylated recombinant N protein was produced by co-transforming Rosetta cells with the N expression plasmid and an inducible BirA expression plasmid. Bacteria were grown in the presence of chloramphenicol, ampicillin, and streptomycin, induced with IPTG, and supplemented with biotin. Recombinant SARS-CoV-2 Avi/His-tagged spike trimeric proteins were produced by co-transfecting each plasmid construct (1AVI:2HIS construct ratio) into FreeStyle 293-F cells. The Avi-His-tagged spike RBD protein was produced by transfecting the single dual-tagged RBD construct into FreeStyle 293-F cells.
- Cytometric Bead Array Measurement of Spike-Specific IgG Responses 50 ⁇ L of serum (diluted to 1/4000 in PBS) or nasal wash (diluted 1/4 in PBS) was arrayed in 96-well u-bottom polystyrene plates.5 ⁇ L of a suspension containing 5 x 10 5 spike beads, RBD beads, and N beads was added to the samples.
- APC-Cy7 channel fluorescence gates were used to segregate the particles by bead identity. Geometric mean fluorescent intensity was calculated in the FITC channel.
- Propagation and Titer Determination of SARS-CoV-2 [0224] The original SARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI Resources (#NR-52281), propagated in Vero E6 cells (ATCC #C1008), and titered as previously described (84).
- Viral RNA Quantitation by qRT-PCR [0225] SARS-CoV-2 viral N RNA and viral subgenomic N RNA was measured by PCR in nasal swipe (300 ⁇ L) samples as previously described. See Schultz, M. D., et al.
- the effect of immunization strategy on IgG titer was assessed on log-transformed data using unpaired t tests or two-way ANOVA with Tukey’s or Sidak’s (if any sample data were missing) multiple comparisons test.
- the effect of immunization strategy on pseudovirus neutralizing antibody titers was assessed on log-transformed data using unpaired t tests or a mixed-effects model with Sidak’s multiple comparisons test.
- the effect of immunization strategy on polyfunctional CD4 and CD8 cell responses was assessed in untransformed data using unpaired t tests or one-way ANOVA with Holm-Sidak’s multiple comparisons test.
- the size and charge of the complex is dictated by the ratio of the number of positively charged amine groups on the DOTAP lipid contained in the NLC to the number of negatively charged phosphate groups from the self-amplifying RNA backbone (N/P ratio).
- N/P ratio the ratio of the number of positively charged amine groups on the DOTAP lipid contained in the NLC to the number of negatively charged phosphate groups from the self-amplifying RNA backbone
- N/P Ratio on Particle Size and Polydispersity
- Particle size and polydispersity was first assessed using dynamic light scattering (DLS).
- NTA nanoparticle tracking analysis
- NLCs complexed with self- amplifying RNA at N/P 15, as shown in FIG.20B, visually appear indistinguishable from non-complexed NLCs.
- Each study group included ten 6- to 8-week-old C57BL/6 mice, evenly split between males and females, as shown in Table 2. Each study group was administered the vaccine at doses indicated in FIG. 22 at day 0 (prime vaccination) and day 22 (boost vaccination) of the study. Blood was collected by the retro-orbital route every 7 days. Each mouse was individually ear-tagged and tracked across the entire study. Post-prime and post- boost serum was analyzed for IgG titer by ELISA and pseudovirus neutralization titers. Bone marrow was collected at harvest to measure B cell IgG secretion, while spleens and lungs were isolated for T cell flow cytometry.
- H5-binding serum IgG titers were measured post-prime (day 21) and post-boost (day 37), as shown in FIG.23A. Serum IgG was detectable at high levels in animals vaccinated with the H5 self-amplifying RNA/NLC vaccine, both intramuscularly and intranasally, with serum IgG at >10 5 ng/mL post-boost, with no significant differences between the two dosing strategies. Pseudovirus neutralization assays indicated that post-prime, i.m.
- Each study group included five 6- to 8-week-old C57BL/6 mice female mice, as shown in Table 3.
- Each mouse was administered vaccine at 5 ⁇ g per mouse as indicated in FIG.26 at day 0 (prime vaccination) and day 21 (boost vaccination) of the study. Blood was collected by the retro-orbital route every 7 days. Each mouse was individually ear-tagged and tracked across the entire study.
- mice were weighed daily for 7 days following prime and boost vaccination and data are shown in FIG. 27. As shown, vaccines with higher N/P ratios (10 and above) led to greater magnitudes of transient bodyweight loss immediately after immunization in the post-prime days, that recovered by day 5. Vaccine formulated at N/P 8 resulted in significantly reduced bodyweight drop, >5% weight loss at day 1 that recovered by day 3. All other study groups (vaccines at N/P ⁇ 8) showed no effect on bodyweight. This effect on bodyweight was more evident after the prime vaccination dose.
- Serum antibody responses were assessed next. IgG ELISA titers demonstrated a steep drop-off in vaccine immunogenicity in vaccines formulated at N/P ratios below 5, with these low N/P groups showing no detectable H5-binding serum IgG response.
- vaccines formulated at N/P 5 and above had induced demonstrated serum neutralizing antibody titers in mice, in patterns similar to those seen with the serum IgG titers measured by ELISA.
- bone marrow was assessed for IgG and IgA antibody-secreting cells, as shown in FIG 30. Similar results were evident across both measures, with no responses seen induced by vaccines formulated at N/P ratios below 5, and significant responses induced by vaccines formulated at N/P 5 and above.
- the base self-amplifying RNA delivery NLC formulation contains squalene, which has known tissue-irritating properties and may not be optimal for use in intranasal vaccine delivery to sensitive mucosal tissues. Additionally, moving away from a squalene- containing formulation may allow for an improved supply chain, as shark-based squalene is a non-renewable material.
- Alternate oils were studied with the H5 vaccine self-amplifying RNA formulated at an N/P ratio of 10, to allow gauging of any reduced reactogenicity of the alternate-oil NLC formulations relative to the standard squalene-based NLC. Using an N/P that showed some evidence of reactogenicity with the squalene NLC formulation allowed for detection of reduction in reactogenicity by any of these alternate-oil NLC formulations.
- New alternate oil NLCs were created with Miglyol ® 810, cottonseed oil, castor oil, and soybean oil, in addition to the standard squalene-based NLCs.
- the Miglyol ® 810-based NLC showed a significant enhancement of antigen-responsive polyfunctional CD4 and CD8 T cell populations. This was demonstrated not only in spleens, but also in lung T RM cells (CD69+).
- an optimal vaccine formulation is based on Miglyol ® 810 containing NLCs, reducing reactogenicity and enhancing vaccine immunogenicity as compared to squalene containing NLCs.
- DEFINITIONS [0263] The following terms have the following meanings unless otherwise indicated. Any undefined terms have their art recognized meanings.
- thermostable lyophilized vaccine composition lyophilized vaccine composition
- lyophilized vaccine composition lyophilized thermostable cake
- lyophilized cake lyophilized cake
- lyophilized cake a lyophilized oil-in-water stable emulsion comprising a biodegradable oil or metabolizable oil, cake-forming excipients used to produce the cake, and optionally one or more bioactive agents.
- alkyl means a straight chain or branched, noncyclic or cyclic, unsaturated or saturated aliphatic hydrocarbon containing the indicated number of carbon atoms. Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms.
- polypeptide “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length.
- the polymer may be linear or branched, it may comprise modified nucleotides or amino acids, and it may be interrupted by non- nucleotides or non-amino acids.
- the terms also encompass a nucleotide or amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component.
- polynucleotides or polypeptides containing one or more analogs of a nucleotide or an amino acid including, for example, unnatural amino acids, etc.
- isolated means the molecule has been removed from its natural environment.
- Purified means that the molecule has been increased in purity, such that it exists in a form that is more pure than it exists in its natural environment and/or when initially synthesized and/or amplified under laboratory conditions. Purity is a relative term and does not necessarily mean absolute purity.
- the nucleotides can be, for example, deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase, or by a synthetic reaction.
- a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of the polymer.
- RNA integrity means the quantity of intact RNA remaining after an event or passage of time. For example, RNA integrity may be evaluated following freezing, lyophilization, or storage. RNA integrity may be evaluated by both the size and strength of bands shown in agarose gel electrophoresis.
- An “individual” or a “subject” is any vertebrate. Vertebrates include, but are not limited to humans, primates, farm animals (such as cows, pigs, sheep, chickens), sport animals, pets (such as cats, dogs, birds, horses), and rodents.
- a “replicon” as used herein includes any genetic element, for example, a plasmid, cosmid, bacmid, phage or virus that is capable of replication largely under its own control.
- a replicon may be either RNA or DNA and may be single or double stranded.
- the term liquid phase lipid refers to a lipid that, prior to mixing with any other component, is liquid at ambient temperature.
- the term solid phase lipid refers to a lipid that, prior to mixing with any other component, is solid at ambient temperature.
- Ambient temperature is between 15°C and 25°C.
- Cake-forming excipient and lyoprotectant are used herein interchangeably.
- a cake-forming excipient refers to a substance added to a liquid stable oil-in-water emulsion formulation prior to lyophilization which yields a cake following lyophilization.
- a stable emulsion forms, that is suitable for delivery of a bioactive agent including vaccine antigens or polynucleotides encoding vaccine antigens.
- cake-forming excipients are those substances which do not disrupt an emulsion upon reconstitution of the lyophilized cake.
- Excipients as used herein refers to substances other than the pharmacologically active drugs, which are included in the manufacturing process, or fill-finish process for storage or shipment of the pharmacologically active drug including, without limitation, lyophilization, and are contained in a finished pharmaceutical process.
- the practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology, recombinant DNA, biochemistry, and chemistry, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Molecular Cloning A Laboratory Manual, 2nd Ed., Sambrook et al., ed., Cold Spring Harbor Laboratory Press: (1989); DNA Cloning, Volumes I and II (D. N.
Abstract
A novel thermostable nanostructured lipid carrier (NLC)-based RNA vaccine delivery system for intranasally delivery of self-amplifying RNA (saRNA) vaccines is disclosed herein. The disclosed delivery system is generally composed of saRNA complexed to NLC particles comprising (a) an oil core comprising a liquid phase lipid and 5 a solid phase lipid, (b) a cationic lipid, (c) a hydrophobic surfactant, and (d) an additional surfactant. The ratio of NLC-contained-amine-group to RNA-phosphate (N/P ratio) in the vaccine delivery system is optimized to minimize reactogenicity and optimize immunogenicity of the vaccine for intranasal delivery. The vaccine delivery system is suitable for intranasal delivery of vaccines for SARS-CoV-2, influenza, and other 10 respiratory viruses.
Description
INTRANASAL ADMINISTRATION OF THERMOSTABLE RNA VACCINES CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Patent Application Serial No.63/345,345, filed on May 24, 2022, the entirety of which is hereby incorporated herein by reference. BACKGROUND Field of the Invention [0002] The present disclosure relates to intranasal vaccine delivery systems. Description of the Related Art [0003] The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to the rapid advancement and development of novel vaccines for coronavirus disease 2019 (COVID-19). Since their introduction in late 2020, two now FDA- approved mRNA vaccines (Comirnaty and Spikevax) have had a remarkable impact on the trajectory of the pandemic and were developed at unprecedented speeds. However, while these vaccines have displayed remarkable efficacy at preventing severe COVID-19 and slowing the worldwide pandemic, the lack of vaccine-induced local immunity in the respiratory tract allows for mild infection of vaccinated individuals, resulting in transmission of the virus, despite prior vaccination. Between lack of vaccine induction of mucosal immunity, newly emerging variants, waning efficacy of currently approved mRNA vaccines, the need for frequent booster doses, vaccine hesitancy in part fueled by a fear of needles, and limited access to cold chain storage, global susceptibility to SARS-CoV-2 remains high. Improved vaccines and associated technologies are therefore necessary to fully combat the epidemic. [0004] Although the World Health Organization recently declared an end to the global COVID-19 health emergency, the pandemic is nonetheless ongoing and second-generation SARS-CoV-2 vaccines are urgently needed. While several vaccines have been developed and approved since the pandemic began—including many using novel mRNA vaccine technologies—that have admirably contributed to the waning of disease mortality globally, emerging trends highlight the insufficiencies of current vaccine approaches. Vaccine
efficacy has waned rapidly and frequent boosters have been recommended for individuals that received the Pfizer and/or Moderna mRNA vaccines. Increasing evidence of post- infection and post-vaccination reinfection, particularly with the Omicron variant of SARS- CoV-2 and its numerous sub-variants, and ongoing viral transmission post-vaccination, has negatively impacted vaccine credibility. Moreover, new variants will continually place pressure on the efficacy of first-generation SARS-CoV-2 vaccines. [0005] While more research is necessary as to why current vaccines are waning, emerging research is pointing to insufficient nasal and mucosal immunity. Increasingly, data are demonstrating that intramuscular vaccination alone may not generate potent mucosal immunity that is predicted to be critical for early control and clearance of SARS-CoV-2. Vaccinees still show evidence of viral RNA in the upper respiratory tract after viral exposure, suggesting ongoing viral replication and transmission even by vaccinated populations. However, breakthrough infection with SARS-CoV-2 allows vaccinees to elicit potent mucosal and nasal immunity. [0006] In addition, although it is impossible to predict the origin of the next global pandemic, over the past century influenza has been a recurrent threat that threatens global health and security. Despite the availability of seasonal influenza vaccines, vaccine effectiveness is only 10-60%, and vaccines provide no protection against new pandemic strains. Historically, as influenza variants spread, they have the potential to cause three to four pandemics per century, most recently the 2009 H1N1 influenza pandemic that stressed medical and military operations. Avian influenza A H5N1 viruses have recently spread throughout domestic and wild animal populations and have been termed “pre-pandemic.” There is a strong concern that H5N1 will mutate and become readily transmissible between humans and drive the next pandemic. Recent cases have shown H5N1 influenza is highly pathogenic and causes human disease with high mortality in Africa, Asia, and the Middle East. [0007] mRNA vaccines have shown exceptional utility during the COVID-19 pandemic as a tool for pandemic response, enabling rapid adaptability to new pathogen targets. For influenza response, the use of RNA vaccine technology would also avoid the need for tedious and resource-limited vaccine production in embryonated chicken eggs. However, current mRNA vaccine technologies have several key limitations that need to be overcome to be optimized for future influenza pandemics. First, all mRNA vaccines to date are administered through intramuscular (i.m.) injection, which induces serum antibody titers and cellular immunity that protect against viremia and serious disease but not against
asymptomatic infection and viral shedding. Second, the currently authorized or approved mRNA vaccines are all monovalent, which limits their flexibility in rapidly evolving pandemic situations. Third, current mRNA vaccines’ use of lipid nanoparticles (LNPs) requires complex manufacturing processes, difficult-to-source ionizable lipids, and encapsulation of the RNA during LNP manufacture—complicating technology transfer and supply chain management. Fourth, the use of LNPs as the delivery vehicle restricts the ability to meaningfully stockpile drug substances because LNPs must be manufactured with the target RNA, thus delaying the speed at which new vaccine constructs to emerging variants or pathogens can be introduced, manufactured, and distributed. Finally, current mRNA vaccines require cold chain storage (-20°C or -80°C), significantly impacting vaccine distribution particularly in low-resource areas or in situations of active military deployment. [0008] Improving the induction of nasal and mucosal immunity following vaccination is a critical component for second-generation SARS-CoV-2 vaccines to finally achieve durable and flexible protection. However, data also show that generating this immunity is generally not possible via standard intramuscular vaccination and likely requires administration of an intranasal vaccine. [0009] Intranasal vaccines to date have primarily been developed as live-attenuated influenza vaccines. Recently, four new intranasal or inhalable vaccines have been approved for SARS-CoV-2 in China, India, Iran, and Russia, including two adenovirus-vectored vaccines. Further development of nasal or airway administration of vaccines for influenza and other respiratory viruses has remained an attractive target given the potential for development of critical airway resident memory T cells (TRM) at this first line of defense. Several other intranasal vaccines are in development for SARS-CoV-2, but most rely on standard protein or adenovirus vector vaccine technologies. An RNA-based vaccine, in contrast, can be developed more rapidly, and allows cross-over intramuscular to intranasal vaccination without developing a new vaccine, allowing for significantly greater utility in pandemic situations. Validating an RNA-based, intranasally administered vaccine technology would be a significant development not only for the SARS-CoV-2 pandemic but for other respiratory pathogens such as influenza, combining the rapidity and reliability of RNA vaccine adaptation to new targets with the key mucosal immune responses induced by mucosal-specific dosing. [0010] While the expected benefits of RNA vaccines have been proven over the course of the COVID-19 pandemic, no intranasally-administered RNA vaccine for COVID-19 has
yet been developed. This is on account of significant challenges of intranasally administering RNA vaccines, including ensuring that the vaccine is delivered via an appropriate particle size and charge to allow efficient crossing of the mucosa and uptake by airway epithelial cells, ensuring that it is protected from enzymatic degradation while traversing the mucosa, and ensuring that it is sufficiently stable to allow delivery via a liquid or powdered nasal spray. [0011] Thus, there remains a need for an effective RNA vaccine delivery systems for intranasal delivery of RNA vaccines. This disclosure is made with respect to these and other considerations. SUMMARY [0012] A novel thermostable nanostructured lipid carrier (NLC)-based RNA vaccine delivery system for intranasally delivery of self-amplifying RNA vaccines is disclosed herein. [0013] NLC-based vaccine delivery systems for intramuscular delivery of RNA vaccines have been disclosed previously. See, e.g., PCT Patent Application Publication No. WO 2022/051022; U.S. Patent Application Publication No. 2020/0230056. These delivery systems are generally composed of NLC particles comprising (a) an oil core comprising a liquid phase lipid and a solid phase lipid, (b) a cationic lipid, (c) a hydrophobic surfactant, and (d) an additional surfactant. These delivery systems were previously known to be effective for intramuscular and subcutaneous vaccine administration but were not known to be suitable for intranasal vaccine administration. [0014] Intranasal vaccine delivery promises many benefits over typical intramuscular or subcutaneous vaccine administration, particularly in the induction of the highly specialized mucosal immune system that confers early and effective protection against infectious respiratory diseases. In addition, intranasal vaccines offer greater ease of administration, eliminating the need for medically-trained personnel as well as potentially improving patient acceptance and compliance. Thus, it is extremely desirable to be able to administer vaccines intranasally. [0015] The challenges of intranasally administering RNA vaccines are significant. As the mucosal system is designed to trap and remove large particles from the nasal passages, the particle size and charge of an intranasally-administered vaccine affect crossing of the mucosa and uptake by airway epithelial cells. Further, as RNA is a molecule particularly prone to degradation, it is desirable for an intranasal RNA vaccine delivery system to
effectively protect vaccine RNA from enzymatic degradation while traversing the mucosa. Finally, the stability of an intranasal vaccine delivery system affects the ability to deliver the vaccine via a liquid or powdered nasal spray. Due to these and other challenges, it is inherently difficult to adapt a vaccine platform to a new route of administration. [0016] Surprisingly, it was determined that the previously disclosed RNA/NLC vaccine delivery systems could be modified to be suitable for use in intranasal vaccine administration. It was determined that adjusting the ratio of NLC-contained-amine-group to RNA-phosphate (N/P) is one parameter governing the size, charge, and ability of the NLC formulation to effectively protect RNA from enzymatic degradation. The N/P ratio is the ratio of delivery NLC formulation to RNA in the complexed vaccine. It was found that enzymatic degradation occurs when the zeta potential of the vaccine is a positive value, which occurs at N/P ratios of 3 or greater. Based on particle size analysis using DLS and NTA, it is likely that at least a small excess of NLC (i.e., NLC is not saturated with bound RNA) is necessary to confer protection to the RNA—a negative zeta potential reflects the fact that NLCs are approaching complete saturation with RNA. Therefore, the zeta potential, and thus by necessity the N/P ratio, is a parameter to take into consideration when optimizing the vaccine to maximize efficacy in a specific application while minimizing cytotoxicity risk. [0017] In addition, the identity of the liquid phase lipid in the oil core of the NLC is also a factor in minimizing reactogenicity and optimizing immunogenicity, as discussed below. [0018] Using the results of experiments on NLC formulations and the composition of the RNA/NLC complexes, it was possible to adjust the composition of the NLC and the N/P ratio for the RNA vaccine and NLC delivery system to develop an RNA vaccine delivery system for effective intranasal vaccination. This delivery system yielded vaccines that showed prophylactic effects and were also surprisingly effective at preventing transmission from infected subjects to uninfected subjects. This benefit of intranasal vaccine delivery was successfully achieved using the intranasal RNA vaccine delivery systems of this disclosure. Thus, vaccines may be delivered intranasally to inoculate subjects against respiratory viruses such as, but not limited to, SARS-CoV-2 and influenza while benefitting from the advantages in vaccine administration and efficacy exhibited by intranasal vaccine delivery. [0019] It is to be understood that one, some, or all of the properties of the various implementations described herein may be combined to form other implementations of the present invention. These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings.
BRIEF DESCRIPTION OF THE DRAWINGS [0020] FIGS. 1A-B illustrate the design of a self-amplifying RNA/NLC vaccine delivery system for SARS-CoV-2. FIG. 1A shows a diagram of the self-amplifying RNA/NLC construct. FIG.1B shows a diagram of the self-amplifying RNA/NLC complex. [0021] FIG.2 shows SARS-CoV-2 protein binding antibody titers 14 days post-boost. [0022] FIG. 3 shows SARS-CoV-2 pseudovirus-neutralizing antibody titers 14 days post-boost. [0023] FIGS. 4A-I show results for systemic immunogenicity of an intranasally administered SARS-CoV-2 self-amplifying RNA/NLC vaccine assessed three weeks post- prime and three weeks post-boost. FIG. 4A shows serum SARS-CoV-2 spike-specific IgG responses measured post-prime and post-boost, where LOD indicates the limit of detection. FIG.4B shows serum SARS-CoV-2 spike Wuhan pseudovirus neutralizing titers measured post-prime and post-boost. FIG.4C shows serum spike-specific IgG1 and IgG2a responses measured post-boost. FIG.4D shows induction of bone marrow-resident spike-specific IgG- secreting ASCs as measured by ELISpot 3 weeks post-boost. FIGS. 4E-G show SARS- CoV-2 spike-responsive secretion of IFNγ, IL-5, or IL-17a by splenocytes post-boost as measured by ELISpot in mice dosed with 10 µg of saRNA. FIGS. H-I show splenic spike- responsive polyfunctional T cells (IFNγ+, IL-2+, and TNFα+ CD4+ or CD8+ T cells) post- boost as measured by intracellular cytokine staining and flow cytometry. [0024] FIGS. 5A-C show mucosal T cell populations following intranasal vaccination with SARS-CoV-2 self-amplifying RNA/NLC vaccine assessed three weeks post-prime and three weeks post-boost. FIGS. 5A-B show CD69+ lung-resident memory for CD8+ and CD103+ CD8+ T cells, respectively. FIG.5C shows CD40L+ (CD154+)-expressing CD4+ T cells. [0025] FIGS.6A-E show mucosal SARS-CoV-2 spike polyfunctionally reactive T cell populations following immunization with the intranasal or intramuscular SARS-CoV-2 self- amplifying RNA/NLC vaccine. FIGS. 6A-B show polyfunctional CD69+ lung-resident memory for CD8+ and CD103+ CD8+ T cells, respectively. FIG.6C shows polyfunctional CD40L-expressing (CD154+) CD4+ T cells. FIGS. 6D-E show polyfunctional CCR4- expressing (CD194+) lung-homing CD4+ and CD8+ T cells, respectively. [0026] FIGS. 7A-F show systemic and mucosal immune responses following boost immunization with the intranasal or intramuscular SARS-CoV-2 self-amplifying RNA/NLC vaccines seven weeks post-prime. FIG.7A shows SARS-CoV-2 spike-specific IgG titers as
measured by ELISA three weeks post-boost. FIG. 7B shows serum SARS-CoV-2 pseudovirus neutralizing titers three weeks post-boost. FIGS. 7C-D show spleen polyfunctional CD4+ and CD8+ T cell responses, respectively. FIG. 7E shows polyfunctional CD40L-expressing (CD154+) CD4+ T cells. FIG.7F shows polyfunctional lung-resident memory CD69+ CD8+ T cell responses. [0027] FIGS. 8A-H show protection from SARS-CoV-2 infection-induced morbidity, viral load, and lung damage in vaccinated hamsters. FIG.8A illustrates the study design for experiments in vaccinated and sham-vaccinated co-housed hamsters. FIGS. 8B-C show vaccine antibody responses in sham-vaccinated, i.n.-prime/i.n.-boost vaccinated, i.m.- prime/i.m.-boost vaccinated, and i.m.-prime/i.n.-boost vaccinated animals. FIG. 8B shows mean fluorescence intensity (MFI) of serum anti-spike IgG on day 21, and FIG.8C shows mean fluorescence intensity (MFI) of serum anti-spike IgG on day 33. FIGS. 8D-H show experimental infection in sham-vaccinated and vaccinated hamsters. FIG. 8D shows body weights of vaccinated-infected, sham-vaccinated-infected, and sham-vaccinated-uninfected hamsters. FIGS. 8E-F show total N RNA and subgenomic N RNA copy number, respectively, in nasal swipes from vaccinated-infected and sham-vaccinated-infected hamsters. FIG.8G shows anti-N IgG in serum of vaccinated-infected and sham-vaccinated- infected animals. FIG. 8H shows lung pathology scores calculated for sham-vaccinated- infected and vaccinated-infected animals. [0028] FIGS.9A-F show prevention of transmission of SARS-CoV-2 to naive hamster cagemates that results from vaccination. FIG. 9A illustrates the study design for transmission experiments in naive cagemates. FIG. 9B shows body weights of the naive cagemates that were re-paired for 24 hours with vaccinated-infected or sham-vaccinated- infected hamsters. FIGS.9C-D show total N RNA and subgenomic N RNA copy numbers, respectively, in nasal swipes from naive cagemates that were re-paired for 24 hours with vaccinated-infected and sham-vaccinated-infected hamsters. FIG. 9E shows anti-N IgG in serum of naive cagemates that were re-paired for 24 hours with vaccinated-infected and sham-vaccinated-infected groups. FIG.9F shows lung pathology scores calculated for naive cagemates that were re-paired for 24 hours with sham-vaccinated-infected and vaccinated- infected animals. [0029] FIG. 10 shows a non-human primate study diagram for a SARS-CoV-2 self- amplifying RNA/NLC vaccine, indicating timepoints where samples were taken. [0030] FIGS.11A-D show serum antibody titers induced by self-amplifying RNA/NLC vaccination against SARS-CoV-2. FIGS.11A-B show ELISA evaluations of IgG levels in
vaccinated non-human primates. FIG. 11A shows IgG titers to the WA 1/2020 strain (vaccine strain), and FIG.11B shows IgG titers to the B.1.617.2 strain (the challenge strain). FIGS.11C-D show the increase from challenge to necropsy in titers for all three groups to WA 1/2020 and B.1.617.2, respectively. [0031] FIGS. 12A-D show antibody levels in the BAL and nasal mucosa for SARS- CoV-2 vaccination. FIG.12A shows IgG levels in the BAL. FIG.12B shows IgA levels in the BAL. FIG. 12C shows IgG levels in the nasal mucosa. FIG. 12D shows IgA levels in the nasal mucosa. [0032] FIGS. 13A-C show serum pseudovirus neutralization titers for SARS-CoV-2 vaccination. [0033] FIGS.14A-D shows T cell immunogenicity in non-human primates for SARS- CoV-2 vaccination. [0034] FIGS.15 A-D show IgG antibody secreting cells post-challenge in non-human primates for SARS-CoV-2 vaccination. [0035] FIG.16 shows viral load in non-human primates post-challenge for SARS-CoV- 2 vaccination. [0036] FIGS. 17A-C show dynamic light scattering (DLS) size and polydispersity analyses of SARS-CoV-2 self-amplifying RNA/NLC complexes of varying N/P ratios. FIG. 17A shows intensity size distribution of complexes formed at increasing N/P ratios. FIG. 17B shows a plot of the Z-average diameters of complexes formed at increasing N/P ratios. FIG.17C shows the polydispersity index (PDI) of complexes at increasing N/P ratios. [0037] FIGS.18A-B show a nanoparticle tracking analysis (NTA) of SARS-CoV-2 self- amplifying RNA/NLC complexes formed at varying N/P ratios. FIG.18A shows NTA size distribution of complexes formed at different N/P ratios. FIG.18B shows mean particle size of complexes as a function of N/P ratio, determined by NTA. [0038] FIGS. 19A-C show a correlation between zeta potential and RNase protection for SARS-CoV-2 self-amplifying RNA/NLC vaccines. FIG. 19A shows zeta potential of self-amplifying RNA/NLC complexes as a function of N/P ratio. FIG. 19B shows percent protection of RNA from degradation by RNase A as a function of N/P ratio, as determined by agarose gel electrophoresis. FIG. 19C shows agarose gel electrophoresis of self- amplifying RNA extracted directly from complexes or “challenged” with RNase A prior to extraction from complexes. [0039] FIGS.20A-D show cryo-TEM imaging of NLCs alone or in complex with self- amplifying RNA at various N/P ratios. FIG.20A shows the NLC alone. FIG.20B shows the
saRNA/NLC complex at N/P = 15. FIG.20C shows the saRNA/NLC complex at N/P = 5. FIG.20D shows the saRNA/NLC complex at N/P = 0.6. [0040] FIG. 21 shows illustrates the design of a self-amplifying RNA/NLC vaccine delivery system for influenza. FIG.1A shows a diagram of the self-amplifying RNA/NLC construct. FIG.1B shows a diagram of the self-amplifying RNA/NLC complex. [0041] FIG.22 shows a timeline of sample collection and assays performed for an initial N/P dosing comparison for influenza vaccination. [0042] FIGS. 23A-B show H5 vaccine-induced serum antibody responses. FIG. 23A shows serum H5-specific IgG responses measured post-prime and post-boost. FIG. 23B shows serum H5 pseudovirus neutralizing antibody titers measured post-prime and post- boost. [0043] FIG. 24 shows ELISpot measurements of the levels of H5 IgG-secreting antibody secreting cells (ASCs) in bone marrow. [0044] FIGS.25A-F show H5-reactive vaccine-induced T cell populations assessed via intracellular cytokine staining and flow cytometry. [0045] FIG.26 shows a timeline of sample collection and assays performed for in-depth N/P ratio comparison for influenza vaccination. [0046] FIGS. 27A-B show post-immunization body weights of mice for influenza vaccination at various N/P ratios. FIG. 27A shows post-prime body weights. FIG. 27B shows post-boost body weights. [0047] FIG. 28 shows vaccine-induced H5-binding serum IgG levels at various N/P ratios. [0048] FIG. 29 shows serum pseudovirus neutralizing antibody titers for intranasal or intramuscular influenza vaccination at various N/P ratios.. [0049] FIGS.30A-B show the presence of IgG and IgA antibody-secreting cells (ASCs) in bone marrow at various N/P ratios as assessed by ELISpot. FIG.30A shows the presence of IgG antibody-secreting cells (ASCs) in bone marrow. FIG. 30B shows the presence of IgA antibody-secreting cells (ASCs) in bone marrow. [0050] FIGS. 31A-F show vaccine-induced antigen-responsive T cell populations for influenza vaccination. [0051] FIG. 32 shows a timeline of sample collection and assays performed for liquid oil comparison studies for influenza vaccination.
[0052] FIGS.33A-B show body weight changes post-immunization with alternative-oil self-amplifying RNA/NLC vaccine formulations for influenza vaccination. FIG.33A shows post-prime body weight change. FIG.33B shows post-boost body weight change. [0053] FIG. 34 shows H5-binding serum IgG titers for influenza vaccination assessed by ELISA. [0054] FIG. 35 shows serum pseudovirus neutralizing antibody titers induced by alternate oil NLC formulated self-amplifying RNAs for influenza vaccination. [0055] FIGS. 36A-F show antigen-specific T cell responses to alternate oil NLC formulated H5 self-amplifying RNA vaccines, as assessed by intracellular cytokine staining with flow cytometry by intracellular cytokine staining with flow cytometry. DETAILED DESCRIPTION [0056] A novel thermostable nanostructured lipid carrier (NLC)-based RNA vaccine delivery system for intranasally delivery of self-amplifying RNA (saRNA) vaccines is disclosed herein. In some implementations, the vaccine delivery system is composed of a self-amplifying RNA vaccine complexed with a nanostructured lipid carrier. [0057] The disclosed delivery systems extend previously disclosed development of RNA/NLC vaccine delivery systems that have been used for intramuscular delivery. The disclosed delivery systems allow delivery of an intranasal RNA vaccine that induces respiratory mucosal immune responses resulting in protective efficacy equal to intramuscular administration and benefits unique to intranasal administration. [0058] These delivery systems are generally composed of NLC particles comprising (a) an oil core comprising a liquid phase lipid and a solid phase lipid, (b) a cationic lipid, (c) a hydrophobic surfactant, and (d) an additional surfactant. These delivery systems were previously known to be effective for intramuscular and subcutaneous vaccine administration but were not known to be suitable for intranasal vaccine administration. [0059] As discussed above, it was determined that the previously disclosed RNA/NLC vaccine delivery systems could be modified to be suitable for use in intranasal vaccine administration. It was determined that adjusting the ratio of NLC-contained-amine-group to RNA-phosphate (N/P) is an important parameter governing the size, charge, and ability of the NLC formulation to effectively protect RNA from enzymatic degradation. It was determined that the N/P ratio is one parameter to take into consideration when optimizing the vaccine to maximize efficacy in a specific application while minimizing cytotoxicity risk. In addition, it was determined that the identity of the liquid phase lipid in the oil core
of the NLC is also a factor in minimizing reactogenicity and optimizing immunogenicity, as discussed below. [0060] Using the results of experiments on NLC formulations and the composition of the RNA/NLC complexes, it was possible to adjust the composition of the NLC and the N/P ratio for the RNA vaccine and NLC delivery system to develop an RNA vaccine delivery system for effective intranasal vaccination. This delivery system yielded vaccines that showed prophylactic effects and were also surprisingly effective at preventing transmission from infected subjects to uninfected subjects. Thus, vaccines may be delivered intranasally to inoculate subjects against respiratory viruses such as, but not limited to, SARS-CoV-2 and influenza while benefitting from the known advantages in vaccine administration and efficacy exhibited by intranasal vaccine delivery. [0061] The disclosed delivery system has been shown to be effective for intranasal delivery of saRNA vaccines for COVID-19 and influenza. It is expected that the disclosed delivery system will similarly be effective for intranasal delivery of other saRNA vaccines. The disclosed NLC-based saRNA vaccine delivery system has enhanced thermostability relative to current clinical RNA vaccine formulations and allows characteristics of the vaccine nanoparticles—such as particle size, charge, and immunostimulatory characteristics—to be easily tuned to achieve effective delivery of an RNA vaccine through an intranasal route. [0062] In some implementations, the self-amplifying RNA vaccine expresses the SARS-CoV-2 S spike protein. In some other implementations, the self-amplifying RNA vaccine expresses antigens associated with the H5N1 strain of influenza or another strain of influenza. [0063] The disclosed delivery system allows intranasal administration of an alphavirus- based self-amplifying RNA vaccine using an NLC delivery system. An optimized NLC delivery system allows for safe and effective intranasal delivery of an RNA vaccine that elicits a robust mucosal immune response. Tuning the size and charge of the vaccine nanoparticle makes it possible to achieve uptake at mucosal surfaces. Further, by tuning the NLC composition for intranasal delivery, the level of immune stimulation at the site of administration may be optimized to allow for maximum vaccine immunogenicity. The vaccine nanoparticle may be delivered as a liquid or lyophilized and delivered in a powdered form. The vaccine may be delivered to subjects using a metered spray. A subject may be a human or non-human mammal.
[0064] The nanoparticle size for the RNA/NLC vaccine complex may be optimized to maximize effective delivery of RNA through the nasal mucosa. Without being bound by any specific theory, it is believed that smaller particles will be better able to cross the mucosa and thus generate a more robust mucosal immune response. Baseline immunogenicity is established by administering the RNA/NLC vaccine at the optimized size to test subjects intranasally at various doses. Additionally, immunogenicity of an intranasally-delivered RNA vaccine may be optimized by varying particle composition through different liquid oils and effective surface charge. For example, the immunostimulatory properties of the NLC vaccine carrier may be optimized by incorporation of different liquid oils and assessing their effect on vaccine immunogenicity. Without being bound by any specific theory, it is believed that for a SARS-CoV-2 RNA vaccine, using Miglyol® 810 as a liquid oil may provide superior immunostimulatory properties relative to squalene, because intranasal delivery of squalene may cause an overly strong immune response. Additionally, the effective surface charge of the vaccine particles may be varied to optimize RNA delivery. [0065] With respect to vaccination against SARS-CoV-2, the intranasally administered RNA vaccine induced systemic immunity in both the humoral and cellular compartments that rivaled intramuscular administration. Additionally, intranasal administration elicited not only robust populations of spike-responsive polyfunctional T cells in the spleen but also in the lung, demonstrating induction of key respiratory mucosal T cell populations by an RNA vaccine. Further, it was demonstrated that the disclosed system may be used as an intranasal booster of prior intramuscular vaccine-induced immunity, a common real-life scenario given the largely COVID-experienced population to whom the delivery system is expected to be used to deliver vaccines. This intranasal boost of prior intramuscular vaccine- induced immunity significantly boosted systemic responses in addition to inducing mucosal T cell populations not stimulated by intramuscular vaccine boosting. In addition, it was demonstrated that both intranasal-intranasal, intramuscular-intramuscular, and heterologous intramuscular-intranasal vaccination regimens prevented virus-associated morbidity in a hamster model and, most importantly, prevented viral transmission and development of disease in naive cagemates. [0066] A SARS-CoV-2 vaccine delivered via the disclosed delivery system elicits both robust systemic humoral immunity and spike-responsive systemic polyfunctional T cells as an intramuscular or intranasal vaccine. Delivered intranasally, it also elicits tissue-resident T cell populations within the lungs, suggesting broad T cell presence across the respiratory tract—an effect that intramuscularly delivered mRNA vaccines have been unable to induce
to date. While CD4 and CD8 T cell populations are now being recognized as a major determinant of disease progression and critical to long-lasting immunity, the main vaccines on the market elicit minimal peripheral T cell responses and negligible mucosal/respiratory T cell responses. The observed thermostability and ability to administer intranasally may make vaccines delivered using the disclosed delivery system substantially more desirable in the fight against respiratory viruses. Self-amplifying RNA/NLC vaccines delivered using the disclosed intranasal delivery system may be effective boosters to pre-existing SARS- CoV-2 immunity. RNA/NLC vaccines delivered using the disclosed intranasal delivery system outperformed an intramuscular booster, showing that the additive effect of delivering a vaccine intranasally to pre-existing systemic immune responses generated the greatest benefit of all vaccination regimens tested. [0067] The intranasal self-amplifying RNA vaccine delivered using the disclosed delivery system may be most effective as a booster dose following an intramuscular prime dose. This aligns with the results of other studies where priming an immune response with a strong intramuscular vaccine followed by intranasal vaccination is able to optimally stimulate the TRM compartment while still boosting the extant intramuscular induced immunity. It has been demonstrated that use of an identical or similar RNA vaccine product for both intramuscular and intranasal vaccination may be appropriate. This potentially eliminates many manufacturing hurdles and relies upon an already clinically tested vaccine platform technology for multiple routes of administration. It was observed that intranasal boosting outperformed intramuscular boosting, particularly in mucosal immune measures, hinting at the potential for intranasal dosing to access novel cell compartments and mechanisms. [0068] In some implementations, intranasal vaccines may be delivered using the disclosed delivery system via use of nasal spray devices. This will promote induction of immunity while avoiding toxicity and reducing heterogeneity in nasal delivery. [0069] The thermostability and concomitant stockpiling ability of the disclosed RNA/NLC vaccine platform additionally provide key attributes for rapid and widespread pandemic response. [0070] In addition to inducing potent systemic serum neutralizing antibodies, bone marrow-resident IgG-secreting cells, and robust lymphoid tissue T cell immune responses, the disclosed intranasal vaccines additionally induce robust respiratory mucosal immune responses, including SARS-CoV-2-reactive lung-resident memory and lung-homing T cell populations. As a booster following previous intramuscular vaccination, the intranasal
vaccine also elicits the development of mucosal virus-specific T cells. The intranasally administered vaccines protect hamsters from infection-associated morbidity upon viral challenge, significantly reducing viral loads and preventing challenged hamsters from transmitting virus to naive cagemates. The disclosed self-amplifying RNA vaccine’s potent systemic immunogenicity, and additional mucosal immunogenicity when delivered intranasally, may be key for combating SARS-CoV-2 and other respiratory pathogens. [0071] Intranasal SARS-CoV-2 self-amplifying RNA vaccination induces systemic and mucosal immunity in mice and prevents morbidity and blocks viral transmission in hamsters. Similar results are observed in non-human primates. [0072] The extensive biophysical characterization of differently formulated self- amplifying RNA/NLC vaccine candidates described herein demonstrates that a parameter governing the size, charge, and ability of the NLC formulation to effectively protect RNA from enzymatic degradation is the N/P ratio, or ratio of delivery NLC formulation to RNA in the complexed vaccine. It was found that enzymatic degradation occurs when the zeta potential of the vaccine is a positive value, which occurs at N/P ratios of about 3 or greater. Based on particle size analysis using DLS and NTA, it is likely that at least a small excess of NLC (i.e., NLC is not saturated with bound RNA) is necessary to confer protection to the RNA—a negative zeta potential reflects the fact that NLCs are approaching complete saturation with RNA. Therefore, the zeta potential, and thus by necessity the N/P ratio, is a parameter to take into consideration when optimizing the vaccine to maximize efficacy in a specific application while minimizing cytotoxicity risk. [0073] With respect to H5N1, the optimized self-amplifying RNA/NLC vaccine for intranasal delivery was shown to effectively induce serum neutralizing antibodies at high titer, as well as bone marrow antibody-secreting cells and both systemic and lung-resident antigen-specific polyfunctional T cell responses. It was observed that certain T-cell responses, such as CD69+ lung cells, were enhanced specifically by i.n. vaccine delivery relative to standard i.m. vaccination. It was shown that minimal reactogenicity and optimal immunogenicity are induced by an intranasal vaccine formulated at about N/P=8-10, and that use of Miglyol® 810 instead of squalene as the liquid oil component of the NLC delivery formulation both further minimizes intranasal reactogenicity and maximizes vaccine immunogenicity. [0074] The disclosed self-amplifying RNA/NLC vaccine platform represents a promising technology to combat both the existing SARS-CoV-2 pandemic and other respiratory illnesses, such as seasonal and pandemic influenza. For respiratory pathogens,
intranasal vaccination or intranasal vaccine boosting of intramuscular vaccination may help raise RNA vaccine technologies to a new level, through stimulating respiratory T cell and B cell populations and generating effector subsets within the lungs and nasal mucosa primed to respond rapidly at the first point of infection. Beyond its efficacy at stimulating TRM subsets and bolstering systemic immunity, intranasal administration may also be desirable as a needle-less delivery method with potentially higher uptake, particularly in pediatric and vaccine-hesitant populations. Altogether, the disclosed unique intranasally delivered RNA vaccine that elicits strong systemic and mucosal immunity is a promising new technology ripe for further development and application. N/P Ratio for RNA/NLC Complexes [0075] In some implementations, the RNA/NLC complex has an NLC-contained- amine-group to RNA-phosphate (N/P) ratio of at least 15. [0076] In some implementations, the RNA/NLC complex has an NLC-contained- amine-group to RNA-phosphate (N/P) ratio of at least 3. This will guarantee protection of the RNA, maintain the positive zeta potential necessary for cellular uptake, and limit the formation of very large aggregate species. [0077] In some implementations, the RNA/NLC complex has an NLC-contained- amine-group to RNA-phosphate (N/P) ratio of between about 3 and about 15. [0078] In some implementations, the RNA/NLC complex has an NLC-contained- amine-group to RNA-phosphate (N/P) ratio of between about 4 and about 14. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA- phosphate (N/P) ratio of between about 5 and about 13. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 5 and about 12. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 5 and about 11. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 6 and about 11. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 6 and about 10. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 7 and about 10. [0079] In some implementations, the RNA/NLC complex has an NLC-contained- amine-group to RNA-phosphate (N/P) ratio of between about 5 and about 10. In some
implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA- phosphate (N/P) ratio of between about 5 and about 9. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 6 and about 9. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 7 and about 9. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 8 and about 9. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 3 and about 6. In some implementations, the RNA/NLC complex has an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of between about 4 and about 7. [0080] In some implementations, the RNA/NLC complex has an NLC-contained- amine-group to RNA-phosphate (N/P) ratio of about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15. [0081] In some preferred implementations, the RNA/NLC complex has an NLC- contained-amine-group to RNA-phosphate (N/P) ratio of between about 8 and about 10. It was observed that vaccine reactogenicity is reduced for vaccines formulated at N/P of 10 and below. Effective immunogenicity was observed at N/P ratios of 8 and above. Composition of Nanostructured Lipid Carriers [0082] The composition of the NLCs may be according to the NLCs described in PCT Patent Application Publication No. WO 2022/051022, U.S. Patent Application Publication No.2020/0230056, or combinations or modifications thereof. These references are hereby incorporated herein in their entireties by reference. [0083] The NLC compositions are composed of NLC particles comprising (a) an oil core comprising a liquid phase lipid and a solid phase lipid, (b) a cationic lipid, (c) a hydrophobic surfactant, preferably a sorbitan ester (e.g., sorbitan monoester, diester, or triester), and (d) a surfactant (preferably, a hydrophilic surfactant). The NLCs typically comprise an unstructured or amorphous solid lipid matrix composed of a mixture of blended solid and liquid lipids dispersed in an aqueous phase. One or more of the surfactants may be present in the oil phase, the aqueous phase, or at the interface between the oil and aqueous phase. In certain aspects the sorbitan ester and the cationic lipid are present at the interface between the oil and aqueous phase.
Solid-Phase and Liquid-Phase Lipids [0084] The NLCs are composed of a blend of solid and liquid lipids. The liquid and solid lipids may be any lipid capable of forming an unstructured or amorphous solid lipid matrix and forming a stable composition. The weight ratio of solid to liquid may vary widely, for example from 0.1:99.9 to 99.9:0.1. In some illustrative implementations, the solid lipids are mixed with liquid lipids in a solid/liquid lipid weight ratio of from about 70:30 to about 99.9:0.1 or from about 1:10 to about 1:30. In some aspects, the solid lipids are mixed with liquid lipids in a solid/liquid lipid weight of about 1:16. [0085] The total oil core component (solid lipid + liquid oil) of the NLC-based composition or formulation is typically present in an amount from about 0.2% to about 50% (w/v). For example, the NLC may comprise from about 0.2% to about 50% (w/v) oil core component, 0.2% to about 40% (w/v) oil core component, from about 0.2% to about 30% (w/v) oil core component, from about 0.2% to about 20% (w/v) oil core component, from about 0.2% to about 15% (w/v) oil core component, from about 0.2% to about 10% (w/v) oil core component, from about 0.2% to about 9% (w/v) oil core component, from about 0.2% to about 8% (w/v) oil core component, from about 0.2% to about 7% (w/v) oil core component, from about 0.2% to about 6% (w/v) oil core component, from about 0.2% to about 5% (w/v) oil core component, from about 0.2% to about 4.3% (w/v) oil core component, from about 0.3% to about 20% (w/v) oil core component, from about 0.4% to about 20% (w/v) oil core component, from about 0.5% to about 20% (w/v) oil core component, from about 1% to about 20% (w/v) oil core component, from about 2% to about 20% (w/v) oil core component, from about 3% to about 20% (w/v) oil core component, from about 4% to about 20% (w/v) oil core component, from about 5% to about 20% (w/v) oil core component, about 0.5% (w/v) oil core component, about 1% (w/v) oil core component, about 1.5% (w/v) oil core component, about 2% (w/v) oil core component, about 2.5% (w/v) oil core component, about 3% (w/v) oil core component, about 3.5% (w/v) oil core component, about 4% (w/v) oil core component, about 4.3% (w/v) oil core component, about 5% (w/v) oil core component, or about 10% (w/v) oil core component or any other amount or range described herein for the oil core component. Higher or lower w/v percentages are contemplated herein, particularly when considering diluted or concentrated formulations. [0086] The oil core of the NLC comprises a liquid phase lipid. Preferably, although not necessarily, the liquid phase lipid is a metabolizable, non-toxic oil; more preferably one of about 6 to about 30 carbon atoms including, but not limited to, alkanes, alkenes, alkynes,
and their corresponding acids and alcohols, ethers and esters thereof, and mixtures thereof. The oil may be, for example, any vegetable oil, fish oil, animal oil, or synthetically prepared oil that can be administered to a subject. In some aspects, the liquid phase lipid will be non- metabolizable. [0087] The oil may be, for example, any long chain alkane, alkene, or alkyne, or an acid or alcohol derivative thereof either as the free acid, its salt, or an ester such as a mono-, or di- or triester, such as the triglycerides and esters of 1 ,2-propanediol or similar poly- hydroxy alcohols. Alcohols may be acylated employing a mono- or poly-functional acid, for example acetic acid, propanoic acid, citric acid, or the like. Ethers derived from long chain alcohols which are oils and meet the other criteria set forth herein may also be used. [0088] The individual alkane, alkene, or alkyne moiety and its acid or alcohol derivatives will generally have from about 6 to about 40 or from 6 to about 30 carbon atoms. The moiety may have a straight or branched chain structure. It may be fully saturated or have one or more double or triple bonds. Where mono or poly ester- or ether-based oils are employed, the limitation of about 6 to about 40 carbons applies to the individual fatty acid or fatty alcohol moieties, not the total carbon count. [0089] Any suitable oils from an animal, fish or vegetable source may be used. Sources for vegetable oils include nuts, seeds, and grains, and suitable oils include, for example, peanut oil, soybean oil, coconut oil, olive oil, and the like. Other suitable seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil, and the like. In the grain group, com oil, and the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale, and the like may also be used. The technology for obtaining vegetable oils is well developed and well known. The compositions of these and other similar oils may be found in, for example, the Merck Index, and source materials on foods, nutrition, and food technology. [0090] Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein. A number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids. Naturally occurring or synthetic terpenoids, also referred to as isoprenoids, may be used herein as a liquid phase lipid. Squalene is a branched, unsaturated terpenoid. A major source of squalene is shark liver oil, although plant oils (primarily vegetable oils), including amaranth seed, rice bran, wheat germ, and olive oils, are also suitable sources. Squalane is the saturated analog to squalene. Oils, including fish oils such as squalene and squalane, are readily available from commercial sources or may be obtained by methods known in the art.
Oils to be used herein may also be made using synthetic means, including genetic engineering (e.g., oils made from bioengineered yeast, including squalene). Synthetic squalene has been successfully produced from bioengineered yeast and exhibits immunomodulating characteristics equal to squalene obtained from sharks. See Tateno, M., et al. “Synthetic Biology-Derived Triterpenes as Efficacious Immunomodulating Adjuvants,” Sci. Rep.2020, 10, 17090. Squalene has also been synthesized by the controlled oligomerization of isoprene. See Adlington, K., et al. “Molecular Design of Squalene/Squalane Countertypes via the Controlled Oligomerization of Isoprene and Evaluation of Vaccine Adjuvant Applications,” Biomacromolecules, 2016, 17(1), 165-72. [0091] Illustrative liquid phase lipids that may be used include, for example, castor oil, coconut oil, corn oil, cottonseed oil, evening primrose oil, fish oil, grapeseed oil, jojoba oil, lard oil, linseed oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, squalane, sunflower oil, wheatgerm oil, mineral oil, capric/caprylic triglyceride (e.g., Miglyol® 810, Miglyol® 812, Labrafac™), vitamin E (e.g., TOS, TPGS), lauroyl polyoxylglycerides (e.g., Gelucire® 44/14), monoacylglycerols (e.g., Myverol 18-99K), soy lecithin (e.g., Epikuron™ 200), famesene, or a combination thereof. [0092] The liquid phase lipid may include for example, squalene, sunflower oil, soybean oil, olive oil, grapeseed oil, squalane, capric/caprylic triglyceride, or a combination thereof. [0093] The liquid phase lipid may include for example, squalene, squalene, capric/caprylic triglyceride, or a combination thereof. [0094] The liquid phase lipid may include for example, capric/caprylic triglyceride, vitamin E, lauroyl polyoxylglycerides, monoacylglycerols, soy lecithin, squalene, squalene, or a combination thereof. [0095] The liquid phase lipid can include for example, squalene, squalene, famesene, or a combination thereof. [0096] The oil core of the NLC comprises a solid phase lipid. A wide variety of solid phase lipids can be used, including for example, glycerolipids. Glycerolipids are fatty molecules composed of glycerol linked esterically to a fatty acid. Glycerolipids include triglycerides and diglycerides. [0097] Illustrative solid phase lipids include, for example, glyceryl palmitostearate (Precitol® ATO 5), glycerylmonostearate, glyceryl dibehenate (Compritol® 888 ATO), cetyl palmitate (Crodamol™ CP), stearic acid, tripalmitin, or a microcrystalline triglyceride. Illustrative microcrystalline triglycerides include those sold under the trade name Dynasan®
(e.g., trimyristin (Dynasan® 114) or tristearin (Dynasan® 118) or tripalmitin (Dynasan® 116)). [0098] The solid phase lipid may be, for example, a microcrystalline triglyceride, for example, one selected from trimyristin (Dynasan® 114) or tristearin (Dynasan® 118). [0099] Preferably, the solid phase lipid of the oil core is solid at ambient temperature. When indoors, ambient temperature is typically between 15°C and 25°C. [0100] In any of the implementations provided herein, the solid phase lipid may be a glycerolipid, for example, a microcrystalline triglyceride. [0101] In any of the implementations provided herein, the liquid phase lipid may be synthetic or naturally-occurring squalene. [0102] In some implementations, the NLC may comprise an oil selected from the group consisting of Miglyol® 810, cottonseed oil, castor oil, soybean oil, and squalene. Cationic Lipids [0103] The NLCs described herein comprise a cationic lipid. The cationic lipid is useful for interacting with negatively charged bioactive agents on the surface of the NLC. Any cationic lipid capable of interacting with negatively charged bioactive agents that will not disturb the stability of the NLC and can be administered to a subject may be used. Generally, the cationic lipid contains a nitrogen atom that is positively charged under physiological conditions. Suitable cationic lipids include, benzalkonium chloride (BAK), benzethonium chloride, cetrimide (which contains tetradecyltrimethylammonium bromide and possibly small amounts of dodecyltrimethylammonium bromide and hexadecyltrimethyl ammonium bromide), cetylpyridinium chloride (CPC), cetyl trimethylammonium chloride (CTAC), primary amines, secondary amines, tertiary amines, including but not limited to N,N’,N’- polyoxyethylene (10)-N-tallow-l,3-diaminopropane, other quaternary amine salts, including but not limited to dodecyltrimethylammonium bromide, hexadecyltrimethylammonium bromide, mixed alkyl-trimethyl-ammonium bromide, benzyldimethyldodecylammonium chloride, benzyldimethylhexadecylammonium chloride, benzyltrimethylammonium methoxide, cetyldimethylethylammonium bromide, dimethyldioctadecyl ammonium bromide (DDAB), methylbenzethonium chloride, decamethonium chloride, methyl mixed trialkyl ammonium chloride, methyl trioctylammonium chloride, N,N-dimethyl-N-[2-(2- methyl-4-(l,1,3,3-tetramethylbutyl)-phenoxy]-ethoxy)ethyl]-benzenemetha-naminium chloride (DEBDA), dialkyldimethylammonium salts, [1-(2,3-dioleyloxy)-propyl]-N,N,N- trimethylammonium chloride, l,2-diacyl-3-(trimethylammonio)propane (acyl
group=dimyristoyl, dipalmitoyl, distearoyl, dioleoyl), l,2-diacyl- 3(dimethylammonio)propane (acyl group=dimyristoyl, dipalmitoyl, distearoyl, dioleoyl), l,2-dioleoyl-3-(4’-trimethyl-ammonio)butanoyl-sn-glycerol, 1,2-dioleoyl 3-succinyl-sn- glycerol choline ester, cholesteryl (4’-trimethylammonio) butanoate), N-alkyl pyridinium salts (e.g., cetylpyridinium bromide and cetylpyridinium chloride), N-alkylpiperidinium salts, dicationic bolaform electrolytes (C12Me6; C12Bu6), dialkylglycetylphosphorylcholine, lysolecithin, L-α-dioleoylphosphatidylethanolamine, cholesterol hemisuccinate choline ester, lipopolyamines, including but not limited to dioctadecylamidoglycylspermine (DOGS), dipalmitoyl phosphatidylethanol- amidospermine (DPPES), lipopoly-L (or D)-lysine (LPLL, LPDL), poly (L (or D)-lysine conjugated to N-glutarylphosphatidylethanolamine, didodecyl glutamate ester with pendant amino group (C12GluPhCnN+), ditetradecyl glutamate ester with pendant amino group (C14GluCnN+), cationic derivatives of cholesterol, including but not limited to cholesteryl- 3-β-oxysuccinamidoethylenetrimethylammonium salt, cholesteryl-3-β- oxysuccinamidoethylenedimethylamine, cholesteryl-3-β-carboxy amidoethylenetrimethylammonium salt, cholesteryl-3-β-carboxy amidoethylenedimethylamine, and 3-γ-[N-(N’,N- dimethylaminoethanecarbomoyl]cholesterol) (DC Cholesterol), l,2-dioleoyloxy-3- (trimethylammonio)propane (DOTAP), dimethyldioctadecylammonium (DDA), 1,2- dimyristoyl-3-trimethylammonium propane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), and combinations thereof. [0104] Other cationic lipids suitable for use in the invention include, e.g., the cationic lipids described in U.S. Patent Application Publication Nos. 2008/0085870 and 2008/0057080. [0105] Other cationic lipids suitable for use in the invention include, e.g., Lipids E0001- E0118 or E0119-E0180 as disclosed in Table 6 (pp. 112-139) of PCT Patent Application Publication No. WO 2011/076807 (which also discloses methods of making and methods of using these cationic lipids). Additional suitable cationic lipids include N-[l-(2,3- dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), N,N-dioleoyl-N,N- dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium propane (DODAP), l,2-dilinoleyloxy-3- dimethylamino propane (DLinDMA).
[0106] The NLCs may comprise one or any combination of two or more of the cationic lipids described herein. [0107] In illustrative implementations, the cationic lipid is selected from the group consisting of l,2-dioleoyloxy-3-(trimethylammonio)propane (DOTAP), 313-[N-(N’,N’- dimethylaminoethane)-carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA), 1,2-dimyristoyl-3-trimethylammonium propane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), Lipids E0001-E0118 or E0119-E0180 as disclosed in Table 6 (pp. 112-139) of PCT Patent Application Publication No. WO 2011/076807, and combinations thereof. [0108] In other illustrative implementations, the cationic lipid is selected from the group consisting of l,2-dioleoyloxy-3-(trimethylammonio)propane (DOTAP), 313-[N-(N’,N’- dimethylaminoethane)-carbamoyl] cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA), 1,2-dimyristoyl-3-trimethylammonium propane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[l-(2,3-dioleyloxy)propyl]-N,N,N- trimethylammonium chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), l,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), l,2-dioleoyl-3- dimethylammonium-propane (DODAP), 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), Lipids E0001-E0118 or E0119-E0180 as disclosed in Table 6 (pp. 112-139) of PCT Patent Application Publication No. WO 2011/076807, and combinations thereof. [0109] Illustrative cationic lipids are selected from the following: l,2-dioleoyloxy-3- (trimethylammonio)propane (DOTAP), 3[3-[N-(N’,N’-dimethylaminoethane)-carbamoyl] cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA), 1,2-dimyristoyl-3- trimethylammonium propane (DMTAP), dipalmitoyl(C16:0)trimethylammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleyloxy)propyl]- N,N,N-trimethylammonium chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), l,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), l,2-dioleoyl- 3-dimethylammonium-propane (DODAP), l,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), or combinations thereof. Additional suitable cationic lipids may be known by one of skill in the art. [0110] In certain implementations, the NLC-based composition or formulation comprises from about 0.5 mg/ml to about 50 mg/ml of the cationic lipid. In certain implementations, the cationic lipid is DOTAP. The NLC may comprise, for example, from
about 0.5 mg/ml to about 25 mg/ml or 30 mg/ml DOTAP or any other amount or range described herein for DOTAP. [0111] In certain implementations, the cationic lipid is DC Cholesterol. In certain aspects, the NLC may comprise DC Cholesterol at from about 0.1 mg/ml to about 5 mg/ml DC Cholesterol. In certain implementations, the cationic lipid is DDA. The NLC may comprise, for example, from about 0.1 mg/ml to about 5 mg/ml DDA. In certain implementations, the cationic lipid is DOTMA. The NLC may comprise, for example, from about 0.5 mg/ml to about 25 or 30 mg/ml DOTMA. In certain implementations, the cationic lipid is DOEPC. The NLC may comprise, for example, from about 0.5 mg/ml to about 25 mg/ml DOEPC. In certain implementations, the cationic lipid is DSTAP. The NLC may comprise, for example, from about 0.5 mg/ml to about 50 mg/ml DSTAP. In certain implementations, the cationic lipid is DODAC. The NLC may comprise, for example, from about 0.5 mg/ml to about 50 mg/ml DODAC. In certain implementations, the cationic lipid is DODAP. The NLC may comprise, for example, from about 0.5 mg/ml to about 50 mg/ml DODAP. [0112] With respect to weight per volume, an illustrative NLC-based composition or formulation may comprise, for example, from about 0.05 % to about 5% or to about 10% w/v cationic lipid such as DOTAP, from about 0.2% to about 10% w/v cationic lipid such as DOTAP, from about 0.2% to about 5% w/v cationic lipid such as DOTAP, from about 0.2% to about 2% w/v cationic lipid such as DOTAP, from about 2% to 10% w/v cationic lipid such as DOTAP, from about 2% to about 5% w/v cationic lipid such as DOTAP, from about 1% to about 5% w/v cationic lipid such as DOTAP, from about 3% to about 5% w/v cationic lipid such as DOTAP, or from about 3% to about 4% w/v cationic lipid such as DOTAP or any other amount or range described herein for the cationic lipid. Higher or lower w/v percentages are contemplated herein, particularly when considering diluted or concentrated formulations. [0113] In some cases, it may be desirable to use a cationic lipid that is soluble in the oil core. For example, DOTAP DOEPC, DODAC, and DOTMA are soluble in squalene or squalane. In other cases, it may be desirable to use a cationic lipid that is not soluble in the oil core. For example, DDA and DSTAP are not soluble in squalene. It is within the knowledge in the art to determine whether a particular lipid is soluble or insoluble in the oil and choose an appropriate oil and lipid combination accordingly. For example, solubility can be predicted based on the structures of the lipid and oil (e.g., the solubility of a lipid may be determined by the structure of its tail). For example, lipids having one or two
unsaturated fatty acid chains (e.g., oleoyl tails), such as DOTAP, DOEPC, DODAC, DOTMA, are soluble in squalene or squalene, whereas lipids having saturated fatty acid chains (e.g., stearoyl tails) are not soluble in squalene. Alternatively, solubility can be determined according to the quantity of the lipid that dissolves in a given quantity of the oil to form a saturated solution). [0114] The NLC may comprise additional lipids (i.e., neutral and anionic lipids) in combination with the cationic lipid so long as the net surface charge of the NLC prior to mixing with the bioactive agent is positive. Methods of measuring surface charge of a NLC are known in the art and include for example, measurement by Dynamic Light Scattering (DLS), Photon Correlation Spectroscopy (PCS), or gel electrophoresis. Hydrophobic Surfactants [0115] The NLC further includes a hydrophobic surfactant, preferably a sorbitan ester. The term “sorbitan ester” as used herein refers to an ester of sorbitan. Sorbitan is as shown in Formula A:
Formula A [0116] Suitable sorbitan esters are sorbitan alkyl esters, wherein the alkyl is a C1-C30 alkyl group, preferably a saturated or unsaturated C1-C20 alkyl group, more preferably a saturated or unsaturated C10-C20 alkyl group. [0117] It was previously discovered that the immune response to encoded proteins in a bioactive nucleic acid may be modulated by selection of sorbitan ester used in the NLC. It was surprisingly discovered that use of a sorbitan monoester was particularly effective at enhancing the effectiveness of the NLC. In some aspects, the acyl chain of the sorbitan monoester is saturated. In addition, without being bound by any specific theory, it was surprisingly discovered that the sorbitan ester, and in particular, sorbitan monoester, acts in combination with the solid lipid (e.g., microcrystalline triglycerides) to enhance the effectiveness of the adjuvant activity of the NLC (e.g., in eliciting antibodies to an antigen in a subject where the bioactive agent is an antigen or encodes antigen and the composition is administered to a subject).
[0118] Illustrative sorbitan monoesters are commercially available under the tradenames Span® or Arlacel®. An illustrative sorbitan monoester for use herein may be represented as a compound of Formula I or a stereoisomer thereof (including, but not limited to, Formula Ia, Ib, Ic, or Id) wherein R is a saturated or unsaturated C1-C30 alkyl group, preferably a saturated or unsaturated C1-C20 alkyl group, and more preferably a saturated or unsaturated C10-C20 alkyl group. In illustrative implementations, the alkyl group is non- cyclic. Illustrative sorbitan monoesters also include positional isomers of Formulas I, Ia, Ib, Ic or Id (e.g., one of the hydroxy functional groups is replaced by an ester functional group (e.g., an alkyl ester wherein the alkyl is a saturated or unsaturated C1-C30 alkyl group, preferably a saturated or unsaturated C1-C20 alkyl group, and more preferably a saturated or unsaturated C10-C20 alkyl group, and R is OH). The skilled artisan will appreciate that illustrative sorbitan monoesters may be salt forms (e.g., pharmaceutically acceptable salts) of Formulas I, Ia, Ib, Ic, Id, and stereoisomers or positional isomers thereof.
Formula Ic Formula Id [0119] Suitable sorbitan monoesters in this regard are sorbitan monostearate (also known as Span® 60 and shown below) and sorbitan monooleate (also known as Span® 80 and shown below), although other sorbitan monoesters can be used (including, but not limited to, sorbitan monolaurate (Span® 20) and sorbitan monopalmitate (Span® 40)). Illustrative sorbitan monostearate is represented by Formula II or IIa or a salt form thereof and illustrative sorbitan monooleate is represented by Formula III or IIIa or a salt form thereof.
[0120] In addition to providing sorbitan monoesters as a component of the NLC, also contemplated is the substitution of the sorbitan monoester for an alternative hydrophobic surfactant, including alternative sorbitan-based non-ionic surfactants. Accordingly, also provided herein are NLC particles comprising an oil core comprising a liquid phase lipid and a solid phase lipid, a cationic lipid, a hydrophobic surfactant (e.g., non-ionic surfactants including sorbitan-based non-ionic surfactants) and a hydrophilic surfactant. Sorbitan-based non-ionic surfactants include sorbitan esters other than sorbitan monoesters, for example sorbitan diesters and sorbitan triesters, such as for example, sorbitan trioleate (Span 85™) and sorbitan tristearate (Span 65™). Generally, the non-ionic surfactant (including sorbitan- based non-ionic surfactants) will have a hydrophilic-lipophilic balance (HLB) number between 1.8 to 8.6. All of the implementations provided herein for the NLCs comprising a sorbitan monoester are applicable and contemplated for the NLCs comprising an alternative hydrophobic surfactant in place of the sorbitan monoester, e.g., NLCs comprising a sorbitan diester or triester in place of the sorbitan monoester. The sorbitan diester and triester or other hydrophobic surfactant may be present in the same concentrations as the sorbitan monoester. In some aspects, the acyl chains of the sorbitan diester or triester will be saturated. [0121] Generally, the sorbitan esters (e.g., sorbitan monoesters) have a hydrophilic- lipophilic balance (HLB) value from 1 to 9. In some implementations, the sorbitan esters
(e.g., sorbitan monoesters) have an HLB value from 1 to 5. In some implementations, the hydrophobic surfactant has an HLB value from about 4 to 5. [0122] An illustrative sorbitan diester for use herein may be represented as a compound of Formula IV below or a stereoisomer thereof (e.g., wherein R is a saturated or unsaturated C1-C30 alkyl group, preferably a saturated or unsaturated C1-C20 alkyl group, and more preferably a saturated or unsaturated C10-C20 alkyl group, and at least one of R1 is H while the other is -C(=O)Y wherein Y is a saturated or unsaturated C1-C30 alkyl group, preferably a saturated or unsaturated C1-C20 alkyl group, and more preferably a saturated or unsaturated C10-C20 alkyl group). In illustrative implementations, the alkyl group is non- cyclic. Illustrative sorbitan diesters also include positional isomers of Formulas IV. The skilled artisan will appreciate that illustrative sorbitan diesters may be salt forms (e.g., pharmaceutically acceptable salts) of Formula IV and stereoisomers or positional isomers thereof.
[0123] An illustrative sorbitan triester for use herein may be represented as a compound of Formula V below or a stereoisomer thereof (including, but not limited to, Formula Va, Vb, or Vc) wherein R is a saturated or unsaturated C1-C30 alkyl group, preferably a saturated or unsaturated C1-C20 alkyl group, and more preferably a saturated or unsaturated C10-C20 alkyl group, and R1 is -C(=O)Y wherein Y may be the same or different in each instance and is a saturated or unsaturated C1-C30 alkyl group, preferably a saturated or unsaturated Cl- C20 alkyl group, and more preferably a saturated or unsaturated C10-C20 alkyl group. In illustrative implementations, the alkyl group is non-cyclic. Illustrative sorbitan triesters also include positional isomers of Formulas V, Va, Vb, or Vc (e.g., the hydroxy functional group is replaced by an ester functional group (e.g., an alkyl ester wherein the alkyl is a saturated or unsaturated C1-C30 alkyl group, preferably a saturated or unsaturated C1-C20 alkyl group, and more preferably a saturated or unsaturated C10-C20 alkyl group) and one of the alkyl esters (e.g., a ring alkyl ester or non-ring alkyl ester) is replaced by a hydroxy functional group). The skilled artisan will appreciate that illustrative
sorbitan triesters may be salt forms (e.g., pharmaceutically acceptable salts) of Formulas V, Va, Vb, or Vc or stereoisomers or positional isomers thereof.
[0124] With respect to stereoisomers, the skilled artisan will understand that the sorbitan esters may have chiral centers and may occur, for example, as racemates, racemic mixtures, or as individual enantiomers and diastereomers. [0125] In implementations wherein the sorbitan-based non-ionic surfactant is a sorbitan ester, typically, the NLC-based composition or formulation typically contains, for example, from about 0.1% to about 15% sorbitan ester (w/v), 0.1% to about 10% sorbitan ester (w/v), from 0.1% to about 5% sorbitan ester (w/v), about 0.1% to about 4 % sorbitan ester (w/v), about 0.1% to about 4% sorbitan ester (w/v), about 0.1% to about 2.5% sorbitan ester (w/v), about 0.1% to about 2% sorbitan ester (w/v), 0.1% to about 1.5% sorbitan ester (w/v), 0.1% to about 1% sorbitan ester (w/v), 0.1% to about 0.5% sorbitan ester (w/v), 0.3% to about 2.5% sorbitan ester (w/v), about 0.3% to about 2% sorbitan ester (w/v), 0.3% to about 1.5% sorbitan ester (w/v), 0.3% to about 1% sorbitan ester (w/v), 0.3% to about 0.5% sorbitan ester (w/v), or any other amount or range described herein for a sorbitan ester, including from about 0.25 % to about 15% sorbitan ester. In some aspects, the NLC-based compositions contain about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or about 4% (w/v) sorbitan ester. Higher or lower w/v percentages are contemplated herein, particularly when considering diluted or concentrated formulations. [0126] Accordingly, when the sorbitan ester is a sorbitan monoester (e.g., Span 60™, Span 80™), the NLC-based composition or formulation typically contains, for example, from about 0.1% to about 15% sorbitan monoester (w/v), 0.1% to about 10% sorbitan monoester (w/v), from 0.1% to about 5% sorbitan monoester (w/v), about 0.1% to about 4 % sorbitan monoester (w/v), about 0. 1% to about 4% sorbitan monoester (w/v), about 0.
1% to about 2.5% sorbitan monoester (w/v), about 0. 1% to about 2% sorbitan monoester (w/v), 0.1% to about 1.5% sorbitan monoester (w/v), 0.1% to about 1% sorbitan monoester (w/v), 0. 1% to about 0.5% sorbitan monoester (w/v), 0.3% to about 2.5% sorbitan monoester (w/v), about 0.3% to about 2% sorbitan monoester (w/v), 0.3% to about 1.5% sorbitan monoester (w/v), 0.3% to about 1% sorbitan monoester (w/v), 0.3% to about 0.5% sorbitan monoester (w/v), or any other amount or range described herein for sorbitan monoester, including from about 0.25 % to about 15% sorbitan monoester. In some aspects, the NLC-based composition or formulation contains about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1%, about 2%, about 3% or about 4% (w/v) sorbitan monoester. Higher or lower w/v percentages are contemplated herein, particularly when considering diluted or concentrated formulations. [0127] Accordingly, when the sorbitan ester is a sorbitan diester, the NLC-based composition or formulation typically contains, for example, from about 0.1% to about 15% sorbitan diester (w/v), 0.1% to about 10% sorbitan diester (w/v), from 0.1% to about 5% sorbitan diester (w/v), about 0.1% to about 4 % sorbitan diester (w/v), about 0.1% to about 4% sorbitan diester (w/v), about 0.1% to about 2.5% sorbitan diester (w/v), about 0.1% to about 2% sorbitan diester (w/v), 0.1% to about 1.5% sorbitan diester (w/v), 0.1% to about 1% sorbitan diester (w/v), 0.1% to about 0.5% sorbitan diester (w/v), 0.3% to about 2.5% sorbitan diester (w/v), about 0.3% to about 2% sorbitan diester (w/v), 0.3% to about 1.5% sorbitan diester (w/v), 0.3% to about 1% sorbitan diester (w/v), 0.3% to about 0.5% sorbitan diester (w/v), or any other amount or range described herein for sorbitan diester, including from about 0.25 % to about 15% sorbitan diester. In some aspects, the NLC-based composition or formulation contains about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or about 4% (w/v) sorbitan diester. Higher or lower w/v percentages are contemplated herein, particularly when considering diluted or concentrated formulations. [0128] Accordingly, when the sorbitan ester is a sorbitan triester (e.g., Span 85™ or Span 65™), the NLC-based composition or formulation typically contains, for example, from about 0.1% to about 15% sorbitan triester (w/v), 0.1% to about 10% sorbitan triester (w/v), from 0.1% to about 5% sorbitan triester (w/v), about 0. 1% to about 4 % sorbitan triester (w/v), about 0. 1% to about 4% sorbitan triester (w/v), about 0. 1% to about 2.5% sorbitan triester (w/v), about 0.1% to about 2% sorbitan triester (w/v), 0.1% to about 1.5% sorbitan triester (w/v), 0.1% to about 1% sorbitan triester (w/v), 0.1% to about 0.5% sorbitan
triester (w/v), 0.3% to about 2.5% sorbitan triester (w/v), about 0.3% to about 2% sorbitan triester (w/v), 0.3% to about 1.5% sorbitan triester (w/v), 0.3% to about 1% sorbitan triester (w/v), 0.3% to about 0.5% sorbitan triester (w/v), or any other amount or range described herein for sorbitan triester, including from about 0.25 % to about 15% sorbitan triester. In some aspects, the NLC-based composition or formulation contains about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, or about 4% (w/v) sorbitan tri ester. Higher or lower w/v percentages are contemplated herein, particularly when considering diluted or concentrated formulations. [0129] In illustrative implementations, the sorbitan ester (e.g., sorbitan monoester, diester, or triester) is present in an amount sufficient to increase the ability of the composition to facilitate delivery and/or expression of RNA as compared to a comparable composition lacking the sorbitan ester (e.g., sorbitan monoester, diester, or triester respectively). In implementations where the composition is administered to the subject in an effective amount, the composition may elicit antibody titers to the antigen equal to or greater than the antibody titers elicited when a comparable composition lacking the sorbitan ester is administered to the subject or when the RNA is administered to the subject without the NLC. In some implementations, the composition induces an immune response (e.g., neutralizing antibody titers) in the subject at a higher level than the immune response induced in the subject by a comparable composition lacking the sorbitan ester. Surfactants [0130] The NLCs comprise a surfactant, in addition to the sorbitan-based non-ionic surfactants (e.g., sorbitan ester). There are a number of surfactants specifically designed for and commonly used in biological applications. Such surfactants are divided into four basic types: anionic, cationic, zwitterionic, and non-ionic. A particularly useful group of surfactants are the hydrophilic non-ionic surfactants and, in particular, polyoxyethylene sorbitan monoesters, and polyoxyethylene sorbitan triesters. These materials are referred to as polysorbates and are commercially available under the mark Tween® and are useful for preparing the NLCs. Tween® surfactants generally have an HLB value falling between 9.6 to 16.7. Tween® surfactants are commercially available. Other non-ionic surfactants which may be used include, for example, polyoxyethylene fatty acid ethers derived from lauryl, acetyl, stearyl, and oleyl alcohols, polyoxyethylene fatty acids made by the reaction of ethylene oxide with a long-chain fatty acid, polyoxyethylene, polyol fatty acid esters,
polyoxyethylene ether, polyoxypropylene fatty ethers, bee’s wax derivatives containing polyoxyethylene, polyoxyethylene lanolin derivatives, polyoxyethylene fatty glycerides, glycerol fatty acid esters or other polyoxyethylene fatty acids, alcohol or ether derivatives of C12-C22 long-chain fatty acids. [0131] In some implementations, it is preferable to choose a non-ionic surfactant which has an HLB value in the range of about 7 to 16. This value may be obtained through the use of a single non-ionic surfactant such as a Tween® surfactant or may be achieved by the use of a blend of surfactants. In certain implementations, the NLC comprises a single non-ionic surfactant, most particularly a Tween® surfactant, as the emulsion stabilizing non-ionic surfactant. In an illustrative implementation, the emulsion comprises Tween® 80, otherwise known as polysorbate 80. [0132] The NLC-based composition or formulation may contain, for example, from about 0.01% to about 15% surfactant (w/v), from about 0.01% to about 10% surfactant (w/v), from about 0.01% to about 5% surfactant (w/v), about 0.01% to about 2.5% surfactant, about 0.01% to about 2% surfactant, 0.01% to about 1.5% surfactant, 0.01% to about 1% surfactant, 0.01% to about 0.5% surfactant, 0.05% to about 0.5% surfactant, 0.08% to about 0.5% surfactant, about 0.08% surfactant, about 0.5% surfactant, about 0.6% surfactant, about 0.7% surfactant, about 0.8% surfactant, about 0.9% surfactant, about 1% surfactant, about 2%, about 3%, about 4 % surfactant, or any other amount or range described herein for the surfactant. Higher or lower w/v percentages are contemplated herein, particularly when considering diluted or concentrated formulations. Optional Components [0133] Additional components may be included in the NLCs including, for example, components that promote NLC formation, improve the complex formation between the negatively charged molecules and the cationic particles, facilitate appropriate release of negatively charged RNA molecules and/or increase the stability of negatively charged RNA molecules (e.g., to prevent degradation of the RNA). [0134] The aqueous phase (continuous phase) of the NLCs is typically a salt solution (e.g., saline) or water. The salt solution is typically an aqueous solution that comprises a salt (e.g., sodium citrate), and may further comprise, for example, a buffer (e.g., a citrate buffer), an osmolality adjusting agent (e.g., a saccharide), a polymer, a surfactant, or a combination thereof. It may be preferable to maintain a pH compatible with normal physiological conditions. Also, in certain instances, it may be desirable to maintain the pH at a particular
level to ensure the stability of certain components of the NLC. For example, it may be desirable to prepare a NLC that is isotonic (i.e., the same permeable solute (e.g., salt) concentration as the normal cells of the body and the blood) and isosmotic. To control tonicity, the NLC may comprise a physiological salt, such as a sodium salt. In some aspects, sodium chloride (NaCl), for example, may be used at about 0.9% (w/v) (physiological saline). Other salts that may be present include, for example, potassium chloride, potassium dihydrogen phosphate, disodium phosphate, magnesium chloride, calcium chloride, and the like. Non-ionic tonicifying agents may also be used to control tonicity. Monosaccharides classified as aldoses such as glucose, mannose, arabinose, and ribose, as well as those classified as ketoses such as fructose, sorbose, and xylulose may be used as non-ionic tonicifying agents. Disaccharides such a sucrose, maltose, trehalose, and lactose may also be used. In addition, alditols (acyclic polyhydroxy alcohols, also referred to as sugar alcohols) such as glycerol, mannitol, xylitol, and sorbitol are non-ionic tonicifying agents that may be used. Non-ionic tonicity modifying agents may be present, for example, at a concentration of from about 0.1% to about 10% or about 1% to about 10%, depending upon the agent that is used. [0135] The aqueous phase may be, but is not necessarily, buffered. Any physiologically acceptable buffer that provides adequate protection for the RNA may be used herein, such as water, citrate buffers, phosphate buffers, acetate buffers, tris buffers, bicarbonate buffers, carbonate buffers, succinate buffer, or the like. The pH of the aqueous component will preferably be between 4.0-8.0 or from about 4.5 to about 6.8. In another illustrative implementation, the aqueous phase is, or the buffer is prepared using, RNase-free water or DEPC treated water. In some cases, high salt in the buffer may interfere with complexation of the negatively RNA charged molecule to the emulsion particle and therefore is avoided. In other cases, a certain amount of salt in the buffer may be included. [0136] In an illustrative implementation, the aqueous solution is sodium citrate with a pH between about 5.0 and 8.0. The sodium citrate solution may have a concentration of between 1-20 mM such as, 5 mM, 10 mM, 15 mM, or 20 mM. In another illustrative implementation, the aqueous phase is, or the buffer is prepared using, RNase-free water or DEPC treated water. [0137] The aqueous phase may also comprise additional components such as molecules that change the osmolarity of the aqueous phase or molecules that stabilize the negatively charged molecule after complexation. Preferably, the osmolarity of the aqueous phase is adjusting using a non-ionic tonicifying agent, such as a sugar (e.g., trehalose, sucrose,
dextrose, fructose, reduced palatinose, or the like), a sugar alcohol (e.g., mannitol, sorbitol, xylitol, erythritol, lactitol, maltitol, glycerol, or the like), or combinations thereof. If desired, a non-ionic polymer (e.g., a poly(alkyl glycol) such as polyethylene glycol, polypropylene glycol, or polybutylene glycol) or nonionic surfactant may be used. [0138] Excipients may be used singly or in combination with other excipients which include, but are not limited to, cake-forming excipients, cake-forming bulking agents, bulking agents, buffering agents, chelating agents, solubilizing agents, isotonicity agents, tonicifying agents, surfactants, emulsifiers, antimicrobial agents, and/or collapse temperature modifiers. [0139] The excipients are substances other than a bioactive agent, which are included in the manufacturing process, or fill-finish process for storage or shipment of the composition including, without limitation, lyophilization, and are contained in a finished vaccine platform or vaccine. An excipient is a substance added to a liquid stable oil-in-water emulsion formulation prior to lyophilization which yields a cake following lyophilization. [0140] Excipients suitable for vaccine formulations and/or lyophilization are known in the art. See, e.g., Bahetia, A., et al. “Excipients Used in Lyophilization of Small Molecules,” J. Excip. Food Chem. 2010, 1(1), 41-54; Grabenstein, J. D. ImmunoFacts: Vaccines and Immunologic Drugs, 2012 (8th ed.), Wolters Kluwer Health. These include cake-forming excipients, cake- forming bulking agents, chelating agents, bulking agents, buffering agents, solubilizing agents, isotonicity agents, tonicifying agents, surfactants, emulsifiers, antimicrobial agents, and/or collapse temperature modifiers. Excipients in approved vaccines include without limitation sucrose, D-mannose, D-fructose, dextrose, potassium phosphate, plasdone C, anhydrous lactose, micro crystalline cellulose, polacrilin potassium, magnesium stearate, cellulose acetate phthalate, alcohol, acetone, castor oil, FD&C Yellow aluminum lake dye, human serum albumin, fetal bovine serum, sodium bicarbonate, human-diploid fibroblast cell cultures (WI-38), Dulbecco’s Modified Eagle’s Medium, aluminum hydroxide, benzethonium chloride, formaldehyde, gluteraldehyde, amino acids, vitamins, inorganic salts, sugars, glycerin, asparagine, citric acid, potassium phosphate, magnesium sulfate, iron ammonium citrate, lactose, aluminum potassium sulfate, aluminum hydroxyphosphate, potassium aluminum sulfate, peptone, bovine extract, thimerosal (trace), modified Mueller and Miller medium, beta-propiolactone, thimerosol (multi-dose vials only), monobasic sodium phosphate, dibasic sodium phosphate, monobasic potassium phosphate, potassium chloride, potassium glutamate, calcium chloride, sodium taurodeoxy
cholate, neomycin sulfate, polymyxin B, egg protein, lactalbumin hydrolysate, and neomycin sulfate. [0141] A cake-forming excipient is a substance added to a liquid stable oil-in-water emulsion formulation prior to lyophilization which yields a cake following lyophilization. Upon reconstitution of the lyophilized cake, an oil-in-water stable emulsion forms which is suitable for delivery of a pharmacologically active drug. In some implementations, cake- forming excipients are those substances which do not disrupt an emulsion upon reconstitution of the cake. In some implementations the agents useful as cake-forming excipients, also referred to as bulking agents, include sugars/saccharides or sugars/saccharides in combination with sugar alcohols. In some implementations disclosed herein, the sugars/saccharides or sugars/saccharides in combination with sugar alcohols are useful as bulking agents or cake-forming excipients include, but are not limited to, trehalose, dextrose, lactose, maltose, sucrose, raffinose, mannose, stachyose, fructose, lactulose, glucose, glycerol, sorbitol, and/or mannitol. In one implementation, the cake-forming excipient is sucrose. In one implementation, the cake-forming excipient is trehalose. [0142] In some implementations, the cake-forming excipient is a saccharide and the saccharide is present in the NLC formulation prior to lyophilization at a concentration range of about 5% w/v to about 22% w/v, about 5% to about 20%, about 5% w/v to about 18% w/v, about 8% w/v to about 15% w/v, or about 9% w/v to about 11% w/v. In some implementations, the saccharide is present in the NLC formulation prior to lyophilization a concentration of about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%. [0143] In some implementations, the compositions comprise a buffering agent. Buffering agents useful as excipients include tris acetate, tris base, tris-HCl, ammonium phosphate, citric acid, sodium citrate, potassium citrate, tartic acid, sodium phosphate, zinc chloride, arginine, and histidine. Concentration of the buffering agents may range between 1-20 mM such as, for example 5 mM, 10 mM, or 20 mM. In some implementations buffering agents include pH adjusting agents such as hydrochloric acid, sodium hydroxide, and meglumine. [0144] Chelating agents such as ethylenediaminetetraacetic acid (EDTA) may be present at concentrations of between about 0.1-1 mM.
Oil/Surfactant Ratios [0145] Illustrative NLCs are composed of a hydrophobic core containing the liquid oil and solid lipid, and surfactants (also known as emulsifiers or emulsifying agents) that make up the interface separating the hydrophobic phase—liquid oil and solid lipid, collectively referred to here as oil—from the aqueous phase. Since surfactants typically reside on the surface of NLC nanoparticles, their amount dictates the total available surface area. On the other hand, the oil resides in the core and primarily contributes to the total available volume. Increasing the surfactant to oil ratio consequently increases the surface area (SA) to volume ratio (V); thus, for a fixed volume of material, increasing the SA/V ratio translates to reducing NLC particle diameter. Instead of, or in addition to, describing illustrative NLC compositions in terms of the w/v percentages of various components, they can be described by the molar ratios of various components. In some aspects, illustrative NLCs have an oil to surfactant molar ratio of from about 0.05 to about 12 or from about 0.05 to about 9 or from about 0.05 to about 8 or from about 0.05 to about 1 or from about 0.1 to about 1. By reducing the oil to surfactant molar ratio, smaller NLCs may be synthesized. In addition, by reducing the amount of oil in the NLCs, potential toxicity of the formulations may be reduced. In other aspects, illustrative NLCs have an oil to surfactant molar ratio of from about 0.5 to about 12, from about 0.5 to about 9, from 1 to about 9, from about 2 to about 9, from about 3 to about 9, from about 4 to about 9, from about 4.5 to about 9, or from about 4.5 or about 5 to about 7. Illustrative formulations have an oil to surfactant molar ratio of about 0.5, about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12. As used herein, the oil to surfactant molar ratio is determined by (i) adding the moles of lipid that make up the oil core (solid phase lipid and liquid phase lipid) to arrive at a value for moles of oil core lipid (ii) adding the moles of the cationic lipid (e.g., DOTAP), hydrophobic surfactant (e.g., sorbitan ester) and hydrophilic surfactant (e.g., Tween® 80) to arrive at a value for moles surfactant, and (iii) dividing moles of oil core lipid by moles of surfactant. Hydrophilic Surfactant/Cationic Lipid Ratios [0146] The ratio of hydrophilic surfactant to cationic lipid may impact the ability of the NLC to have a protective effect from RNase degradation and may impact the immunogenicity of the formulations. In particular, hydrophilic surfactant/cationic lipid ratios at about 0.6 are beneficial for obtaining consistent results for delivery and expression of RNA bioactive agents whereas hydrophilic surfactant/cationic lipid ratios at about 2.0
and higher are not as beneficial for obtaining such consistency. Accordingly, illustrative NLCs have a hydrophilic surfactant/cationic lipid ratio of from about 0.2 to about 1.5, from about 0.2 to about 1, or from about 0.5 to about 1. When Tween and DOTAP are in the composition, illustrative NLCs have a Tween/DOTAP ratio of from about 0.2 to about 1.5, from about 0.2 to about 1, or from about 0.5 to about 1. As used herein, the hydrophilic surfactant: cationic lipid ratio is determined by (i) adding the moles of hydrophilic surfactant to arrive at a value for moles of hydrophilic surfactant, (ii) adding the moles of the cationic lipid to arrive at a value for moles of cationic lipid, and (iii) dividing moles of hydrophilic surfactant by moles of cationic lipid. Loading Capacities [0147] The loading capacity of the NLC formulations may be manipulated by modulating the ratio of hydrophilic surfactant to cationic lipid and the amount of oil present in the formulations, thereby reducing the average NLC particle size. Illustrative NLC formulations have loading capacity for RNA of at least about 10 pg/ml RNA, at least about 20 pg/ml RNA, at least about 50 pg/ml RNA, at least about 100 pg/ml RNA, at least about 200 pg/ml RNA, at least about 300 pg/ml, or at least about 400 pg/ml RNA. NLC formulations having an average particle size of from 20 nm to about 110 nm, from about 20 nm to about 80 nm, from about 20 nm to about 70 nm, and from about 20 nm to about 60 nm typically have increased loading capacity. Persons of ordinary skill in the art will appreciate how to adjust the NLC formulation to achieve a desired loading capacity. Examples of NLC Formulations [0148] In some implementations, the NLC may comprise about 3.75% w/v GMP shark squalene, about 0.24% w/v Dynasan® 114, about 3.00% w/v DOTAP (1,2-dioleoyl-3- trimethylammonium propane), about 3.70% w/v Span® 60, about 3.70% Tween® 80, and about 10 mM sodium citrate. [0149] In some alternate preferred implementations, the NLC may preferably comprise Miglyol® 810. [0150] In some other alternate implementations, the NLC may comprise any of the NLC formulations described in U.S. Patent Application Publication No. 2020/0230056, filed on December 13, 2019 and entitled “Nanostructured Lipid Carriers and Stable Emulsions and Uses Thereof.” In other alternate implementations, the NLC may comprise any of the NLC formulations described in U.S. Patent Application Serial No.63/144169, filed on February
1, 2021 and entitled “A Thermostable, Flexible RNA Vaccine Delivery Platform For Pandemic Response.” Both of these references are incorporated herein in their entireties by reference. EXPERIMENTAL RESULTS AND METHODS SARS-CoV-2 Studies [0151] Without being bound by any specific theory, it is believed that mucosal immune responses are important to improving sustained, potent immunity to SARS-CoV-2 and other respiratory pathogens. Unlike i.m. administered vaccines, i.n. vaccines induce critical immune cells within the mucosa and respiratory tract, generating IgA-secreting cells as well as specific effector cell subsets, including TRM cells that are maintained within the lung. Such mucosal immunity, mediated by IgA antibodies and lung-resident memory T and B cells, can prevent early-stage infection and viral replication and shedding, minimizing chances for viral transmission. Effective i.n. vaccines can also induce cross-reactive antibodies and thus provide expanded protection to multiple strains. Intranasal vaccination also presents many other advantages, such as easier needle-free administration, higher patient compliance, simpler pediatric dosing, and easier storage and transport, and thus potentially increased vaccine uptake. However, while several i.n. vaccines are currently under development for SARS-CoV-2, most of these rely on older vaccine technologies, i.e., live-attenuated viruses and viral vectors, creating a slow pathway to manufacturing, testing, and licensing. Fortunately, bridging RNA vaccine technologies to i.n. delivery is possible, combining the production speed of RNA vaccines with the mucosal immune stimulation of i.n. vaccines. [0152] It was observed that both i.n. and i.m. administrations of self-amplifying RNA SARS-CoV-2 vaccine delivered via the disclosed vaccine delivery system strongly induce systemic immunity in preclinical models and prevent viral transmission by vaccinated, virally-challenged hamsters. Intranasal dosing uniquely induces strong mucosal T cell immunity, and a heterologous dosing strategy—i.m. prime followed by i.n. boosting— appears to show the greatest potential to maximize mucosal and systemic immunity, leading to prevention of viral transmission. The self-amplifying RNA/NLC vaccine delivered via the disclosed delivery system combines the flexibility and manufacturability of RNA vaccines with potent induction of mucosal immunity using a thermostable formulation that represents a significant new tool for current and future pandemic responses.
RESULTS [0153] The previously developed long-term thermostable SARS-CoV-2 self-amplifying RNA/NLC vaccine, see Voigt, E. A., et al. “A Self-Amplifying RNA Vaccine against COVID-19 with Long-Term Room-Temperature Stability,” npj Vaccines, 2022, 7, 1-13, was used to develop an intranasally delivered self-amplifying RNA vaccine against SARS- CoV-2. This vaccine contains a codon-optimized Wuhan-strain D614G SARS-CoV-2 spike protein sequence driven by a Venezuelan equine encephalitis virus (VEEV)-based replicon, as shown in FIG. 1A. This self-amplifying RNA is complexed to the exterior of an NLC nanoparticle to create the final vaccine product, as shown in FIG.1B. Intranasal Self-Amplifying RNA/NLC Vaccine Induces Antibody Generation [0154] C57Bl/6 mice were immunized intranasally with the optimized SARS-CoV-2 self-amplifying RNA/NLC vaccine and immunogenicity was evaluated relative to a traditional intramuscularly-administered SARS-CoV-2 vaccine. [0155] A self-amplifying RNA vaccine expressing the SARS-CoV-2 S spike protein, as illustrated in FIG. 1, was complexed with a nanostructured lipid carrier comprising 3.75% w/v GMP shark squalene, 0.24% w/v Dynasan 114, 3.00% w/v DOTAP (1,2-dioleoyl-3- trimethylammonium-propane), 3.70% w/v Span 60, 3.70% Tween 80, and 10 mM sodium citrate. The complex had an NLC-contained-amine-group to RNA-phosphate (N/P) ratio of 15, creating vaccine nanoparticles in a liquid solution of 5 mM citrate, 10% sucrose for isotonicity. [0156] A prime dose was administered intranasally to C57Bl/6 mice (n=6) with a prime dose of 5 µg RNA per mouse delivered in a 20 µl volume (10 µl/nare, 6 mice total) or i.m. (20 µl 1x i.m. injection, 2 control mice). Dosing was performed using standard techniques. The mice were lightly anesthetized using isoflurane, breathing was monitored, and the liquid vaccine droplet was pipetted in front of a nostril just before the mouse was about to breathe—at which point the droplet was inhaled by the mouse via its nose. This was then repeated for the second nostril. [0157] The mice were given a boost dose of 12 µg RNA/mouse administered intranasally in 50 µl (25 µl per nare, 6 mice total) or i.m. (50 µl 1x i.m. injection, 2 control mice) 21 days post-prime.
[0158] Mouse serum samples were taken from all eight mice 14 days post-boost and tested for SARS-CoV-2 binding and neutralizing antibodies, as shown in FIGS. 2 and 3 respectively. Intranasal Self-Amplifying RNA/NLC Vaccine Stimulates Robust Systemic Immune Responses [0159] To investigate the ability of the self-amplifying RNA/NLC vaccine to generate effective immunogenicity when delivered intranasally, 6–8-week-old C57BL/6J mice were given prime and boost vaccine doses of 1, 5, or 10 µg, 3 weeks apart. Control mice were i.n. dosed with 10 µg of a non-immunogenic self-amplifying RNA/NLC expressing the reporter protein secreted alkaline phosphatase 2 (SEAP). Systemic immunogenicity was compared between groups. Serum, bone marrow, lung, and spleen tissues were harvested after vaccination and tested for humoral (serum IgG and pseudovirus neutralization titers; bone marrow antibody-secreting cells [ASCs] by enzyme-linked immunospot [ELISpot]) and cellular (systemic T cell responses by intracellular cytokine staining and flow cytometry [ICS-flow] and T cell ELISpot of splenocytes; mucosal T cell responses by ICS-flow of lungs) vaccine-induced SARS-CoV-2-directed immune responses. [0160] As shown in FIG. 4, systemic immunogenicity of intranasally administered SARS-CoV-2 saRNA/NLC vaccine was assessed. [0161] The i.n. self-amplifying RNA/NLC vaccine elicited high serum spike-specific IgG and SARS-CoV-2 Wuhan-strain neutralization titers that would be predicted to be protective (>1000 IC50) at all i.n. doses after prime and boost, as shown in FIGS. 4A-B. Strikingly, at the 5 and 10-µg doses, no significant differences were observed between i.n. and i.m. vaccines post-boost, suggesting equivalent induction of serum responses—the key correlates of protection for SARS-CoV-2—by the i.n. vaccine. IgG1 and IgG2a serum antibody titers indicated that i.n. vaccination with the self-amplifying RNA/NLC vaccine maintains the desired Th1 bias seen with the corresponding i.m. vaccine, as shown in FIG. 4C. Next, bone marrow-resident ASCs were assessed post-boost by ELISpot to determine if there was establishment of a memory niche for IgG-secreting ASCs. No differences were seen between the i.n. and i.m. vaccines at either the 5- or 10-µg dose i.n. as compared to the 10-µg dose i.m., as shown in FIG.4D. This further suggests effective systemic induction by both delivery routes and suggesting durability of response established by both vaccines. [0162] Cell-mediated immunity, particularly T cell immunity, is also thought to be important for sustained, long-term protection against SARS-CoV-2. Thus, systemic cellular
responses were investigated in i.n. and i.m. vaccinated mouse spleens after boost, both by ELISpot and ICS. Significant populations of IFNγ-secreting T cells were observed in both the i.n. and i.m. dosed (10-µg dose) mouse groups as measured by ELISpot, as shown in FIG.4E. This indicated effective induction of effector T cells primed to respond to SARS- CoV-2. While the cell numbers were significantly higher in the i.m. dosed group, both groups showed robust T cell responses. IL-5- and IL-17-secreting cells were seen at negligible populations in either group, as shown in FIGS. 4F-G. This suggested a strong Th1-biased response induced by both the i.n. and i.m. vaccines with very little induction of a potentially harmful Th2 response associated with immunopathology and natural infection. [0163] These robust, strongly Th1-skewed systemic CD4+ and CD8+ T cell responses were verified using ICS-flow performed on mouse splenocytes collected post-vaccination. After prime-boost immunization, significant populations of spike-reactive polyfunctional (IFNγ+, IL-2+, and TNFα+) CD8+ and CD4+ T cells were observed in mice immunized with the 5- and 10-μg i.n. vaccine doses and the 10-μg i.m. dose, as shown in FIGS.4H-I. This, demonstrated strong T cell-mediated responses induced by both i.m. and i.n. vaccines. The spike-reactive polyfunctional T cell populations of CD4+ T cells induced by the i.n. vaccine were lower than those induced by the i.m. vaccine (20-30% reduction between the i.n. and i.m. vaccines at a 10-µg dose, p = 0.0191); however, spike-reactive polyfunctional CD8+ T cell populations were not significantly different between the i.n. and i.m. vaccinated mice, and CD4+ T cell responses induced by the i.n. vaccine were still high, demonstrating effective seeding of systemic T cell immunity across all i.n. and i.m. vaccinated mice. As seen with vaccine-induced antibody titers, a stronger induction of a Th1-specific response (secretion of IFNγ+, IL-2+, or TNFα+) compared to a Th2 response (secretion of IL-5+ or IL- 10+) or a Th17 response (secretion of IL-17+) occurred within the T cell compartment in both i.n. and i.m. vaccinated mice and across all doses. This suggested an overall systemic functional response to the virus. These data therefore indicate that the i.n. self-amplifying RNA/NLC vaccine elicits humoral and cellular responses at levels predicted to be protective. Intranasal Vaccine Administration Induces Specialized Lung T Cell Populations [0164] While both i.m. and i.n. vaccines induce excellent systemic immunity, a key objective to assessing i.n. immunization was to determine whether effective mucosal responses could be generated with i.n. administration of an RNA vaccine. To that end, the lung T cell compartment was analyzed from C57BL/6J mice vaccinated i.n. or i.m. with 10
µg of AAHI-SC23 weeks post-prime and 3 weeks post-boost; the lung T cell compartment was analyzed by ICS-flow for the presence of specialized T cell subsets that would indicate the development of long-lasting respiratory-specific immunity. [0165] FIG. 5 shows mucosal T cell populations following intranasal vaccination with a SARS-CoV-2 self-amplifying RNA/NLC vaccine. [0166] First, post-vaccination lung infiltration of antigen-experienced memory T cells was examined. These TRM cells are characterized by CD69 expression as well as CD103 expression in the CD8 compartment. The percentage of TRM cells were significantly increased in the CD8 compartment with i.n. vaccination (median of CD69+ cells >20% of CD8+) compared to i.m. vaccination (median of CD69+ cells <10% of CD8+) following boost (CD69+ CD8+ cells, p = 0.0029; CD69+ CD103+ CD8+ cells, p < 0.0001), as shown in FIGS. 5A-B. While the fractions of CD8+ TRM cells were equivalent post-prime, lung expansion of TRM cells followed boost administration in the i.n. dosed group only, suggesting seeding of these durable populations followed by recall and expansion upon boost dosing. [0167] CD154+ CD4+ T cells were then assessed. CD154 (CD40 ligand [CD40L]) is often expressed on activated T cells and T follicular helper cells and is critical for licensing dendritic cells and engaging with B cells to enhance mucosal antibody production. Here, it was found that similar patterns to those seen with TRM cells; significantly increased populations of CD154+ CD4+ cells were observed in the lungs after i.n. self-amplifying RNA vaccination post-boost compared to i.m. vaccination (p = 0.0029), as shown in FIG. 5C. Collectively, these data show that i.n. administration appears to elicit an expansion of TRM and CD40L+ activated CD4+ T cells within the lung. In contrast, i.m. vaccination elicits minimal levels of these cell subsets, suggesting that these specialized respiratory cells are not inducible by i.m. vaccination. Intranasal Administration Elicits Polyfunctional SARS-CoV-2 Reactive Mucosal T Cell Responses [0168] While the lung T cell subsets were present in large populations post-i.n. administration, it was desirable to verify that these cell subsets were functional effector cells and confirm that they responded to SARS-CoV-2. Here, mice that received the vector control or had been immunized and boosted with AAHI-SC2 i.m. (10 µg) or i.n. (1 µg, 5 µg, or 10 µg) were used, and ICS-flow cytometry was used to determine the frequency of polyfunctional lung IFNγ+IL-2+TNFα+ CD4+ and CD8+ T cells following re-stimulation for
6 hours with overlapping spike peptides. Polyfunctional IFNγ+IL-2+TNFα+-secreting SARS-CoV-2 spike-responsive T cells composed a large fraction of the key TRM, CD69+ population in the 5- and 10-µg i.n. immunized mice (12.8% and 9.11%, respectively), which was significant in the CD69+ CD8+ subset of these TRM cells compared to the i.m. immunized mice (p = 0.0005 for the 5-µg dose and p = 0.0258 for the 10-µg dose), as well as in the CD69+ CD103+ CD8+ subset (p = 0.0181) from 5-µg i.n. immunized mice, as shown in FIGS. 6A-B. Intramuscularly immunized groups again induced consistently negligible levels of polyfunctional CD8+ cells. The activated CD154+/CD40L+ CD4+ T cells and the lung-homing CD194+/CCR4+ CD4+ and CD8+ cells were also examined. Similar to the TRM cells, CD154+ CD4+ cells showed significantly higher percentages of polyfunctionally responding cells at the 5-µg i.n. dose compared to the i.m. dose (p = 0.0006), as shown in FIG.6C. Likewise, CD194+ CD4+ and CD8+ cells were also induced by the i.n. vaccine at significantly higher percentages at the 5-µg dose (p = 0.0441 and p = 0.0071, respectively) compared to the i.m. vaccine, as shown in FIGS.6D-E. [0169] Finally, the quality of the response by lung T cells was examined to confirm that i.n. administration elicited Th1-biased lung T cell responses, as was observed in the spleen. The majority of the responses to both the i.n. and i.m. vaccines were Th1-specific responses, with negligible Th2 and Th17 responses, similar to what was observed in the spleen. Th2 responses were not significantly different between i.m. vaccinated mice and mice receiving the vaccine via the i.n. route, did not scale with increasing vaccine dose, and were not significantly increased from buffer-only groups. Collectively, these data demonstrate that i.n. administration seeds specialized polyfunctional CD4+ and CD8+ T cell populations in the lung – populations which are not elicited following i.m. administration. Intranasal Boosting of Previous Intramuscular Vaccination Induces Both Systemic and Mucosal Immune Responses [0170] To understand whether i.n. administration could be viable as a boosting strategy for individuals previously vaccinated with an i.m. SARS-CoV-2 vaccine, mice that were primed with an i.m. vaccine and then boosted with a medium dose (5 µg) either i.m. or i.n. were examined. Intranasally boosted mice showed equivalent serum anti-spike IgG levels and similar systemic neutralizing antibody responses to the i.m. boosted mice, as shown in FIGS. 7A-B. Within the splenic CD4+ and CD8+ T cell compartment, i.n. boost immunization induced equivalent or increased spleen-resident polyfunctional T cell responses in CD4+ or CD8+ (p = 0.0454) cells, respectively, compared to an i.m. boost
immunization, as shown in FIGS.7C-D. This indicated that an i.n. booster may effectively boost the systemic immunity developed in response to an original i.m. vaccination. With respect to mucosal immunity, the i.n. booster induced a higher but not significant percentage of CD40L+ (CD154+) activated CD4+ T cells within the lungs than the i.m. booster, as shown in FIG. 7E. Most importantly, the i.n. booster elicited significantly more polyfunctional lung-resident CD8+ CD69+ TRM cells (p = 0.0236) than the i.m. booster, as shown in FIG. 7F. This indicated that just boosting with an i.n. dose may be sufficient to elicit the full mucosal immune-stimulating effect of i.n. vaccination. These data are consistent with other i.n. vaccines that suggest i.n. boosting can have enhanced efficacy systemically as compared to i.m. vaccines. This suggests that an i.n. boost vaccination strategy may be ideal to boost systemic and induce respiratory immunity in previously vaccinated individuals, reflecting the real-world scenario of second-generation SARS-CoV-2 vaccine rollouts. Self-Amplifying RNA Vaccination Protects Against SARS-CoV-2-Induced Disease in Hamsters [0171] Given the data showing that i.m. prime and i.n. boost with the self-amplifying RNA/NLC SARS-CoV-2 vaccine described herein elicited strong systemic and pulmonary immunity in mice, it was hypothesized that vaccination, particularly via the i.m./i.n. route, would be sufficient to protect animals from morbidity due to SARS-CoV-2 infection and would prevent these animals from transmitting the virus to naive bystander animals. To test this hypothesis, hamster pairs were co-housed (1:1) for several weeks to acclimate them to one another. Then, paired animals were separated and one animal in each pair was either sham-vaccinated or vaccinated with 5 µg of the self-amplifying RNA/NLC SARS-CoV-2 vaccine given either i.m. or i.n., as shown in FIG.8A. After 24 hours, the sham-vaccinated and vaccinated animals were re-paired with their naive (non-vaccinated) cagemates. On day 21, peripheral blood was collected from all animals. On day 28, all pairs of animals were separated, and the sham-vaccinated and vaccinated animals were boosted via the i.m. or i.n. route. All animals were re-paired with their naive cagemates after 24 hours and blood was collected from all animals five days later. As expected, vaccinated hamsters, particularly i.m.-dosed hamsters, demonstrated strong induction of spike-specific serum IgG post-prime, which was absent in the sham-vaccinated group, as shown in FIG. 8B, and in all the naive cagemates (not shown). Intranasally primed animals also showed development of significant serum IgG titers, albeit at titers significantly lower than those observed in i.m.-primed animals (p < 0.0001). Boosting on day 28 did not result in a significant increase in systemic
anti-spike IgG responses in any of the vaccinated groups, as shown in FIG.8C. This may have been due to the still ongoing robust primary response. [0172] At 9 days post-boost (day 37), the vaccinated and sham-vaccinated hamsters were separated from their naive cagemates, as shown in FIG. 8A. Some sham-vaccinated hamsters were set aside to serve as uninfected negative controls (sham-vaccinated- uninfected), and all other vaccinated or sham-vaccinated hamsters were experimentally infected with 1 x 106 pfu SARS-CoV-2 USA/WA-1 strain delivered intranasally. Morbidity of the vaccinated-infected and sham-vaccinated-infected animals was then compared to the sham-vaccinated-uninfected controls. As expected, the sham-vaccinated-uninfected hamsters exhibited a modest increase in weight over the next 14 days, as shown in FIG.8D. By contrast, the sham-vaccinated-infected animals had increased morbidity with peak body weight loss of 9-10% by day 6 post-infection and minimal body weight recovery by termination of the study. The vaccinated-infected animals (i.n.-i.n., i.m.-i.n., and i.m.-i.m. vaccination), on the other hand, showed minimal weight loss and exhibited rapid recovery in weight by day 3-4 post-infection, with statistically significantly reduced virus infection- induced morbidity when compared to the sham-vaccinated-infected group (p = 0.0091, p = 0.0074, and p = 0.0206 for i.n.-i.n., i.m.-i.n., and i.m.-i.m. vaccinated-infected animals, respectively). Body weight loss after challenge did not correlate with systemic anti-spike IgG titers, suggesting that either all three vaccination regimens induced sufficient systemic IgG to protect against SARS-CoV-2-induced weight loss and/or cellular or mucosal responses played a role in protection (not shown). [0173] To further understand the dynamics of infection and transmission, total and subgenomic viral nucleocapsid (N) RNA was measured in nasal swipes from all infected hamsters across the first 10 days after infection. Total viral N RNA was detected in all infected hamsters as early as 1 hour post infection, as shown in FIG. 8E. This confirmed successful intranasal instillation of SARS-CoV-2. Total viral copies peaked between 24-48 hours in all infected groups. However, total viral N RNA copies were significantly lower in the vaccinated-infected groups compared to the sham-vaccinated-infected group (p < 0.0001, p < 0.0001, and p = 0.0003 for i.n.-i.n., i.m.-i.n., and i.m.-i.m., respectively). Next, subgenomic viral N RNA was quantified in the nasal discharge to compare infectious, actively replicating viral load between the sham-vaccinated-infected and vaccinated- infected hamsters. Subgenomic viral N RNA was detected in the nasal swipes from all infected hamsters. However, significantly diminished subgenomic viral N RNA copies were observed in all vaccinated-infected animals relative to the sham-vaccinated-infected
animals, as shown in FIG.8F (p < 0.0001, p = 0.0002, and p < 0.0001 for i.n.-i.n., i.m.-i.n., and i.m.-i.m. vaccine regimens, respectively). Moreover, the peak copies of subgenomic N RNA in nasal swipes were observed within 24 hours of infection in the vaccinated-infected hamsters, while subgenomic N RNA peaked in the sham-vaccinated-infected hamsters between days 1-2, as shown in FIG. 8F. Importantly, the vaccinated-infected hamsters had increased clearance of viral subgenomic N RNA that declined to undetectable levels by day 6 (i.m.-i.n. and i.m.-i.m. groups) and day 8 (i.n.-i.n. group) post-infection. In contrast, the sham-vaccinated-infected control animals had detectable viral subgenomic N RNA until day 10, indicating that vaccination promoted more rapid reduction in replicating virus. [0174] The viral RNA measurements from nasal swipes suggested that none of the self- amplifying RNA/NLC vaccination regimens induced sterilizing immunity following direct intranasal instillation with 1x106 pfu of SARS-CoV-2. To address whether the vaccinated animals made an immune response to experimental infection, systemic anti-N IgG antibodies were measured on day 35 post-infection. Indeed, anti-N IgG antibody was detected in the serum from all three groups of vaccinated-infected animals, as shown in FIG. 8G. This indicated that the amount of N protein made by the infectious virus was sufficient to elicit a de novo N-specific antibody response in these hamsters. However, compared to the sham-vaccinated-infected animals, the amount of anti-N IgG antibody was significantly lower in the i.m.-i.m. and i.m.-i.n. vaccinated-infected hamsters (p < 0.0001 and p = 0.0470, respectively) and modestly lower in the i.n.-i.n. vaccinated-infected hamsters, again consistent with a decreased viral load in all vaccinated animals. [0175] Next, to assess SARS-CoV-2-induced pulmonary pathology, cross sections of the hamster lungs were examined and scored for histology by a board-certified pathologist. As expected, the sham-vaccinated-infected hamsters had mild to moderate histology scores confirming that the SARS-CoV-2 viral inoculum used to infect the hamsters caused detectable pulmonary immunopathology as late as day 35 post-infection, as shown in FIG. 8H. These sham-vaccinated-infected hamsters exhibited signs of inflammation that consisted primarily of accumulation of mononuclear and polymorphonuclear infiltrates in the alveolar interstitium and lumen, and adjacent inflammation around blood vessels and bronchioles (not shown). Conversely, all three groups of vaccinated-infected hamsters had significantly decreased total histology scores, as shown in FIG. 8H, and exhibited only sporadic interstitial, perivascular, and peribronchiolar inflammation that were comparable to sham-vaccinated-uninfected negative control animals (not shown). This suggested that vaccination reduced the extent and severity of lung pathology following infection with a
high dose of SARS-CoV-2. Therefore, while vaccination did not prevent infection following a robust viral challenge, all vaccine regimens effectively prevented disease-associated morbidity as measured by weight loss, decreased peak viral copies in the nasal discharge, suppression of viral replication, increased viral clearance, and protection against SARS- CoV-2-induced lung damage. Self-Amplifying RNA Vaccination Prevents Viral Transmission by Virally Challenged Hamsters [0176] Although all three groups of vaccinated-infected hamsters appeared to have been productively infected following experimental SARS-CoV-2 exposure, the amount of subgenomic viral N RNA in the nasal secretions of these hamsters had already declined significantly by day 2 post-infection relative to the sham-vaccinated-infected group, as shown in FIG.8F. To assess whether this reduction in infectious viral load was sufficient to prevent transmission, the sham-vaccinated-infected and vaccinated-infected hamsters were re-paired with their naive cagemates on day 2 post-infection (day 39 on timeline in FIG.8A; day 0 on timeline in FIG.9A) for a period of 24 hours, as shown in FIG.9A, and assessed morbidity, nasal swipe viral RNA, serum IgG antibodies, and lung immunopathology in the naturally virally challenged cagemates. As expected, naive cagemates of the sham- vaccinated-infected animals began losing weight within 24 hours of re-pairing, reaching maximum weight loss of 6-7% by day 7 post-re-pairing and exhibiting minimal body weight recovery by the termination of the study, as shown in FIG.9B. In striking contrast, the naive cagemates of the vaccinated-infected hamsters exhibited no body weight loss following re- pairing (p = 0.0412, p = 0.0470, and p = 0.0478 for i.n.-i.n., i.m.-i.n., and i.m.-i.m., respectively). [0177] Given the little morbidity observed in the naive cagemates co-housed with the vaccinated-infected hamsters, it was hypothesized that viral transmission between the vaccinated-infected animals and their naive cagemates would also be diminished. To test this, total and subgenomic viral N RNA was measured in the nasal swipes, as shown in FIGS.9C and 9D respectively, from the naive cagemates that were paired for 24 hours with the sham-vaccinated-infected and vaccinated-infected groups. Total viral N RNA, which reflects both replicating and non-replicating virus, was present in nasal swipes from all the naive cagemates as early as 24 hours post-re-pairing with infected hamsters, as shown in FIG. 9C. Interestingly, the naive cagemates paired with vaccinated-infected hamsters had on average 70-fold lower total viral N RNA at 24 hours post-re-pairing compared to naive
hamsters that were co-housed with sham-vaccinated-infected animals, as shown in FIG.9C. Hence, immediately following re-pairing, the viral load transmitted to naive cagemates by the vaccinated-infected animals was lower than that transmitted by the sham-vaccinated- infected animals. Importantly, total viral N RNA in nasal secretions from the naive cagemates paired with vaccinated-infected hamsters never surpassed 104 copies/mL, as shown in FIG.9C, and remained just above the limit of detection starting at day 4 post-re- pairing (p < 0.0001 for all groups). Conversely, the naive cagemates paired with sham- vaccinated-infected hamsters had total viral N RNA nasal discharge titers that peaked at 107 copies/mL by day 2 post-re-pairing, with minimal clearance by end of study at day 8 post- re-pairing, as shown in FIG.9C. Similarly, subgenomic viral N RNA in the nasal discharge, which is indicative of viral replication/infection, was detected at 24 hours post-re-pairing in the naive cagemates co-housed with sham-vaccinated-infected hamsters, peaked at 105 copies/mL by day 2-3 post-re-pairing and remained detectable even out to day 8 post-re- pairing, as shown in FIG. 9D. This was in striking contrast to the naive cagemates of the vaccinated-infected animals, which had minimal to non-detectable levels of subgenomic viral N RNA in the nasal discharge, as shown in FIG.9D (p < 0.0001 for all three groups). [0178] To assess whether the naive cagemates exposed to the vaccinated-infected animals were protected from active infection, de novo anti-N serum IgG responses were measured. As expected, the naive cagemates co-housed with sham-vaccinated-infected hamsters developed high serum N-specific IgG responses, as shown in FIG.9E. The naive cagemates co-housed with vaccinated-infected hamsters, on the other hand, exhibited negligible responses (p < 0.0001 for all vaccine regimen groups). Indeed, no anti-N IgG response was detected in the naive cagemates of the i.n.-i.n. vaccinated-infected group, and only one naive cagemate from the i.m.-i.n and the i.m.-i.m. vaccinated-infected groups developed a measurable anti-N IgG serum antibody response. Thus, all three vaccine regimens were effective at preventing significant transmission of infectious virus capable of inducing an immune response to naive cagemates. [0179] Next, the total histology score of each group of naive cagemates was compared, as shown in FIG.9F. Naive hamsters co-housed with the sham-vaccinated-infected hamsters exhibited mild to moderate histology scores, primarily due to mild inflammation in the alveolar interstitium and lumen that was similar in severity to that observed in the sham- vaccinated-infected hamsters (not shown). Naive hamsters co-housed with the vaccinated- infected hamsters, regardless of vaccination regimen, exhibited a significantly decreased histology score (p < 0.0001 for all vaccine regimen groups), with minimal lung pathology
that was very similar to that observed in the vaccinated-infected cagemates (not shown). Taken together, the data demonstrate that i.m.-i.m., i.n.-i.n., or i.m.-i.n. dosing of the self- amplifying RNA/NLC spike vaccine was not only effective in preventing disease-associated morbidity in hamsters but also prevented the vaccinated and subsequently experimentally infected hamsters from transmitting infectious virus to naive cagemates, even at a time when viral load peaked in the nasal discharge. Non-Human Primate Studies [0180] To establish feasibility of use of the disclosed SARS-CoV-2 intranasal vaccine delivery system in large primates, an i.n. vaccine arm was added to an existing nonhuman primate (NHP) SARS-CoV-2 i.m. self-amplifying RNA/NLC vaccine immunogenicity and efficacy study conducted by Dr. Sudhir Kasturi at the Emory National Primate Research Center using rhesus macaques. This study sought to establish safety, tolerability, and immunogenicity of the proof-of-concept self-amplifying RNA/NLC vaccine. As indicated in Table 1, the study consisted of 15 animals total, 5 each in the i.m.-vaccinated, unvaccinated, and i.n.-vaccinated arms. The i.m. vaccinated animals were dosed using our base self-amplifying RNA/NLC SARS-CoV-2 vaccine formulation (N/P=15), and the i.n. vaccinated animals dosed with a similar self-amplifying RNA/NLC SARS-CoV-2 vaccine formation with a reduced RNA loading ratio for i.n. delivery (N/P=5). After prime-boost vaccination, animals were then challenged with the heterologous Delta strain of SARS- CoV-2 to investigate ability of the vaccine to protect against robust challenge of a further- evolved viral strain. Over the course of the study, as shown in FIG.10, blood, nasal swabs, bronchoalveolar lavage (BAL) and bone marrow samples were taken to assess vaccine immunogenicity and protection against viral infection. Upon conclusion of the study one week post-challenge, study animals were euthanized and tissue samples taken to investigate immune responses and viral loads.
Table 1 [0181] The purpose of this study was to assess the immunogenicity and efficacy of the vaccines in NHPs, assess whether i.m. and/or i.n. vaccine preparation protected NHPs from virus-induced morbidity, and to compare the efficacy of the intranasal and intramuscular preparations of the vaccine. Collectively these data demonstrate that i.n. and i.m. vaccination elicit qualitatively different immune responses, but both show protection from challenge in the NHPs. [0182] First, serum immunogenicity was assessed across the study, as illustrated in FIG.11. Both vaccinated groups generated IgG antibodies to the vaccine strain (WA1/2020) as well as the challenge strain (B.1.617.2). Vaccinated animals showed increased titers after prime and boost vaccination, with boost particularly beneficial to boosting the i.n.- vaccinated animals. The i.m. vaccinated animals showed generally higher serum IgG titers than the i.n. vaccinated animals. Titers had dipped slightly by the day of challenge (5 weeks post-boost) but increased by the day of necropsy (7/8 days post challenge, in response to challenge), with both i.m. and i.n. vaccinated animals demonstrating high titers at necropsy. [0183] Antibody levels were also assessed in the mucosal tract, specifically in the BAL and nasal mucosa, as shown in FIG. 12. Only the i.m. vaccinated primates elicited IgG antibodies in either of these compartments prior to infection. However, upon infection the i.n. vaccinated animals peaked to the same BAL IgG antibody levels as seen in the i.m. vaccinated animals. Furthermore, only the i.n. vaccinated animals were capable of eliciting BAL anti-RBD IgA after infection, indicating seeding of a mucosal antibody response in this compartment. Similarly in the nasal mucosa there was no response initially noted in the i.n. vaccinated animals. However, there was indication of a higher IgA response in the i.n. vaccinated animals as well. [0184] Next, virus neutralization potential of animal sera was measured for the same two viral strains for the vaccinated animals, as shown in FIG.13. The intramuscular animals responded clearly with neutralization potential in all animals against the vaccine and challenge strain. However, this was not the case in the i.n. group: just 2/5 animals post- vaccination showed measurable levels of neutralizing antibodies in serum, and only one of those had demonstrated cross-protective neutralizing antibodies to the challenge strain. Any protective responses induced by the intranasal vaccine, therefore, are unlikely due to circulating serum neutralizing antibodies.
[0185] However, post-challenge neutralizing antibody data clearly show that the while the i.n. vaccinated animals show lower titers of serum neutralizing antibody prior to challenge than the i.m. vaccinated animals, they are able to robustly respond with antibody post-challenge, as shown in FIG. 13. The control animals were unable to produce serum neutralizing antibodies in this timeframe, despite being challenged with virus, suggesting that the serum response in the i.n. vaccinated animals was a recall response to vaccine- induced memory rather than any de novo response to viral challenge. This suggests further that humoral memory B-cells established in response to the intranasal vaccine exist in a compartment unable to be easily sampled pre-necropsy. [0186] T cell responses to vaccination were also assessed across the study, as shown in FIG.14. During the study, the i.m. vaccinated group showed a dramatic induction in CD4+ and CD8+ T cells found in peripheral blood. No circulating CD4+ T cells were seen in i.n. vaccinated animals, and only transient populations of circulating CD8+ T cells were detected prior to challenge. However, similar to the pattern seen with humoral immune responses, upon viral challenge both CD4+ and CD8+ T cells were detected at high levels in PBMCs in the i.n.-vaccinated animals, at levels that rivaled or exceeded the levels seen in i.m.-vaccinated animals, representing a robust recall response to infection. Unvaccinated animals were again unable to produce detectable T cell responses to viral challenge within this timeframe. These data thus repeat the humoral immunogenicity patterns—while vaccine-induced T cell populations were not seen systemically in i.n.-vaccinated animals post-vaccination, cellular memory responses were clearly established by vaccination, allowing for rapid T cell expansion and response to viral infection. [0187] Lastly, the induction of SARS-CoV-2 spike-binding IgG secreting cells was assessed. Lymph nodes, spleen, lung and bone marrow were all sampled at necropsy, one week after viral challenge, and the presence of IgG+ RBD or spike specific plasma cells was measured by ELISpot, as shown in FIG.15. The unvaccinated animals had essentially no reactive plasma cells, as expected. However, both vaccine strategies seeded significant populations of reactive plasma cells across tissues. While the i.m. vaccinated animals showed significantly higher levels of these plasma cells than i.n.-vaccinated animals in the lymph nodes and bone marrow, i.n. animals still saw significant induction of these cell subsets across all tissues measured indicating robust establishment of vaccine-induced immune memory prior to and capable of responding to infection. [0188] With all of this immunogenicity data on the disparity in the response following i.n. or i.m. vaccination, it was also desired to observe how different vaccine strategies
affected susceptibility to infection. Thus the viral load in nasal swabs, throat swabs, and BAL was measured across 7 or 8 days of infection, as shown in FIG.16. All animals showed evidence of productive infection, with rising subgenomic RNA in all sites by day 1 post challenge and peaking viral load on day 2. However, both the i.m. and i.n. vaccinated animals showed clear evidence of faster resolution of infection, with most animals having viral loads return to baseline by day 7/8, unlike the naïve controls which continued. Although a complete statistical analysis is ongoing, it is hypothesized that these data will demonstrate that the i.m. vaccine is reducing peak viral load in the upper and lower respiratory tract and i.n. vaccination is reducing peak viral load in the upper respiratory tract only. MATERIALS AND METHODS Study Design [0189] Research subjects. Research was conducted on C57BL/6J mice obtained from The Jackson Laboratory. Lakeview Golden (LVG) Syrian hamsters were obtained from Charles River Laboratories. [0190] Experimental design. Several mouse vaccine immunogenicity experiments were conducted, involving vaccinating mice i.m and/or i.n. with the above-described SARS-CoV- 2 self-amplifying RNA vaccine. Mice were vaccinated using different doses and dosing strategies (homologous vs. heterologous prime-boost vaccine regimens), and immunogenicity was assessed by ELISA and pseudoneutralization assay on serum samples, T cell intracellular cytokine staining (ICS) on spleen and lung samples, bone marrow B cell ELISpot, and T cell ELISpot to assess systemic antibody responses and induction of specific vaccine-induced T cell and B cell populations. [0191] Randomization. Rodents were obtained commercially and randomized into study groups prior to study onset. [0192] Blinding. Investigators were not blinded to the study groups during data collection and analysis as this is typically unnecessary for this type of inbred animal study and introduces more systemic and human error than it prevents. Quantitative, unbiased assays were developed with highly regulated SOPs to minimize data biases. [0193] Sample size. Statistical analyses were the guiding strategy to maximize statistical power while reducing the number of animals used to a minimum. It was previously determined that 6-8 animals per group (3-4 male, 3-4 female) is the lowest estimate to
achieve meaningful comparisons between vaccine candidates with subtle differences in immunogenicity. 10 mice/group, 5 male and 5 female, is required to provide statistical power of 90% with an alpha (p-value) of 0.05 to detect a statistically significant difference in pseudovirus neutralizing antibody titers between vaccinated groups with two-fold differences in mean antibody titers with expected statistical variance. Both male and female mice were used in most study groups to avoid sex-driven data biases and allow for identification of any sex-specific differences in vaccine immunogenicity. For one select study where mouse numbers were limited, as shown in FIG.5), n = 5 all-female mice were used per group to provide statistical power of 80% to detect two-fold differences in serum antibody titers. The use of all female mice in this study was conducted to reduce data variability sufficiently to minimize animal use without compromising the main study immunogenicity readouts. [0194] Data inclusion/exclusion criteria. No data were excluded from any plots or analyses except two cases: (1) for flow cytometry after ICS where <50,000 cells were collected in the well (this was established as a guideline prospectively) and (2) one i.n. vaccinated hamster was removed from FIG. 8 where the complete lack of anti-spike IgG antibody established that it had not been effectively vaccinated. [0195] Outliers. Outliers were not excluded. Assays were repeated on any suspected outliers to verify data prior to inclusion. [0196] Replicates. Replication of data was conducted whenever possible. All experiments were conducted with a minimum of biological triplicates. ELISAs and pseudoneutralization assays were conducted with technical duplicates for each study sample. T cell immunogenicity was only assessed in technical singlicate due to limiting tissue quantity and cell number. Bridging groups were used between independent animal studies to provide replication of key study groups across multiple studies offset by months. All attempts at replication verified the robustness of the scientific approach. Self-Amplifying RNA Expression Plasmid Design, Cloning, and Production [0197] The self-amplifying RNA plasmid was designed and selected based on immunogenicity measures from i.m. immunization. Briefly, the self-amplifying RNA encodes a SARS-CoV-2 spike sequence based on a GenBank sequence (MT246667.1) containing the D614G mutation, a diproline at sites 987-988, and a QQAQ substitution for RRAR in the furin cleavage site (683-686). The sequence was codon-optimized for expression in humans, synthesized by BioXp, and inserted via Gibson cloning into AAHI’s
backbone self-amplifying RNA expression vector. A SEAP-expressing plasmid was also used as a control, created similarly with the SEAP sequence in the place of the vaccine antigen. Sanger sequencing was used to confirm plasmid sequences. These were then amplified in Escherichia coli and extracted using Qiagen maxi- or gigaprep kits, linearized with NotI (New England Biolabs), and purified using a Qiagen DNA purification kit. RNA Manufacture [0198] NotI-linearized DNA plasmids containing T7 promoters were used as templates for in vitro transcription (IVT) of self-amplifying RNA for vaccination. An in-house optimized IVT protocol with T7 polymerase, RNase inhibitor, and pyrophosphatase (Aldevron) was used. Next, a Dnase step was used to digest the templates, and Cap0 structures were added to the RNA transcripts with guanylyltransferase (Aldevron), GTP, and S-adenosylmethionine (New England Biolabs). CaptoCore 700 resin (GE Healthcare) was used to chromatographically purify the RNA followed by diafiltration and concentration. self-amplifying RNA material was filtered through a 0.22-µm polyethersulfone filter and stored at -80°C until further use. Self-amplifying RNA size and integrity was characterized by gel electrophoresis, and RNA concentration was quantified by UV absorbance (NanoDrop 1000) and RiboGreen assay (Thermo Fisher). NLC Manufacture [0199] A mixture of trimyristin (IOI Oleochemical), squalene (Sigma-Aldrich), sorbitan monostearate (Sigma-Aldrich), and the cationic lipid 1,2-dioleoyl-3-trimethylammonium- propane (DOTAP; Corden) was heated at 70°C in a bath sonicator. Separately, polysorbate 80 (Fisher Scientific) was diluted in 10 mM sodium citrate trihydrate and heated to 70°C in a bath sonicator. After all components were in suspension, a high-speed laboratory emulsifier (Silverson Machines) running at 7000 rpm was used to blend the oil and aqueous phases. Particle size of the mixture was further decreased through high-shear homogenization. The colloid mixture was then processed at 30,000 psi for 11 discrete microfluidization passes using an M-110P microfluidizer (Microfluidics). The NLC product was then filtered through a 0.22-µm polyethersulfone filter and stored at 2-8°C until use. Vaccine Complexing and Characterization [0200] Vaccine complexes were produced by combining aqueous RNA at a 1:1 volume ratio with NLC that was pre-diluted in a 10 mM sodium citrate and 20% w/v sucrose buffer.
Vaccines were prepared at a nitrogen/phosphate (N/P) ratio of 5-15, representing the ratio of amine groups on the NLC DOTAP to the RNA’s backbone phosphate groups. This complexing resulted in vaccine containing the intended dose of complexed self-amplifying RNA/NLC in an isotonic 10% w/v sucrose, 5 mM sodium citrate solution. The vaccine solution was incubated on ice for 30 minutes after mixing to ensure complete complexing. Mouse Studies [0201] All mouse studies were conducted according to the Bloodworks Northwest Research Institute’s Institutional Animal Care and Use Committee. All mouse work was in compliance with all applicable sections of the Final Rules of the Animal Welfare Act regulations, see 9 C.F.R. Parts 1, 2, and 3, and the Guide for the Care and Use of Laboratory Animals. [0202] C57BL/6J mice purchased from The Jackson Laboratory were used for all mouse studies. Mice were between 6 and 8 weeks of age at study onset and evenly split between male and female. At arrival, mice were simultaneously randomized into study groups, half male and half female, housed separately 3-5 mice per cage with irradiated bedding in Allentown individually ventilated cages. Sterile water gel packs were given to all newly arrived animals during the acclimation period, and animals had access to fresh potable water ad libitum via an Edstrom automatic reverse-osmosis and chlorinated water system. Cages were changed every 2 weeks inside a laminar flow cage change station. A spot check for dirty cages was conducted on the non-change weeks. [0203] Mice were observed daily for 3 days post-injection after both prime and boost injections by trained personnel. Isoflurane delivered by inhalation was used for temporary anesthesia immediately prior to retro-orbital blood collection and i.n. immunization to mitigate animal pain and distress. At study completion, animals were humanely euthanized by CO2 overdose. [0204] Animal handling technicians were not blinded to study groups. After 1 week of acclimatization to the facility, mice were then primed with vaccine. Mice were then boosted 3 weeks later and harvested 3 weeks after boost. Mouse weights were monitored for 4 days following prime and boost vaccinations. Mice were immunized by i.m. injection in both rear quadriceps muscles (50 µL/leg, 100 µL total) or by i.n. inoculation in two 25-µL doses. Intranasal inoculation was done under full anesthesia, and mice were allowed to recover under a heat lamp. During ongoing studies, serum samples were taken by retro-orbital bleed.
Three-weeks post-boost, mice were harvested, terminal bleeds were taken, spleens and lungs were dissected, and femurs were harvested for bone marrow purification. Mouse Serum IgG, IgG1, and IgG2a Titers by ELISA [0205] SARS-CoV-2 spike-specific IgG was measured by ELISA. Plates (Corning 384- well high-binding #CLS3700) were coated with Recombinant SARS-Cov-2 Spike His Protein, Carrier Free (R&D Systems #10549-CV), at 1 µg/mL and incubated overnight at 4°C. Plates were incubated in blocking buffer (2% dry milk, 0.05% Tween 20, 1% goat serum) for over 1 hour. Samples were plated on low-binding plates, starting at a dilution of 1:40 and then serially diluting 1:2 across the plate. High-binding plates were washed, and samples were then transferred from the low-binding plates to the coated, high-binding plates. Naive mice serum at 1:40 was used as a negative control. A SARS-CoV-2 neutralizing monoclonal antibody (GenScript #A02057) was used as a positive control at a starting concentration of 3.2 ng/µL. Following a 1 hour incubation, plates were washed, and a secondary antibody, Anti-Mouse IgG (Fc Specific)-Alkaline Phosphatase antibody (Sigma-Aldrich #A2429) at a 1:4000 dilution was added. Following the secondary antibody and another wash step, phosphatase substrate tablets (Sigma-Aldrich #S0942) were dissolved in diethanolamine substrate buffer (Fisher Scientific #PI34064) at a final concentration of 1 mg/mL and added to the plates. Plates were incubated for 30 minutes and then read spectrophotometrically at 405 nm. A 4-point logistic (4PL) curve was used to fit the antibody standard titration curve, and sample concentrations were interpolated off the linear region of the curve. [0206] For IgG1 and IgG2a isotype-specific ELISAs, plates were coated and blocked as described above. For IgG1 and IgG2a, the standard curve was run using SARS-CoV-2 neutralizing antibodies (GenScript #A02055 and #BS-M0220, respectively). Sample dilution and incubation were identical to the total IgG curve, and plates were probed with IgG1- and IgG2a-specific secondary alkaline phosphatase (AP)-conjugated detection antibodies (Sigma-Aldrich #SAB3701172 and #SAB3701179, respectively) prior to development, reading, and quantification as described above. Pseudovirus Neutralization Assay [0207] SARS-CoV-2 pseudovirus neutralizing antibody titers in mouse sera were measured via a pseudoneutralization assay. Lentiviral SARS-CoV-2 spike protein pseudotyped particles were prepared by co-transfecting HEK-293 cells (American Type
Culture Collection CRL #11268) with plasmids containing a lentiviral backbone-expressing luciferase and ZsGreen (BEI Resources #NR-52516), lentiviral helper genes (BEI Resources #NR-52517, NR-52518, and NR-52519), or a delta19 cytoplasmic tail-truncated SARS-CoV-2 spike protein (Wuhan strain plasmids from Jesse Bloom of Fred Hutchinson Cancer Center). Cells were incubated for 72 hours at standard cell culture conditions (37°C, 5% CO2), and cell culture media were harvested and filtered through a 0.2-μm filter. Pseudovirus-containing supernatant was frozen until titering and use. [0208] To perform the assay, plates were seeded with Human Angiotensin-Converting Enzyme 2 (hACE2)-expressing HEK-293 cells (BEI Resources #NR52511) and incubated overnight. Serum samples were pre-diluted 1:10 in media (Gibco Dulbecco’s Modified Eagle Medium + GlutaMAX + 10% fetal bovine serum [FBS]) and then serially diluted 1:2 for 11 total dilutions. These were then incubated with polybrene (Sigma-Aldrich #TR-1003- G) and pseudovirus for 1 hour. Then, the serum samples were added onto the hACE2 cells in duplicate and incubated at 37°C and 5% CO2 for 72 hours. To determine 50% inhibitory concentration (IC50) values, plates were scanned on a fluorescent imager (Molecular Devices ImageXpress Pico Automated Cell Imaging System) for ZsGreen expression. Total integrated intensity per well was used to calculate the percent of pseudovirus inhibition per well. Neutralization data for each sample were fit with a 4-parameter sigmoidal curve, which was used to interpolate IC50 values. Spleen, Lung, and Bone Marrow Cell Harvest [0209] Spleens were prepared in 4 mL of RPMI medium by manual maceration through a filter using the back of a syringe. Dissociated splenocyte samples were centrifuged briefly at 400 x g to pellet fat cells, and the supernatants containing lymphocytes were either transferred to 5-mL mesh-cap tubes to strain out any remining tissue debris or lysed with ammonium-chloride-potassium (ACK) lysing buffer. Cells were counted on a Guava easyCyte cytometer (Luminex) and plated in round-bottom 96-well plates at 1-2 x 106 cells per well in complete RPMI (cRPMI) medium containing CD28 costimulatory antibody (BD Biosciences #553294) and brefeldin A. One of three stimulation treatments was added to each well: 0.0475% dimethyl sulphoxide [DMSO], 2 μg/μL spike peptide pool (JPT peptides #PM-WCPV-S-1), or phorbol myristate acetate (PMA)-ionomycin. Plates were incubated for 6 hours at 37 C with 5% CO2. [0210] Lung cells were isolated via enzymatic digestion using a gentleMACS Dissociator (Miltenyi Biotec). Lungs were dissociated in 4 mL of Hanks’ Balanced Salt
Solution (HBSS) supplemented with 10% Liberase (MilliporeSigma), 10% aminoguanidine, 0.1% KN-62, and 1.25% Dnase. Lungs and enzymatic mix were added to a gentleMACS M tube (Miltneyi Biotec), and the m_lung_01.02 program was run. Samples were then incubated at 37°C and 5% CO2 for 30 minutes. Directly after, samples were run again on the gentleMACS Dissociator using the m_lung_02.01 program. The resulting slurry was added to 10 mL of RPMI medium and centrifuged for 5 minutes. The supernatant was discarded, and the cells were either filtered through a 5-mL snap-top tube or washed again in RPMI medium prior to counting on a Guava easyCyte cytometer and plated in round-bottom 96-well plates at 1-2 x 106 cells per well in RPMI medium containing 10% FBS, 50 μM beta-mercaptoethanol, CD28 costimulatory antibody, brefeldin A, and one of three stimulation treatments: 0.0475% DMSO, 2 μg/μL spike peptide pool (JPT peptides #PM-WCPV-S-1), or PMA-ionomycin. Plates were incubated for 6 hours at 37 C with 5% CO2. Intracellular Cytokine Staining and Flow Cytometry [0211] Following incubation, plates were centrifuged at 400 x g for 3 minutes, the supernatants were removed, and cells were resuspended in phosphate-buffered saline (PBS). Splenocytes were stained for viability with Zombie Green (Biolegend) in 50 μL of PBS. Cells were washed twice, and then spleen samples were incubated with CD16/CD32 antibody (Invitrogen #14-0161-86) to block Fc receptors. Next, the cells were surface stained in an additional 50 μL of staining buffer (PBS with 0.5% bovine serum albumin and 0.1% sodium azide). Spleen samples were stained with fluorochrome-labeled monoclonal antibody (mAb) specific for mouse CD4 (eBioscience #45-0042-82), CD8 (BD Biosciences #563068), CD44 (BD Biosciences #560568), and CD107a (BioLegend #121614), while lung samples were stained for CD4 (BioLegend #100526), CD8 (BD Biosciences #563068), CD44 (BD Biosciences #562464), CD69 (BioLegend #104508), CD103 (BioLegend #121435), CD194 (BioLegend #131220), and CD154 (BD Biosciences #745242). Cells were washed twice, permeabilized using the Fixation/Permeabilization Kit (BD Biosciences #554714), and stained intracellularly. Spleens were stained for TNFα (BioLegend #506327), IL-2 (BioLegend #503824), IFNγ (Invitrogen #25731182), IL-5 (eBioscience #12-7052-82), IL-10 (BD Biosciences #564081), and IL-17a (BD Biosciences #560820), while lungs were stained for TNFα (BioLegend #506327), IL-2 (BioLegend #503824), IFNγ (Invitrogen #25731182), IL-5 (BioLegend #504306), and IL-17a (BD Biosciences #560820). After two washes in staining buffer, cells were resuspended in 100 μL of staining
buffer and analyzed using an LSRFortessa flow cytometer (BD Biosciences). After initial gating for live CD4+ or CD8+ lymphocytes, cells gating positive for all three activation markers IL-2, IFNγ, and TNFα were counted as activated polyfunctional T cells. Bone Marrow Harvest and ASC ELISpot [0212] Antibody-secreting bone marrow-resident cell counts were measured by ELISpot. MultiScreenHTS IP Filter plates (0.45 µm, MilliporeSigma) were treated with 15 µL of 35% ethanol for 30 seconds. Recombinant SARS-CoV-2 Spike His Protein, Carrier Free (R&D Systems #10549-CV-100), was diluted at 2 µg/mL in ELISpot coating buffer (eBioscience), and plates were coated with 100 µL. Plates were incubated overnight at 4°C. The next day, plates were washed with PBS with 0.1% Tween 20 and blocked with cRPMI medium for 2 hours. [0213] Femurs were removed from mice and inserted into a snipped-end 0.6-mL Eppendorf tube and then inserted into a 1.5-mL Eppendorf tube with 1 mL of cRPMI medium. Femurs were centrifuged for 15 seconds at 10,000 rpm, and supernatant was discarded. Cell pellets were vortexed, resuspended in 200 µL of RBC Lysis Buffer (Invitrogen), and then incubated on ice for 30 seconds. An additional 800 μL of RPMI medium was added, and cells were centrifuged for 5 minutes at 400 x g before the supernatant was decanted. Cells were resuspended in 1 mL of cRPMI medium, counted, and transferred to prepared filter plates at 1 million cells per well followed by a 3-fold dilution across five adjacent wells. [0214] Plates were incubated for 3 hours, then washed three times with PBS plus 0.1% Tween 20. Secondary antibody (Goat Anti-Mouse IgG-HRP or IgA-HRP [SouthernBiotech #1030-05 and #1040-05, respectively]) was added at a 1:1000 dilution in PBS with 0.1% Tween and 5% FBS overnight at 4°C. Plates were then washed three times in PBS with 0.1% Tween 20 and two times in PBS. 100 µL of Vector NovaRED Substrate Peroxidase (Vector Laboratories #SK-4800) was applied for 7 minutes to develop the plates. The reaction was quenched by rinsing plates with distilled water for 2 minutes, and plates were dried in the dark. Spots were counted and data were analyzed using ImmunoSpot v7 software (Cellular Technology Limited). T Cell ELISpot Assay [0215] IFNγ (BD Biosciences #51-2525KZ), IL-17A (Invitrogen #88-7371-88), or IL- 5 (BD Biosciences #51-1805KZ) at a 1:200 dilution in Dulbecco’s PBS (DPBS; Gibco) was
used to coat ELISpot plates (MilliporeSigma). Plates were incubated overnight at 4°C and then washed and blocked with cRPMI medium for at least 2 hours. Previously harvested splenocytes (see above) were added at 2 x 105 cells per well. Samples were then stimulated with 1 µg/mL PepMix SARS-CoV-2 (JPT Peptide Technologies #PM-WCPV-S-1). Plates were incubated at 37°C and 5% CO2 for 48 hours. Then plates were washed with PBS with 0.1% Tween 20. Next, detection antibody (IFNγ, BD Biosciences #51-1818KA; IL-17A, Invitrogen #88-7371-88; and IL-5, BD Biosciences #51-1806KZ) was diluted in ELISpot diluent (eBiosciences) at 1:250 and added overnight at 4°C. Plates were washed and then developed using Vector NovaRED Substrate Peroxidase for 15 minutes. The reaction was quenched with deionized water. Plates were then dried in the dark. Spots were counted and data were analyzed using ImmunoSpot. Hamster Studies [0216] Nine-week-old male Lakeview Golden (LVG) Syrian hamsters were purchased from Charles River Laboratories and maintained in the University of Alabama at Birmingham (UAB) animal facilities, which include the UAB Southeastern Biosafety Lab (SEBLAB) ABSL3 facilities. All hamster procedures were approved by the UAB Institutional Animal Care and Use Committee (IACUC protocol 22628) and the UAB Biosafety Committee (Protocol 22-160 and 22-161). All procedures were performed in accordance with National Resource Council guidelines. Hamster Vaccination and Infection [0217] Adult male hamsters were housed in pairs and separated at the time of vaccination. One hamster from each pair was vaccinated with 5 mg of self-amplifying RNA/NLC delivered i.m. (50 mL per rear quadriceps muscle, 100 mL total) or i.n. (25 mL/nare, 50 mL total). Sham-vaccinated hamsters received dPBS i.m. Vaccinated and sham-vaccinated animals were re-paired with naive cagemates after 24 hours. Cagemates were separated on day 28, and vaccinated animals were boosted with the same vaccine given via the i.m. or i.n. route. Animals were re-paired after 24 hours. Nine days after the boost, animals were separated, and the vaccinated and sham-vaccinated hamsters were infected i.n. with 1 x 106 pfu SARS-CoV-2 USA/WA-1 variant (50 mL/nare, 100 mL total). Uninfected controls received 100 mL (50 mL/nare) of dPBS (vehicle). The infected animals were re- paired with the uninfected, unvaccinated naive cagemates at 48 hours post-infection.
Cagemates were separated 24 hours later and remained apart until the end of the study. Hamster weights were measured before infection and daily until day 15 post-infection. Hamster Blood Collection and Processing [0218] Blood samples from sedated hamsters were collected from the lateral saphenous vein on day 21 post-prime and 5 days post-boost vaccinations. Blood samples following euthanasia were collected from terminal bleed via the posterior vena cava. Blood samples were transferred into BD Microtainer blood collection tubes (BD Biosciences), and serum was separated by centrifugation at 10,000 rpm at RT for 10 minutes. Serum samples collected post-infection were heated at 60°C for 20 minutes to inactivate SARS-CoV-2 virus. All samples were aliquoted and frozen at -80°C until analyzed by cytometric bead array (CBA). Hamster Nasal Viral Load Samples [0219] Nasal swipes were collected immediately prior to i.n. infection to establish baseline, at 1 hour post-infection, and then daily until day 10 post-infection. Awake hamsters were transferred into an open container to minimize movement, and the exterior surface of their nose was swiped for 5-10 seconds with a polyester-tipped swab (Medical Packaging #SP-7D) that had been dipped in a screw-cap tube containing 300 mL of viral transport medium (VTM; HBSS (+Ca2+ +Mg2+) containing 2% FBS, 100 mg/mL gentamicin, and 0.5 mg/mL amphotericin B). The tip of the swab was cut and placed inside the VTM-containing tube. The tubes were vortexed, and swab tips were discarded. Samples were then processed for viral RNA quantitation. Hamster Nasal Wash Samples [0220] Hamsters were sedated with isoflurane and euthanized with an intraperitoneal injection of tribromoethanol (500 mg/kg, 3 mL/animal). The trachea was exposed, an incision was made, and a blunt 19-gauge needle attached to a 1-mL insulin syringe was inserted into the trachea. While holding the mouth of the hamster shut with one hand, 400 mL of VTM was squeezed through the nasal passages, out of the nose, and into a screw-cap tube. Samples were heated at 60°C for 20 minutes to inactivate SARS-CoV-2 virus, then aliquoted, and stored at -80°C until analyzed by CBA.
Recombinant SARS-CoV-2 Spike, RBD, and N Protein Production [0221] Recombinant SARS-CoV-2 spike ectodomain trimeric proteins were prepared as previously described. See King, R. G., et al. “Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge,” Vaccines (Basel), 2021, 9, 881. Briefly, two human codon-optimized constructs were generated with a human IgG leader sequence, the SARS- CoV-2 spike ectodomain (amino acids 14-1211), a GGSG linker, T4 fibritin foldon sequence, a GS linker, and a 15 amino acid biotinylation consensus site (AviTag, construct 1) or 6X-HisTag (construct 2). Each construct was engineered with two sets of mutations to stabilize the protein in a pre-fusion conformation. Recombinant SARS-CoV-2 spike RBD domain monomers (human codon-optimized) were generated with a human IgG leader sequence, the spike RBD (amino acids 319-541 from SARS-CoV-2 Wuhan-Hu-1 strain), a GS linker, an AviTag, and a 6X-HisTag. The coding sequence of N from SARS-CoV-2 Wuhan-Hu-1 strain was synthesized in frame with the coding sequence for an AviTag and was cloned in frame to the 6X-HisTag in the pTrcHis2C expression vector (Invitrogen). Biotinylated recombinant N protein was produced by co-transforming Rosetta cells with the N expression plasmid and an inducible BirA expression plasmid. Bacteria were grown in the presence of chloramphenicol, ampicillin, and streptomycin, induced with IPTG, and supplemented with biotin. Recombinant SARS-CoV-2 Avi/His-tagged spike trimeric proteins were produced by co-transfecting each plasmid construct (1AVI:2HIS construct ratio) into FreeStyle 293-F cells. The Avi-His-tagged spike RBD protein was produced by transfecting the single dual-tagged RBD construct into FreeStyle 293-F cells. All recombinant proteins were purified by FPLC using a nickel-affinity column and subsequent size exclusion chromatography. After buffer exchange, purified spike ectodomain trimers and RBD domain protein were biotinylated by the addition of biotin-protein ligase (Avidity). Biotinylated proteins were buffer exchanged into PBS, sterile filtered, aliquoted, and stored at -80ºC until used. SARS-CoV-2 Spike Cytometric Bead Array [0222] CBAs with recombinant SARS-CoV-2 proteins were prepared as previously described. See King, et al., infra. Briefly, recombinant proteins were passively absorbed onto streptavidin functionalized 4-µm fluorescent microparticles (Carboxy Blue Particle Array Kit, Spherotech).500 µg of biotinylated recombinant protein was incubated with 2 x
107 streptavidin functionalized fluorescent microparticles in 400 µL of 1% BSA in PBS. Protein coupled beads were washed and resuspended at 1 x 108 beads/mL and stored at 4°C. Cytometric Bead Array Measurement of Spike-Specific IgG Responses [0223] 50 µL of serum (diluted to 1/4000 in PBS) or nasal wash (diluted 1/4 in PBS) was arrayed in 96-well u-bottom polystyrene plates.5 µL of a suspension containing 5 x 105 spike beads, RBD beads, and N beads was added to the samples. Suspensions were mixed, incubated for 15 minutes at RT, washed in PBS, stained with FITC-conjugated polyclonal anti-hamster IgG (Southern Biotech) for 15 minutes at RT, washed in PBS, and then resuspended in 100 µL of 1% paraformaldehyde in PBS. Samples were collected on a BD CytoFLEX flow cytometer in plate mode at a sample rate of 100 µL/minute for 1 minute. Following acquisition, the FCS files were analyzed in FlowJo (TreeStar). Briefly, the beads were identified by gating on singlet 4-µm particles in log scale in the forward scatter and side scatter parameters. APC-Cy7 channel fluorescence gates were used to segregate the particles by bead identity. Geometric mean fluorescent intensity was calculated in the FITC channel. Propagation and Titer Determination of SARS-CoV-2 [0224] The original SARS-CoV-2 isolate USA-WA1/2020 was obtained from BEI Resources (#NR-52281), propagated in Vero E6 cells (ATCC #C1008), and titered as previously described (84). Viral RNA Quantitation by qRT-PCR [0225] SARS-CoV-2 viral N RNA and viral subgenomic N RNA was measured by PCR in nasal swipe (300 µL) samples as previously described. See Schultz, M. D., et al. “A Single Intranasal Administration of AdCOVID Protects Against SARS-CoV-2 Infection in the Upper and Lower Respiratory Tracts,” Human Vaccines & Immunotherapeutics, 2022, 0, 2127292. AccuPlex SARS-CoV-2 Reference Material (SeraCare Life Sciences, Inc., # 0505-0126) was extracted and amplified in parallel to generate a standard curve enabling viral N quantitation. The subgenomic RNA standard was constructed and validated in- house.
Histopathology [0226] Hamster lungs were inflated with 10% neutral-buffered formalin (Thermo Fisher) using a blunt 19-gauge needle. Each lung was excised en bloc and fixed for 7 days at RT in 15-fold volume of 10% neutral-buffered formalin. The fixed tissues were then embedded dorsal side down in paraffin using standard procedures. Samples were sectioned at 5 µm, and resulting slides were stained with hematoxylin and eosin (H&E). All tissue slides were evaluated by light microscopy by a board-certified veterinary pathologist blinded to study group allocations. Representative photo images were collected using a Nikon Eclipse Ci microscope (Nikon Inc) and analyzed with NIS-Elements software (Nikon Inc). Scoring was performed following a published algorithm. See Carroll, T., et al. “The B.1.427/1.429 (epsilon) SARS-CoV-2 Variants Are More Virulent Than Ancestral B.1 (614G) in Syrian Hamsters,” PLOS Pathogens, 2022, 18, e1009914; Gruber, A.D., et al. “Standardization of Reporting Criteria for Lung Pathology in SARS-CoV-2-Infected Hamsters: What Matters?” Am. J. Respir. Cell. Mol Biol. 2020, 63, 856-859. Briefly, the airway, alveolar, and vascular pathology in affected areas were assessed and scored on a scale of 0-4, see Schultz, et al., infra, and then added together to generate a total histopathological score of the whole lung. Statistical Analysis [0227] The effect of dosing strategy on CD4 and CD8 cell polyfunctionality was assessed by one-way ANOVA with Tukey’s multiple comparisons test. The effect of dosing strategy on IgG titer and pseudovirus neutralizing antibody titers was assessed in log- transformed data using a mixed-effects model with Tukey’s multiple comparisons test. The effect of immunization strategy on IgG titer was assessed on log-transformed data using unpaired t tests or two-way ANOVA with Tukey’s or Sidak’s (if any sample data were missing) multiple comparisons test. The effect of immunization strategy on pseudovirus neutralizing antibody titers was assessed on log-transformed data using unpaired t tests or a mixed-effects model with Sidak’s multiple comparisons test. The effect of immunization strategy on polyfunctional CD4 and CD8 cell responses was assessed in untransformed data using unpaired t tests or one-way ANOVA with Holm-Sidak’s multiple comparisons test. Lung, bone marrow, and splenocyte ELISpot data were analyzed using log-transformed data by one-way ANOVA with Tukey’s multiple comparisons test. Hamster body weight data was analyzed using area under the curve measures assessed statistically by one-way ANOVA with Tukey’s multiple comparison test. Hamster viral load measures were
analyzed using log-transformed area under the curve measures, assessed with one-way ANOVA with Tukey’s multiple comparison test. All statistical analyses were conducted using Prism version 9 (GraphPad Software). Optimization of Vaccine Particle Size and Charge for Intranasal Delivery [0228] Particle size and surface charge are optimized for intranasal delivery of the self- amplifying RNA/NLC vaccine complex described herein. The size and charge of the complex is dictated by the ratio of the number of positively charged amine groups on the DOTAP lipid contained in the NLC to the number of negatively charged phosphate groups from the self-amplifying RNA backbone (N/P ratio). To understand how particle size and surface charge affect the delivery efficiency of the drug product, a range of N/P ratios were tested, and the particle size, polydispersity, zeta potential, particle concentration, and protection of the self-amplifying RNA from degradation by RNase A were characterized. These experiments were performed in conjunction with the H5N1 vaccine immunogenicity testing experiments described below. Effect of N/P Ratio on Particle Size and Polydispersity [0229] To investigate the effect of the N/P ratio on particle size, complexes were formed at N/P ratios ranging from N/P = 0.6 to N/P = 15. N/P = 15 was the highest N/P ratio selected as a historical starting point due to previous intramuscular dosing studies conducted by the Applicant. An N/P = 0.6 was previously determined to be the point at which the NLCs are saturated with self-amplifying RNA. Below this point, significant levels of free (non- complexed) self-amplifying RNA are detectable by agarose gel electrophoresis. [0230] Particle size and polydispersity was first assessed using dynamic light scattering (DLS). Immediately apparent in the intensity size distribution is the presence of two major species: a smaller species (~40 nm) corresponding to free NLCs, and a larger species (~130 nm) corresponding to the final self-amplifying RNA/NLC complex, as shown in FIG.17A. As the N/P ratio is decreased from 15, the particle size distribution profile shifts towards larger species, reflecting a decrease in the amount of free NLC in solution as it becomes complexed with the increasing amount of RNA. At N/P = 1, multiple large peaks greater than 1 µm are observed, and the two peaks corresponding to free NLC and the self- amplifying RNA/NLC complex are largely absent. This is likely due to the formation of large insoluble aggregates, as will be discussed further below. When the N/P ratio is further lowered below N/P = 1, the size distribution shifts towards a smaller size and the large
aggregate peak greater than 1 µm is no longer present. This indicates that the previously aggregated self-amplifying RNA/NLC complexes are now fully solubilized by the RNA – visually the turbidity of the formulation is substantially decreased below N/P = 1. This trend in particle size becomes readily apparent when plotting the Z-average diameter as a function of the N/P ratio, as shown in FIG.17B. Sample polydispersity remained constant across all N/P ratios at a value of approximately 0.4 apart from N/P = 1, which increased to a value of nearly 0.8, reflecting the increased degree of nanoparticle aggregation at this ratio, as shown in FIG.17C. Effect of N/P Ratio on Apparent Particle Size and Concentration using Nanoparticle Tracking Analysis [0231] Particle size and concentration as a function of N/P ratio was further evaluated using nanoparticle tracking analysis (NTA). In contrast to DLS, which records an ensemble measurement of the solution, NTA tracks individual nanoparticles, providing increased resolution of the self-amplifying RNA/NLC complex size distribution. This affords us greater insight as to the true state of the complexes once formed. In contrast to DLS, the size distribution profiles remained relatively similar in shape at all N/P ratios tested, the only difference being the height of the peak at approximately 50 – 70 nm in diameter, as shown in FIG. 18A. This peak can be attributed to non-complexed NLC. Like DLS, the particle concentration of this peak decreases with decreasing N/P ratio, reflecting the fact that less NLCs are free in solution as they are used to form complexes with the increasing amount of RNA. This is also reflected in the mean particle size - as the N/P ratio is decreased, mean particle size begins to increase, as shown in FIG. 18B. However, unlike with DLS, no apparent increase in particle size is observed at N/P = 1 by NTA. [0232] Particle concentration also decreases with decreasing N/P ratio, as shown in FIG. 18C. This is unsurprising considering that to achieve a lower N/P ratio at a constant RNA concentration, the concentration of NLCs used must be decreased. Interestingly, at N/P = 1 very few particles are detected, such that the particle concentration nearly appears to be zero, however, very large aggregate species are clearly detectable by DLS at this ratio. A possible explanation for this is that at N/P = 1, RNA and NLC molecules are forming very large and complex networks of crosslinked material beyond the range of detection of the instrument, leaving only a few particles that are small enough to be detected by NTA. Alternatively, at N/P = 1 the net surface charge of the complex is approaching neutral, leading to physical precipitation of the nanoparticles out of solution. This appears to be the
more likely explanation since of the few particles that were observed by NTA, a very small fraction of those were approaching the 1 µm range. At N/P = 0.6 the particle concentration is increased compared to N/P = 1, indicating that some threshold has been surpassed whereby the RNA now sufficiently saturates the NLC surface to allow for charge repulsion and solubilization of the once aggregated self-amplifying RNA/NLC complex. However, complete saturation of the NLC surface may have potential implications on the efficiency of RNA protection from enzymatic degradation by RNase A, as will be discussed further below. Relationship Between Zeta Potential and Protection of RNA from Enzymatic Degradation [0233] To assess the effect of the N/P ratio on complex zeta potential, self-amplifying RNA/NLC complexes were formed at N/P ratios ranging from N/P = 0.6 to N/P = 15. The zeta potential of the complexes was then measured after diluting 100-fold with water, as shown in FIG. 19A. The complexes maintained a constant zeta potential of approximately +12 mV from N/P = 15 to N/P = 5. At N/P = 1 the zeta potential dropped substantially to a value of nearly -40 mV, and at N/P = 0.6 where the RNA is fully saturating the NLCs, the zeta potential dropped further to nearly -60 mV. As discussed above, it is likely that at around N/P = 1 the RNA fully masks the surface of the NLCs and thus the dominant factor determining the surface charge of the complex. A highly cooperative effect of RNA binding to NLC begins to take place, which could result in a significant fraction of the particles having a net neutral charge at N/P = 1, contributing to the large increase in particle aggregation and decreased solubility at this ratio. Below N/P = 1, more RNA is present on the NLC surface, further decreasing the charge. This is consistent with the RNA effectively solubilizing the NLCs, which would simultaneously have the effect of increasing the apparent particle concentration below N/P = 1, as discussed above. Based on the zeta potential, a decrease in delivery efficiency of the RNA is expected at N/P = 1 and below due to charge repulsion between the complexes and cell membranes, which are largely anionic in nature. [0234] Protection of the complexed RNA at different N/P ratios was assessed by treating complexes with a small amount of RNase A at room temperature for 30 minutes, extraction of RNA from the complexes, followed by agarose gel electrophoresis and visualization with ethidium bromide, as shown in FIG. 19B-C. Protection is equally maintained from N/P = 15 down to N/P = 5, however protection is completely lost at N/P = 1 and below. This rapid loss in protection occurs simultaneously with the rapid switch in zeta potential from a
positive to a negative value when the N/P ratio is decreased to a value of 1 and below, indicating that RNA protection depends on the particle charge. Taken together with the information gained from size and particle concentration analysis, this is consistent with a mechanism by which the RNA overcrowds the NLC surface in the final complex, resulting in an increase the amount of RNA that is extending away from the NLC surface and left exposed to degradation by RNases in solution. Overall, these data suggest that an N/P ratio of about 3 or greater is beneficial, as this will protect the RNA, maintain the positive zeta potential necessary for cellular uptake, and limit the formation of very large aggregate species. Cryo-TEM Imaging of self-amplifying RNA/NLC Complexes [0235] Cryo-TEM was used to visualize the appearance of NLCs as well as the self- amplifying RNA NLC complex, as shown in FIG. 20. Non-complexed NLCs show a size of approximately 40-50 nm in diameter, with some heterogeneity in the particle morphology that is to be expected for NLCs, as shown in FIG. 20A. NLCs complexed with self- amplifying RNA at N/P = 15, as shown in FIG.20B, visually appear indistinguishable from non-complexed NLCs. However, the appearance of a second, larger peak of approximately 130 nm in the DLS intensity size distribution which does not appear in the size distribution of the bulk NLC material indicates that the self-amplifying RNA is forming a complex with the NLC at this ratio. This would suggest that the bulk of the NLCs at N/P = 15 are not in complex with the self-amplifying RNA; that is, there is a large excess of free NLC in solution. It should be noted that DLS measurements are easily skewed by the presence of large particles, which makes it appear as though there are more large particles present in the media than there are in reality. When the N/P ratio is decreased to N/P = 5, dark string-like material may be observed protruding from the surfaces of the NLCs—this is the self- amplifying RNA becoming visible as it is no longer saturated by the NLCs, as shown in FIG.20C. Further decreasing to N/P = 0.6 allows the self-amplifying RNA to fully saturate the NLCs, an expansive RNA “shell” around the NLC surface, as shown in FIG.20D. [0236] At N/P = 5 the RNA ais protruding away from the RNA surface to a high degree and visually appears largely similar to complexes formed at N/P = 0.6. However, it is known that at N/P = 5 RNA protection is maintained and the zeta potential remains positive, whereas at N/P = 0.6 RNA protection is completely lost and the zeta potential has now decreased to nearly -60 mV. A likely explanation for this is that at N/P = 5, there is still a significant population of non-complexed (free) NLCs that are not readily apparent by TEM imaging, but still serve to confer protection of the RNA from enzymatic degradation,
possibly by denaturing RNase A through a hydrophobic and/or electrostatic means. At N/P = 0.6, no NLCs remain free in solution. As a result, protection of the RNA from enzymatic degradation is completely lost, as well as the contribution of the excess DOTAP from the free NLCs to the zeta potential. This may also partially explain the decreased potency of the vaccine at low N/P ratios, as there is no longer sufficient positive charge present in the final complexed product to assist in efficient transfection of cells with self-amplifying RNA for antigen expression. This will be further discussed below. H5N1 Studies [0237] The H5N1 influenza construct was produced using the HA sequence from H5N1, A/Vietnam/1203/2004 (Genbank: EU122404) inserted into an optimized VEEV-based self- amplifying RNA replicon, as shown in FIG. 21. The sequence was produced using an optimized in vitro transcription protocol. The resulting RNA construct is complexed to the exterior of a nanostructured lipid carrier (NLC) described herein to create the final vaccine product. Initial H5 Vaccine Immunogenicity Confirmation [0238] To confirm whether an H5 influenza vaccine induces similar immune profiles to the intranasal SARS-CoV-2 spike vaccine described herein, initial vaccine immunogenicity was tested at the previously-used N/P ratio of 15, with a 5 µg dose/mouse as previously demonstrated to be optimal for the SARS-CoV-2 i.n.-delivered self-amplifying RNA/NLC vaccine. While this delivery formulation is known to show some signs of reactogenicity, as indicated by transient mouse weight loss, attributed to the NLC component, it is clearly functional as an intranasal RNA delivery formulation as described herein. [0239] Each study group included ten 6- to 8-week-old C57BL/6 mice, evenly split between males and females, as shown in Table 2. Each study group was administered the vaccine at doses indicated in FIG. 22 at day 0 (prime vaccination) and day 22 (boost vaccination) of the study. Blood was collected by the retro-orbital route every 7 days. Each mouse was individually ear-tagged and tracked across the entire study. Post-prime and post- boost serum was analyzed for IgG titer by ELISA and pseudovirus neutralization titers. Bone marrow was collected at harvest to measure B cell IgG secretion, while spleens and lungs were isolated for T cell flow cytometry.
Experimental Groups for Initial N/P Dosing Comparison
Table 2 [0240] To assess the induction of serum immunogenicity, H5-binding serum IgG titers were measured post-prime (day 21) and post-boost (day 37), as shown in FIG.23A. Serum IgG was detectable at high levels in animals vaccinated with the H5 self-amplifying RNA/NLC vaccine, both intramuscularly and intranasally, with serum IgG at >105 ng/mL post-boost, with no significant differences between the two dosing strategies. Pseudovirus neutralization assays indicated that post-prime, i.m. vaccine dosing was able to generate IC50s greater than 1:100, while minimal responses were seen post-prime in the i.n. vaccinated group with a minimal detectable response was seen in a single animal, as shown in FIG. 23B. This is generally consistent with the SARS-CoV-2 vaccine responses, where i.n. priming induced significantly lower serum antibody titers than i.m. dosing, differences that disappeared after a boost dose. Similarly, for this H5 vaccine, both dosing strategies induced post-boost serum IC50 averages > 1:1000. This indicates the i.n. dosing of this vaccine construct can establish comparable serum antibody responses to i.m. dosing after a prime-boost regimen. [0241] Cellular immunogenicity with bone marrow ELISpots was then assessed to detect H5-specific IgG-secreting antibody secreting cells in bone marrow, as shown in FIG. 24. High levels of these ASCs, >32 spots/million bone marrow cells, were detected in both immunized mouse groups after the prime-boost regimens, and no significant differences between the two groups were observed. [0242] To assess the induction of antigen-responding polyfunctional CD4+ and CD8+ T cell populations, both spleens (systemic immunogenicity) and lungs (respiratory immunogenicity) were isolated and stimulated with H5 overlapping peptides. ICS and flow cytometry were used to evaluate the levels of polyfunctional T cells. Substantial levels of polyfunctional CD4 and CD8 T cells were detected in spleens of both i.m. and i.n.
vaccinated animals, with no significant differences seen between the two groups, as shown in FIGS.25A-B. [0243] Both i.m. and i.n. vaccination also induced antigen-reactive CD4 and CD8 T cells in the lungs. While differences were not always statistically significant due to the natural variance observed in T cell data, there is a consistent trend towards higher responses with intranasal administration, as shown in FIGS.25C-D. Looking at the specialized CD69+ TRM subset, there were significantly higher responses in CD4+ T cells induced by the i.n. vaccine relative to the i.m. vaccine, and a trend in the same direction with CD8+ cells, as shown in FIG.25E-F. These results are consistent with the data described above using the intranasally-delivered SARS-CoV-2 self-amplifying RNA/NLC vaccine candidate. [0244] These data demonstrate the in vitro immunogenicity of this vaccine construct. Further optimization of the vaccine size and charge parameters, controlled predominantly by the formulation N/P ratio, was carried out by screening intranasally-dosed vaccines at various N/P ratios, as described below. In-Depth N/P Ratio Comparison [0245] To further optimize the vaccine construct described herein for intranasal delivery, a range of vaccine N/P ratios were assessed to determine which was optimal. The optimal ratio of N/P for this vaccine formulation minimizes reactogenicity while maximizing immunogenicity. [0246] Study groups spanned a range from N/P=0.6-15, and included a control of mice i.m. dosed with the H5 self-amplifying RNA/NLC vaccine at N/P=15, as well as a vector control group as before. Each study group included five 6- to 8-week-old C57BL/6 mice female mice, as shown in Table 3. [0247] Each mouse was administered vaccine at 5 µg per mouse as indicated in FIG.26 at day 0 (prime vaccination) and day 21 (boost vaccination) of the study. Blood was collected by the retro-orbital route every 7 days. Each mouse was individually ear-tagged and tracked across the entire study. Vaccine reactogenicity was assessed by tracking the body weight of each mouse for the 5 days post-dosing. Post-prime and post-boost serum was analyzed for IgG titer by ELISA and pseudovirus neutralization assays. Bone marrow was collected at harvest to measure B cell IgG secretion, and spleens and lungs were isolated for T cell flow cytometry. The resulting data were analyzed to address whether the N/P ratio affects vaccine reactogenicity as assessed by weight loss, whether the N/P ratio affects
vaccine immunogenicity, and what the optimal N/P ratio is to balance reactogenicity and immunogenicity. Experimental Groups for In-Depth N/P Ratio Comparison
Table 3 [0248] The first measure of N/P ratio effect was vaccine reactogenicity. Mice were weighed daily for 7 days following prime and boost vaccination and data are shown in FIG. 27. As shown, vaccines with higher N/P ratios (10 and above) led to greater magnitudes of transient bodyweight loss immediately after immunization in the post-prime days, that recovered by day 5. Vaccine formulated at N/P=8 resulted in significantly reduced bodyweight drop, >5% weight loss at day 1 that recovered by day 3. All other study groups (vaccines at N/P<8) showed no effect on bodyweight. This effect on bodyweight was more
evident after the prime vaccination dose. These dynamics suggest that N/P of 8 or lower show reduced reactogenicity for intranasal dosing than the previous N/P=15 vaccine. [0249] Serum antibody responses were assessed next. IgG ELISA titers demonstrated a steep drop-off in vaccine immunogenicity in vaccines formulated at N/P ratios below 5, with these low N/P groups showing no detectable H5-binding serum IgG response. However, H5-binding IgG titers were induced at significant levels at N/P=5 and above. IgG levels were highly similar across all groups formulated at N/P ratios of 8 and above, as shown in FIG.28. These data demonstrate that vaccine formulated at lower N/P clearly is unable to effectively deliver vaccine self-amplifying RNA to cells, resulting in a total lack of immune response. Vaccine formulated at N/P=5 shows significant induction of responses, and vaccines at N/P above 5 stimulate the highest and equivalent levels of serum IgG. These results were confirmed by a full repeat of this study, with very similar data collected (not shown). [0250] Likewise, the serum pseudovirus neutralizing antibody titer data demonstrated a similar response cliff at N/P 5 and below, as shown in FIG.29. Here, there was no response below N/P=8 post-prime, though the N/P=5 group did recover a response upon boost vaccination. Boost immunization overall had a greater effect on serum pseudovirus neutralizing antibody titers in boosting final titers. After boost, vaccines formulated at N/P=5 and above had induced demonstrated serum neutralizing antibody titers in mice, in patterns similar to those seen with the serum IgG titers measured by ELISA. [0251] Next, bone marrow was assessed for IgG and IgA antibody-secreting cells, as shown in FIG 30. Similar results were evident across both measures, with no responses seen induced by vaccines formulated at N/P ratios below 5, and significant responses induced by vaccines formulated at N/P=5 and above. Again, this confirms that while there is a cutoff below N/P=5, below which no vaccine-induced immune responses are detected and presumably self-amplifying RNA is not effectively delivered to cells, vaccine formulation at N/P ratios above 5 appear generally equivalent in their ability to induce bone marrow- resident immune responses. [0252] Lastly, T cell immunogenicity was assessed in splenocytes and lung T cells, as shown in FIG 31. The splenocytes showed increases in responses as N/P ratio increased, with vaccine formulated at N/P=8 and above inducing noticeably higher CD4+ and C8+ T cell responses, as shown in FIGS.31A-B, than seen induced by vaccine formulated at lower N/P ratios. Similar patterns were observed in lung CD4+ cells, though the CD8+ cells showed low polyfunctional responses to antigen stimulation overall relative to CD4+ cells,
across vaccines formulated at all effective N/P ratios, as has been seen in previous experiments, as shown in FIGS.25C-D. Finally, the specialized T resident memory cells in the lungs, CD69+ T cells, also showed enhanced polyfunctionality in both CD4+ T cells and CD8+ T cells at N/P=8 and above, as shown in FIGS.25E-F. [0253] Based on the experimental results discussed above, it was determined that an N/P ratio of 8-10 optimizes both vaccine reactogenicity and immunogenicity. Testing Alternate Oils [0254] Further optimization of the NLC formulation for intranasal vaccination was achieved through testing of alternative liquid oils for suitability. The oil used in the NLC formulation may further improve vaccine immunogenicity while reducing signs of vaccine reactogenicity. The base self-amplifying RNA delivery NLC formulation contains squalene, which has known tissue-irritating properties and may not be optimal for use in intranasal vaccine delivery to sensitive mucosal tissues. Additionally, moving away from a squalene- containing formulation may allow for an improved supply chain, as shark-based squalene is a non-renewable material. Alternate oils were studied with the H5 vaccine self-amplifying RNA formulated at an N/P ratio of 10, to allow gauging of any reduced reactogenicity of the alternate-oil NLC formulations relative to the standard squalene-based NLC. Using an N/P that showed some evidence of reactogenicity with the squalene NLC formulation allowed for detection of reduction in reactogenicity by any of these alternate-oil NLC formulations. [0255] New alternate oil NLCs were created with Miglyol® 810, cottonseed oil, castor oil, and soybean oil, in addition to the standard squalene-based NLCs. H5-expressing self- amplifying RNA formulated with each of these NLCs comprised the study groups, all complexed at N/P=10. The vaccine was administered intranasally (i.n.) at 5 µg per mouse. A non-immunogenic vector control self-amplifying RNA/NLC construct (SEAP self- amplifying RNA) was used as a negative control and administered i.n. formulated with squalene-containing NLCs at N/P=10. Each study group included 6 (controls) or 8 (study groups) 6- to 8-week-old C57BL/6 mice, evenly split between males and females, as shown in Table 4. [0256] Each study group was administered vaccine as indicated in FIG. 32 at day 0 (prime vaccination) and day 22 (boost vaccination) of the study. Blood was collected by the retro-orbital route every 7 days. Each mouse was individually ear-tagged and tracked across the entire study. Post-prime and post-boost serum was analyzed for IgG titer by ELISA and pseudovirus neutralizing antibody titers. Spleens and lungs were isolated for T cell flow
cytometry at the end of the study. The resulting data were statistically analyzed to address whether any of the alternate oil NLCs are less apparently reactogenic than the standard squalene NLC and whether any of the alternate oil NLCs exhibit equivalent or enhanced immunogenicity relative to the standard squalene NLC.
Experimental Groups for Testing Alternate Oil NLC-Delivered Self-Amplifying RNA Vaccines
Table 4 [0257] To address a primary goal of reducing apparent intranasal vaccine reactogenicity, mice were weighed after prime and boost vaccinations. Several of the new preparations induced reduced weight loss relative to the squalene NLC formulation, as shown in FIG 33. In particular, vaccines formulated with the Miglyol® 810, cottonseed, and castor oil NLCs showed improved profiles relative to vaccine formulated with the standard NLC post-prime, as shown in FIG 33A. Post-boost there was far less variability in the mouse weights, as previously seen, as shown in FIG 33B., with all vaccine formulations showing generally the same slight reduction immediately post-vaccination with a rapid return to baseline over the course of a few days, as may be observed in response to mouse handling for dosing. [0258] Serum immunogenicity was then assessed to determine how these alternate oil NLCs affected the vaccines’ induction of systemic antibody responses. The ELISA measures demonstrated that none of the oils markedly reduced the antibody response induced by the various vaccine formulations relative to the squalene NLC formulated
vaccine, as shown in FIG 34. However, the Miglyol® 810 NLC was significantly higher than the castor and soybean oil NLCs post boost. And the cottonseed oil based NLCs appeared to have induced enhanced serum antibody titers relative to the standard preparation both post-prime and post-boost. [0259] This was further confirmed by assessing the capacity of these vaccine preparations to induce serum pseudovirus neutralizing antibodies in mice, as shown in FIG 35. It was observed that the Miglyol® 810 oil and cottonseed oil containing NLCs all induced improved serum pseudovirus neutralization in mice relative to the standard squalene NLCs, though with some greater spread in the responses (cottonseed oil NLC formulated vaccine). [0260] T cell responses in these different vaccine groups were then assessed via ICS/flow cytometry, as shown in FIG 36. Compared to all other formulations and the standard squalene-based formulation, the Miglyol® 810-based NLC showed a significant enhancement of antigen-responsive polyfunctional CD4 and CD8 T cell populations. This was demonstrated not only in spleens, but also in lung TRM cells (CD69+). [0261] Collectively, these data indicate that an optimal vaccine formulation is based on Miglyol® 810 containing NLCs, reducing reactogenicity and enhancing vaccine immunogenicity as compared to squalene containing NLCs. [0262] DEFINITIONS [0263] The following terms have the following meanings unless otherwise indicated. Any undefined terms have their art recognized meanings. [0264] In the present description, the terms “about,” “around,” “approximately,” and similar referents mean ± 20% of the indicated range, value, or structure, unless otherwise indicated. [0265] The use of the alternative (e.g., “or”) should be understood to mean either one, both, or any combination thereof of the alternatives. [0266] As used herein, the terms “include,” “have” and “comprise” are used synonymously, which terms and variants thereof are intended to be construed as non- limiting. [0267] As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly indicates otherwise. [0268] The terms thermostable lyophilized vaccine composition, lyophilized vaccine composition, lyophilized thermostable cake, and lyophilized cake are used interchangeably herein. These terms generally refer to a lyophilized oil-in-water stable emulsion comprising
a biodegradable oil or metabolizable oil, cake-forming excipients used to produce the cake, and optionally one or more bioactive agents. [0269] The term “alkyl” means a straight chain or branched, noncyclic or cyclic, unsaturated or saturated aliphatic hydrocarbon containing the indicated number of carbon atoms. Unsaturated alkyls contain at least one double or triple bond between adjacent carbon atoms. [0270] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified nucleotides or amino acids, and it may be interrupted by non- nucleotides or non-amino acids. The terms also encompass a nucleotide or amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polynucleotides or polypeptides containing one or more analogs of a nucleotide or an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. [0271] The term “isolated” means the molecule has been removed from its natural environment. [0272] “Purified” means that the molecule has been increased in purity, such that it exists in a form that is more pure than it exists in its natural environment and/or when initially synthesized and/or amplified under laboratory conditions. Purity is a relative term and does not necessarily mean absolute purity. [0273] A “polynucleotide” or “nucleic acid,” as used interchangeably herein, refer to polymers of nucleotides of any length, include DNA and RNA. The nucleotides can be, for example, deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase, or by a synthetic reaction. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of the polymer. [0274] The term “RNA integrity” as used herein means the quantity of intact RNA remaining after an event or passage of time. For example, RNA integrity may be evaluated following freezing, lyophilization, or storage. RNA integrity may be evaluated by both the size and strength of bands shown in agarose gel electrophoresis.
[0275] An “individual” or a “subject” is any vertebrate. Vertebrates include, but are not limited to humans, primates, farm animals (such as cows, pigs, sheep, chickens), sport animals, pets (such as cats, dogs, birds, horses), and rodents. [0276] A “replicon” as used herein includes any genetic element, for example, a plasmid, cosmid, bacmid, phage or virus that is capable of replication largely under its own control. A replicon may be either RNA or DNA and may be single or double stranded. [0277] The term liquid phase lipid refers to a lipid that, prior to mixing with any other component, is liquid at ambient temperature. [0278] The term solid phase lipid refers to a lipid that, prior to mixing with any other component, is solid at ambient temperature. [0279] Ambient temperature is between 15°C and 25°C. [0280] Cake-forming excipient and lyoprotectant are used herein interchangeably. A cake-forming excipient refers to a substance added to a liquid stable oil-in-water emulsion formulation prior to lyophilization which yields a cake following lyophilization. Upon reconstitution of the lyophilized cake, a stable emulsion forms, that is suitable for delivery of a bioactive agent including vaccine antigens or polynucleotides encoding vaccine antigens. As used herein, cake-forming excipients are those substances which do not disrupt an emulsion upon reconstitution of the lyophilized cake. [0281] Excipients as used herein refers to substances other than the pharmacologically active drugs, which are included in the manufacturing process, or fill-finish process for storage or shipment of the pharmacologically active drug including, without limitation, lyophilization, and are contained in a finished pharmaceutical process. [0282] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology, recombinant DNA, biochemistry, and chemistry, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Molecular Cloning A Laboratory Manual, 2nd Ed., Sambrook et al., ed., Cold Spring Harbor Laboratory Press: (1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al., U.S. Pat. No: 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); B. Perbal, A Practical Guide to Molecular Cloning (1984); the treatise, Methods in Enzymology (Academic Press, Inc., N.Y.); and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Maryland (1989).
CONCLUSION [0283] The previous description of the disclosed implementations is provided to enable any person skilled in the art to make or use the invention disclosed herein. Although the various inventive aspects are disclosed in the context of one or more illustrated embodiments, implementations, and examples, it should be understood by those skilled in the art that the invention extends beyond the specifically disclosed implementations to other alternative implementations and/or uses of the invention and obvious modifications and equivalents thereof. It should be also understood that the scope of this disclosure includes the various combinations or sub-combinations of the specific features and aspects of the implementations disclosed herein, such that the various features, modes of implementation, and aspects of the disclosed subject matter may be combined with or substituted for one another. The generic principles defined herein may be applied to other implementations without departing from the spirit or scope of the disclosure. Thus, the present disclosure is not intended to be limited to the implementations shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein. [0284] All references listed herein, including patent applications and patent publications are herein incorporated by reference in their entirety, as if each individual reference is specifically and individually indicated to be incorporated by reference.
Claims
CLAIMS What is claimed is: 1. A method of inducing an immune response in a subject by intranasal administration comprising administering a composition comprising an RNA/NLC complex formed by complexing a nanostructured lipid carrier (NLC) with a self-amplifying ribonucleic acid (saRNA).
2. The method of claim 1, wherein the NLC comprises a liquid oil, a solid oil, a cationic lipid, a first hydrophobic surfactant, and a second surfactant.
3. The method of claim 2, wherein the liquid oil comprises an oil selected from the group consisting of castor oil, coconut oil, corn oil, cottonseed oil, evening primrose oil, fish oil, grapeseed oil, jojoba oil, lard oil, linseed oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, squalane, sunflower oil, wheatgerm oil, mineral oil, capric/caprylic triglyceride, vitamin E, lauroyl polyoxylglycerides, monoacylglycerols, soy lecithin, famesene, or a combination thereof.
4. The method of claim 2, wherein the liquid oil comprises an oil selected from the group consisting of squalene, squalene, capric/caprylic triglyceride, or a combination thereof.
5. The method of claim 2, wherein the liquid oil comprises an oil selected from the group consisting of capric/caprylic triglyceride, vitamin E, lauroyl polyoxylglycerides, monoacylglycerols, soy lecithin, squalene, squalene, or a combination thereof.
6. The method of claim 2, wherein the liquid oil comprises an oil selected from the group consisting of squalene, squalene, famesene, or a combination thereof.
7. The method of claim 2, wherein the liquid oil comprises capric/caprylic triglyceride.
8. The method of claim 7, wherein the capric/caprylic triglyceride comprises Miglyol® 810.
9. The method of any of claims 2-8, wherein the solid oil comprises a glycerolipid.
10. The method of any of claims 2-8, wherein the solid oil is selected from the group consisting of glyceryl palmitostearate, glycerylmonostearate, glyceryl dibehenate, cetyl palmitate, stearic acid, tripalmitin, and a microcrystalline triglyceride.
11. The method of claim 10, wherein the solid oil is a microcrystalline triglyceride selected from the group consisting of trimyristin, tristearin, and tripalmitin.
12. The method of any of claims 2-11, wherein the cationic lipid is selected from the group consisting of benzalkonium chloride, benzethonium chloride, cetrimide, CPC, CTAC, N,N’,N’-polyoxyethylene (10)-N-tallow-l,3-diaminopropane, dodecyltrimethylammonium bromide, hexadecyltrimethylammonium bromide, mixed alkyl-trimethyl-ammonium bromide, benzyldimethyldodecylammonium chloride, benzyldimethylhexadecylammonium chloride, benzyltrimethylammonium methoxide, cetyldimethylethylammonium bromide, methylbenzethonium chloride, decamethonium chloride, methyl mixed trialkyl ammonium chloride, methyl trioctylammonium chloride, dialkyldimethylammonium salts, [1-(2,3-dioleyloxy)-propyl]-N,N,N-trimethylammonium chloride, l,2-diacyl-3-(trimethylammonio)propane, l,2-diacyl- 3(dimethylammonio)propane, l,2-dioleoyl-3-(4’-trimethyl-ammonio)butanoyl-sn-glycerol, 1,2-dioleoyl 3-succinyl-sn-glycerol choline ester, cholesteryl (4’-trimethylammonio) butanoate), N-alkyl pyridinium salts, N-alkylpiperidinium salts, dicationic bolaform electrolytes, dialkylglycetylphosphorylcholine, lysolecithin, L-α- dioleoylphosphatidylethanolamine, cholesterol hemisuccinate choline ester, LPLL, LPDL, poly (L (or D)-lysine conjugated to N-glutarylphosphatidylethanolamine, didodecyl
glutamate ester with pendant amino group (C12GluPhCnN+), ditetradecyl glutamate ester with pendant amino group (C14GluCnN+), cholesteryl-3-β- oxysuccinamidoethylenetrimethylammonium salt, cholesteryl-3-β- oxysuccinamidoethylenedimethylamine, cholesteryl-3-β-carboxy amidoethylenetrimethylammonium salt, cholesteryl-3-β-carboxy amidoethylenedimethylamine, DC Cholesterol, DOTAP, DDA, DMTAP, DPTAP, DSTAP, DOTMA, DODAC, DOEPC, DODAP, DLinDMA, DDA, DDAB, DEBDA, DOGS, DPPES, and combinations thereof.
13. The method of any of claims 2-11, wherein the cationic lipid is selected from the group consisting of DC Cholesterol, DOTAP, DDA, DMTAP, DPTAP, DSTAP, DOTMA, DODAC, DOEPC, DODAP, DLinDMA, DDA, DDAB, DEBDA, DOGS, DPPES, and combinations thereof.
14. The method of any of claims 2-11, wherein the cationic lipid is DOTAP.
15. The method of any of claims 2-14, wherein the first hydrophobic surfactant is a sorbitan ester.
16. The method of any of claims 2-14, wherein the first hydrophobic surfactant is a sorbitan alkyl esters, wherein the alkyl is a saturated or unsaturated C10-C20 alkyl group.
17. The method of any of claims 2-14, wherein the first hydrophobic surfactant is a sorbitan monoester.
18. The method of any of claims 2-14, wherein the first hydrophobic surfactant is a sorbitan diester.
19. The method of any of claims 2-14, wherein the first hydrophobic surfactant is a sorbitan triester.
20. The method of any of claims 2-14, wherein the first hydrophobic surfactant is selected from the group consisting of sorbitan monostearate, sorbitan monooleate, sorbitan monolaurate, and sorbitan monopalmitate.
21. The method of any of claims 2-14, wherein the first hydrophobic surfactant is sorbitan monostearate.
22. The method of any of claims 2-21, wherein the second surfactant is a polysorbate.
23. The method of any of claims 2-21, wherein the second surfactant is polysorbate 80.
24. The method of any of claims 2-23, wherein the NLC further comprises an aqueous citrate.
25. The method of any of claims 1-24, wherein the self-amplifying RNA encodes the SARS-COV2 spike protein.
26. The method of claim 1-24, wherein the self-amplifying RNA encodes an influenza antigen.
27. The method of claim 26, wherein the influenza antigen is an H5N1 antigen.
28. The method of any of claims 1-27, wherein the immune response is generation of binding antibodies, neutralizing antibodies, or both.
29. The method of any of claims 1-27, wherein the immune response is a respiratory mucosal immune response.
30. The method of any of claims 1-29, wherein the RNA/NLC complex has an N/P ratio of between about 3 and about 15.
31. The method of any of claims 1-29, wherein the RNA/NLC complex has an N/P ratio of between about 5 and about 12.
32. The method of any of claims 1-29, wherein the RNA/NLC complex has an N/P ratio of between about 6 and about 11.
33. The method of any of claims 1-29, wherein the RNA/NLC complex has an N/P ratio of between about 6 and about 10.
34. The method of any of claims 1-29, wherein the RNA/NLC complex has an N/P ratio of between about 7 and about 10.
35. The method of any of claims 1-29, wherein the RNA/NLC complex has an N/P ratio of between about 8 and about 10.
36. The method of any of claims 1-35, wherein inducing an immune response in a subject results in vaccination of the subject against a respiratory disease.
37. The method of claim 36, wherein the respiratory disease is COVID-19.
38. The method of claim 36, wherein the respiratory disease is influenza.
39. The method of any of claims 36-38, wherein the subject is a human.
40. A method of vaccinating a subject against an infectious respiratory disease by intranasal administration of a nanostructured lipid carrier (NLC) complexed with self- amplifying RNA.
41. The method of claim 40, wherein the infectious respiratory disease is COVID-19 or influenza.
42. The method of any of claims 40-41, wherein the subject is a human.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263345345P | 2022-05-24 | 2022-05-24 | |
US63/345,345 | 2022-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023228116A1 true WO2023228116A1 (en) | 2023-11-30 |
Family
ID=86899419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/055355 WO2023228116A1 (en) | 2022-05-24 | 2023-05-24 | Intranasal administration of thermostable rna vaccines |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023228116A1 (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US20080057080A1 (en) | 2004-05-18 | 2008-03-06 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
US20080085870A1 (en) | 2002-12-23 | 2008-04-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
US20200230056A1 (en) | 2017-06-15 | 2020-07-23 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
WO2021214204A1 (en) * | 2020-04-22 | 2021-10-28 | BioNTech SE | Rna constructs and uses thereof |
WO2022051024A1 (en) * | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Genetically-adjuvanted rna vaccines |
WO2022051022A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
US20220096625A1 (en) * | 2020-03-23 | 2022-03-31 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
-
2023
- 2023-05-24 WO PCT/IB2023/055355 patent/WO2023228116A1/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683195B1 (en) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US20080085870A1 (en) | 2002-12-23 | 2008-04-10 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US20080057080A1 (en) | 2004-05-18 | 2008-03-06 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
US20200230056A1 (en) | 2017-06-15 | 2020-07-23 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
US20220096625A1 (en) * | 2020-03-23 | 2022-03-31 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
WO2021214204A1 (en) * | 2020-04-22 | 2021-10-28 | BioNTech SE | Rna constructs and uses thereof |
WO2022051024A1 (en) * | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Genetically-adjuvanted rna vaccines |
WO2022051022A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
Non-Patent Citations (20)
Title |
---|
"B. Perbal, A Practical Guide to Molecular Cloning", 1984 |
"DNA Cloning", vol. 1, 2, 1985 |
"Genbank", Database accession no. EU122404 |
"Methods in Enzymology", ACADEMIC PRESS, INC. |
ADLINGTON, K. ET AL.: "Molecular Design of Squalene/Squalane Countertypes via the Controlled Oligomerization of Isoprene and Evaluation of Vaccine Adjuvant Applications", BIOMACROMOLECULES, vol. 17, no. 1, 2016, pages 165 - 72 |
ANDERLUZZI GIULIA ET AL: "The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency", JOURNAL OF CONTROLLED RELEASE, vol. 342, 1 February 2022 (2022-02-01), AMSTERDAM, NL, pages 388 - 399, XP093075852, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2021.12.008 * |
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1989, COLD SPRING HARBOR LABORATORY PRESS |
BAHETIA, A. ET AL.: "Excipients Used in Lyophilization of Small Molecules", J. EXCIP. FOOD CHEM., vol. 1, no. 1, 2010, pages 41 - 54 |
BLAKNEY ANNA K ET AL: "Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 338, 18 August 2021 (2021-08-18), pages 201 - 210, XP086825955, ISSN: 0168-3659, [retrieved on 20210818], DOI: 10.1016/J.JCONREL.2021.08.029 * |
CARROLL, T. ET AL.: "The B. 1.427/1.429 (epsilon) SARS-CoV-2 Variants Are More Virulent Than Ancestral B.1 (614G) in Syrian Hamsters", PLOS PATHOGENS, vol. 18, 2022, pages e1009914 |
GERHARDT ALANA ET AL: "A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, vol. 25, 1 June 2022 (2022-06-01), GB, pages 205 - 214, XP093075470, ISSN: 2329-0501, DOI: 10.1016/j.omtm.2022.03.009 * |
GRABENSTEIN, J. D.: "ImmunoFacts: Vaccines and Immunologic Drugs", 2012, WOLTERS KLUWER HEALTH |
GRUBER, A.D. ET AL.: "Standardization of Reporting Criteria for Lung Pathology in SARS-CoV-2-Infected Hamsters: What Matters?", AM. J. RESPIR. CELL. MOL BIOL., vol. 63, 2020, pages 856 - 859 |
JENNEWEIN MADELEINE ET AL: "492. An Intranasal saRNA/NLC Vaccine Induces Robust Mucosal and Systemic Immunity to SARS-CoV-2 in Mice", MOLECULAR THERAPY, ELSEVIER INC, US, vol. 30, no. 4 , suppl 1, 1 April 2022 (2022-04-01), pages 234, XP009547002, ISSN: 1525-0016 * |
JENNEWEIN MADELEINE F. ET AL: "Intranasal self-amplifying RNA SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission", BIORXIV, 5 May 2023 (2023-05-05), XP093075857, Retrieved from the Internet <URL:https://doi.org/10.1101/2022.11.10.515993> [retrieved on 20230823], DOI: 10.1101/2022.11.10.515993 * |
KING, R. G. ET AL.: "Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge", VACCINES (BASEL), vol. 9, 2021, pages 881 |
MAI YAPING ET AL: "Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 354, 4 June 2020 (2020-06-04), XP086216004, ISSN: 0008-8749, [retrieved on 20200604], DOI: 10.1016/J.CELLIMM.2020.104143 * |
SCHULTZ, M. D. ET AL.: "A Single Intranasal Administration of AdCOVID Protects Against SARS-CoV-2 Infection in the Upper and Lower Respiratory Tracts", HUMAN VACCINES & IMMUNOTHERAPEUTICS, vol. 0, 2022, pages 2127292 |
TATENO, M. ET AL.: "Synthetic Biology-Derived Triterpenes as Efficacious Immunomodulating Adjuvants", SCI. REP., vol. 10, 2020, pages 17090 |
VOIGT, E. A. ET AL.: "A Self-Amplifying RNA Vaccine against COVID-19 with Long-Term Room-Temperature Stability", NPJ VACCINES, vol. 7, 2022, pages 1 - 13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11141377B2 (en) | Nanostructured lipid carriers and stable emulsions and uses thereof | |
EP2701734B1 (en) | Liposomal formulations | |
TW202200605A (en) | Coronavirus vaccine compositions and methods | |
Anderluzzi et al. | The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency | |
KR102483033B1 (en) | PEGylated Liposomes and Uses Thereof | |
US20230310323A1 (en) | Co-lyophilized rna and nanostructured lipid carrier | |
Smith et al. | Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus | |
WO2023228116A1 (en) | Intranasal administration of thermostable rna vaccines | |
Scherließ | Delivery of antigens used for vaccination: recent advances and challenges | |
Liu et al. | Transcutaneous immunization via dissolving microneedles protects mice from lethal influenza H7N9 virus challenge | |
Wang et al. | Monophosphoryl lipid A-adjuvanted nucleoprotein-neuraminidase nanoparticles improve immune protection against divergent influenza viruses | |
Tree et al. | An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung | |
Wu et al. | Nanovaccines to combat virus‐related diseases | |
CA3219206A1 (en) | Sars-cov-2 subunit vaccine | |
EP4210741A1 (en) | Vaccine for viral pathogens | |
GB2573649A (en) | Pharmaceutical compositions and associated kits and uses | |
Jennewein et al. | An intranasal self-amplifying RNA SARS-CoV-2 vaccine produces durable respiratory and systemic immunity | |
US20240115693A1 (en) | Sars-cov-2 antigen nanoparticles and uses there of | |
Jennewein et al. | Intranasal self-amplifying RNA SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission | |
JP2016505622A (en) | Therapeutic vaccine for treating herpes simplex virus type 2 infection | |
US11786592B2 (en) | Compositions of cardiolipin adjuvants and methods of use thereof | |
US20230321230A1 (en) | Compositions and Methods for Adjuvanted Vaccines | |
WO2023169500A1 (en) | Mrna vaccine for encoding s protein of sars-cov-2 | |
US10174100B1 (en) | Multivalent DNA composition for Yersinia pestis | |
Nie et al. | Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23733061 Country of ref document: EP Kind code of ref document: A1 |